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Summary 
Enzyme linked immunosorbent assay (ELISA) is a useful "initial screening test" 
for the detection of a particular drug class for example opiates. It is a rapid, 
highly sensitive and in most laboratories automated procedure. This is highly 
beneficial in a busy toxicology laboratory with high sample throughput as a 
means of eliminating negative samples. Appropriate cross reactivity of the ELISA 
kits with a range of drugs or drug metabolites within a drug class is essential to 
the success of this screening method. 
Liquid chromatography-tandem mass spectrometry (LC-MS-MS) combines 
selective chromatographic and mass selective detection of analytes. It has 
established itself as a complementary technique to gas chromatography-mass 
spectrometry (GC-MS) in the analysis of less volatile compounds and/or high 
molecular weight compounds and an increasing number of laboratories are using 
it. A major advantage of LC is that unlike GC, time-consuming derivatisation 
steps are not generally required: 
The aim of this study was to investigate the potential use of ELISA and LC-MS-MS 
in combination and as individual techniques, for the detection of drugs of abuse 
in biological matrices. 
An ELISA method was validated for the detection of buprenorphine in urine 
samples and the results were compared with an in-house LC-MS-MS method. 69 
urine samples were received into the laboratory as routine samples and from 
volunteers on the Subutex® treatment programme. The limit of detection (LOD) 
was calculated as 0.5 ng/mL buprenorphine. The intra-day (n=20) and inter-day 
precision (n=100) were good (6.4 and 12.9 % respectively). The kit 
demonstrated appropriate cross reactivity with norbuprenorphine at low and 
high concentrations. 21 urine samples were confirmed positive and 48 samples 
were confirmed negative by LC-MS-MS. Using a cut-off value of 0.5 ng/mL 
buprenorphine, the immunoassay demonstrated a sensitivity and specificity of 
100%. 
An ELISA method was validated for the detection of amphetamines, cocaine, 
benzodiazepines and opiates in hair. The kits for each drug class demonstrated 
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high sensitivity with LOD values <_ 0.1 ng/mg using a 10 mg hair sample, good 
precision (intra-day <9%, inter-day < 18 %) and appropriate cross reactivity with 
analytes found in hair. The method was applied successfully for the screening of 
post-mortem samples as discussed in chapters 6-8. However more data is 
required to determine if the cut-off values recommended by the Society of Hair 
Testing for amphetamines, cocaine and opiates are suitable for screening hair 
samples. 
This ELISA method was also validated for the detection of methamphetamine in 
hair and the results compared to GC-MS as part of collaboration with the 
National Institute of Scientific Investigation in South Korea. 29 scalp hair 
samples were obtained as routine cases submitted to the forensic toxicology 
laboratory in South Korea by the police. 28 of these samples were screened and 
confirmed as positive using a cut-off concentration of 0.5 ng/mg 
d-methamphetamine. The ELISA demonstrated a sensitivity and specificity of 
97 % and 100 % respectively using this cut-off concentration. The ELISA kit 
demonstrated appropriate cross-reactivity with d-methamphetamine and did not 
cross-react to any significant extent with the licit 1-methamphetamine isomer. 
The intra-day and inter-day assay precisions were good (7.4 % and 7.6 % 
respectively). The LOD was calculated as 0.05 ng/mg d-methamphetamine using 
a 10 mg hair sample. 
The study in chapter 7 was designed to compare the ELISA method with a 
validated LC-MS-MS method for the detection of 9 benzodiazepines in hair. The 
LC-MS-MS method provided the sensitivity necessary to quantify benzodiazepine 
levels in post-mortem hair samples. Mild alkaline extraction conditions and an 
incubation time of 16 hours were demonstrated to be suitable for the extraction 
of benzodiazepines in the LC-MS-MS method. 13 out of 16 hair samples were 
screened and confirmed as positive. The benzodiazepines detected included 
diazepam, nordiazepam, temazepam, oxazepam, nitrazepam, and lorazepam. 
Using a cut-off concentration of 0.1 ng/mg oxazepam, the ELISA method 
demonstrated a sensitivity and specificity of 100 % and 81 % respectively, 
compared with LC-MS-MS results. 
Also in chapter 7, a preliminary study into the use of a diazepam molecularly 
imprinted polymer (MIP) is described for the successful detection of 
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benzodiazepines in post-mortem hair samples. The molecularly imprinted solid- 
phase extraction (MISPE) method was compared to the classical solid-phase 
extraction (SPE) method for 10 hair samples. The MISPE method detected a 
higher number of diazepam positive case samples than the classial SPE method 
because of the higher extraction recovery of the MISPE method and the excellent 
molecular recognition of the template molecule (diazepam) imparted by the 
imprinting process. The MISPE method also demonstrated selectivity for other 
benzodiazepine analogues. MISPE could be used as a complementary method to 
classical SPE for the detection of benzodiazepines in post-mortem hair samples. 
An LC-MS-MS method was developed and validated for the simultaneous 
identification and quantification of opiates, cocaine and its metabolites, 
amphetamines and diazepam and its metabolites from one hair sample without 
roots (8-30 mg) and root samples (in some cases <1 mg) as described in chapter 
8. The method was applied to 17 post-mortem hair samples, detecting at least 
one drug class in 16 out of 17 samples. The results of the analysis were 
compared to GC-MS results obtained by in-house methods. 
Overall, the LC-MS-MS method showed good correlation results for the opiates 
compared to the GC-MS method. 6-MAM was however detected in more root 
segments and segments excluding roots by LC-MS-MS. Morphine was detected in 
a greater number of root segments by LC-MS-MS compared to GC-MS. However 
morphine was detected in a greater number of segments excluding roots by GC- 
MS. Codeine and dihydrocodeine were also detected in a greater number of root 
segments and segments excluding roots by GC-MS. The cocaine results showed 
excellent qualitative correlation between the LC-MS-MS and GC-MS methods for 
cocaine and benzoylecgonine. The GC-MS method did however extract greater 
concentrations of cocaine and its metabolites compared to LC-MS-MS due to the 
higher recovery of the drug group specific GC-MS method. Cocaethytene and 
EME were detected in some samples by LC-MS-MS where GC-MS detected none. 
As a result of the lower recovery of the LC-MS-MS method for opiates and 
cocaine and its metabolites compared to the GC-MS method, there may be some 
cases where the GC-MS method would detect the analytes where the LC-MS-MS 
method would not. This has been demonstrated in 3 samples for morphine and 
in 6 samples for codeine. 
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The LC-MS-MS method analysed for and detected amphetamines in samples that 
were not tested for amphetamines by GC-MS. In 1 sample that was tested by 
both methods, amphetamine was detected in the root sample by LC-MS-MS 
where GC-MS failed to detect it. Also a greater concentration of amphetamine 
was extracted using the LC-MS-MS method in the segment without roots. 
The LC-MS-MS method was useful for the analysis of 17 drugs of abuse in post- 
mortem hair samples in forensic toxicology cases. Using this method, it is 
possible to obtain maximum information from 1 hair sample which is extremely 
useful when the sample weight is limited. The ability of the LC-MS-MS method 
to extract and analyse a greater number of drug groups from one hair sample 
highlights the advantages of using this method over GC-MS which targets 
individual drug groups and requires splitting of the sample. This method is 
particularly applicable for implementation in the forensic toxicology laboratory 
at the University of Glasgow where currently GC-MS methods that target 
individual drug groups are used for routine hair screening and confirmation. 
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I Introduction 
Enzyme linked immunosorbent assay (ELISA) is well established and routinely 
practiced in forensic and toxicological analyses as an "initial screening test" for 
drugs of abuse in blood and urine samples. ELISAs have more recently been 
adapted to detect and semi-quantify a wide range of drugs or drug metabolites 
in a variety of less conventional biological matrices such as hair and oral fluid. 
ELISA is a highly sensitive method for determining the amount of drug present in 
a sample by means of an enzyme-catalysed change in absorbance signal. In 
drugs of abuse screening, ELISA serves as a useful means of eliminating negative 
samples from further confirmatory tests and also identifying any drug class that 
requires confirmation by a second step test such as liquid chromatography- 
tandem mass spectrometry (LC-MS-MS). 
The use of liquid chromatography-mass spectrometry (LC-MS) in all areas of 
analytical chemistry has increased exponentially from 1990. The development 
of a suitable interface for coupling LC to MS in the form of atmospheric pressure 
ionisation (API) is responsible for the success of the technique. LC-MS has many 
attractive features for analytical toxicologists including the direct analysis of 
polar, less volatile and high molecular weight compounds. Prior to its 
availability, LC was used with an ultraviolet (UV) detection system for 
compounds that were not suitable for gas chromatography-mass spectrometry 
(GC-MS). Unlike GC-MS, time-consuming derivatisation steps are generally not 
required in LC-MS. The combination of selective LC with mass-selective 
detection provides two pieces of information gained from chromatography and 
MS data, which is highly specific to a particular analyte. LC-MS also provides the 
flexibility required for screening or quantification. 
Hair testing for drugs of abuse has been an area of interest, particularly over the 
last decade. It is a useful sample for establishing drug use over the weeks or 
even months prior to collection, depending on the length of the hair sample and 
the stability of the drug within the hair. This has led to its international 
application in many areas of forensic and clinical toxicology. Hair results are 
currently used to complement blood or urine analysis. 
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An investigation into the potential use of ELISA and LC-MS-MS for the 
complementary detection of drugs of abuse in urine and hair is described in this 
thesis. An LC-MS-MS method was developed and validated as described in 
chapter 8 for the identification and quantification of a wide range of drugs of 
abuse in hair. This method will be implemented in the forensic toxicology 
laboratory at the University of Glasgow initially as a complementary technique 
to the drug group specific GC-MS methods currently being used for routine hair 
screening and confirmation. 
2 Hair 
2.1 Introduction 
Testing human hair for the presence of drugs is an extremely useful toot in 
forensic and clinical toxicology and has been applied internationally. It has been 
used to investigate drug-related deaths', in employee screening', to assess 
physical fitness to obtain a driving license;, to monitor compliance or abstinence 
in drug treatment programmes', in child custody' and criminal cases6, in military 
court-martials7, in sports testing8 and to monitor pre-natal drug exposure. ' 
Hair analysis is useful for establishing drug use over the weeks or even months 
prior to collection, depending on the length of the hair sample and the stability 
of the drug within the hair. In contrast, blood and urine samples only provide 
information on drug use related to time intervals of hours to a few days prior to 
collection. Hair analysis is particularly useful in cases where proof of abstinence 
from drug use is required for example in workplace testing. It is well known that 
both parent drugs and metabolites incorporate into hair where often only 
metabolites are detected in blood and urine. 
Hair testing offers several advantages over more conventional blood and urine 
testing. It is difficult to adulterate a hair sample and hair is unaffected by 
short-term abstinence. It is a stable and biologically inert material and it can 
retain drugs for extended time periods. The first forensic case involving the 
detection of a poison in human scalp hair was the detection of arsenic in 1857. 
The hair had been collected from a body exhumed eleven years after burial. " 
Hair is a readily accessible and non-invasive choice of sample which can be 
collected under close supervision. This excludes the embarrassment and lack of 
privacy associated with urine collection. In addition, it is usually possible to 
collect a second representative sample for analysis if the sample integrity is in 
question. 
Hair stability is such that it can be stored at ambient temperature indefinitely, 
without refrigeration. Storage and transportation of hair samples is easier and 
the analysis does not require to be carried out immediately. 
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Although hair testing is extremely useful, there are still many controversial 
issues surrounding it which need to be addressed. These include conflicting data 
on the exact contribution of external drug contamination and the effectiveness 
of decontamination procedures. There is the possibility of bias from 
cosmetically treated hair and also hair from individuals of different cultures. In 
addition, the exact mechanism of drug incorporation is not yet known. Until 
these issues are resolved, hair testing should not be used as a single source of 
evidence in a toxicological investigation but should be used in combination with 
blood and urine analysis, to provide information on both acute and chronic drug 
use or to rule out the role of drugs in a case. The consensus opinion of the 
Society of Forensic Toxicologists (SOFT) in 1990 was that "Hair may be a useful 
specimen in forensic investigations when supported by other evidence of drug 
use. "" Since then the Society has not changed its opinion on hair testing. The 
issues contributing to a lack of a firm scientific basis are discussed in subsequent 
sections of this chapter and are partly responsible for the current opinion of the 
SOFT. 
2.2 Hair Physiology 
2.2.1 Introduction 
Despite the lack of conclusive scientific knowledge on drug incorporation 
mechanisms, the contribution of external contamination and inter-individual 
variations, an integral part of the accurate interpretation of hair results is to 
have an understanding of hair structure and growth. Therefore this is discussed 
in sections 2.2.2-2.4.4. 
2.2.2 Structure 
Hair tissue is a complex cross-linked polymeric network, which is synthesised in 
the hair follicle. It contains functional chemical groups such as acidic, basic and 
peptide groups which can potentially bind to small drug molecules. Hair is 
composed of 65-95 % protein, 1-9 % lipids, 0.1-5 % pigments (melanin) and small 
quantities of water, polysaccharides and trace elements. " 
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The hair shaft consists of three distinct layers namely the cuticle, cortex and 
medulla (Figure 2-1). Pigment granules are present in the cortex and medulla 
and their presence or absence can affect drug incorporation. These structural 
components are discussed in more detail in sections 2.2.2.1-2.2.2.4. 
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Figure 2-1 Schematic diagram of the hair follicle13 (© 2007 by Taylor & Francis Group, LLC) 
The layers are distinguishable by microscopy. Figure 2-2 shows a scanning 
electron microscope (SEM) image of the surface of a hair taken in the University 
of Glasgow. The flattened cuticle scales are visible. The raised cuticle scales 
are typical of damage resulting from everyday haircare such as brushing. 
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Figure 2-2 SEM image (x 1000) of the surface of a hair 
2.2.2.1 Cuticle 
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The function of the cuticle is to attach the shaft to the follicle and to protect 
the inner fibres. In human hair, the cuticle is made up of six to ten layers14 of 
imbricated (flattened) scales which are formed by the keratinisation of specific 
cells during post-follicular development. The scales in the different layers 
narrowly overlap with one another and always point from the root (proximal 
end) to the tip (distal end). Different species have characteristically shaped 
cuticle scales which can be used for species identification. Hair can become 
damaged or destroyed following exposure to heat, light, chemical treatments 
and mechanical abrasion. If the cuticle gets damaged, drugs can be removed 
more readily from hair. 12,15 
2.2.2.2 Cortex 
The cortex constitutes the bulk of the hair shaft and is made up of long fibres of 
sulfur rich keratin. It is mainly responsible for the stability and retention of 
structural features in hair and contributes most to the mechanical strength of 
the hair fibre. " Fusi can be present between the fibres in the cortex. These are 
small areas filled with fluid in the living section of the hair root but as the hair 
grows and dehydrates, they become air spaces which can be distributed 
throughout the hair shaft. 
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2.2.2.3 Medulla 
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The medulla may be present in the core of the cortex. In human hair, it can be 
present in various forms, or absent for example in fine vellus hair. If present, it 
can be continuous or interspersed with air spaces throughout the hair shaft. In 
human hair, the medulla is usually present in the fragmented form or is absent; 
it is rarely in the continuous form. Mongoloid hair is the exception to this as it 
usually possesses continuous medullae. The medulla can be complex in beard 
hair and may even possess a double medulla. 12 It is usually amorphous in 
appearance but different species demonstrate differently shaped medullae. 
The medullar cells at the follicle are loosely packed together. These cells 
become dehydrated to form vacuoles further away from the follicle. Generally, 
the number of medullar cells increases with hair shaft diameter. Fine hairs may 
for example possess only a cuticle and cortex while thicker hairs may possess a 
relatively high number of medullar cells. 
2.2.2.4 Pigment Granules 
Pigment granules are present mainly in the cortex, to a lesser extent in the 
medulla and rarely in the cuticle. Melanin is the main pigment in hair and is 
made in melanosomes, which are specialist organelles contained in melanocytes 
within the apex of the dermal papilla. It is transferred into the cells migrating 
from the hair follicle bulb and distributed throughout the body of the hair shaft. 
Pigment formation (follicular melanogenesis) occurs in four stages. Tyrosinase 
and protein are the basic structural components in the first stage, followed by 
the formation of an inner membrane in which melanin is synthesised and 
accumulates. The metanosome is finally transformed into a melanin particle and 
transferred into cortical and medulla keratinocytes which then distribute the 
pigment through the shaft. This whole process is regulated by enzymes, 
structural and regulatory proteins, transporters and receptors and their ligands 
during the anagen phase of the hair growth cycle. 
Hair colour is genetically controlled and there is a diverse range of pigmentation 
phenotypes. The type, quantity, size and distribution of pigment granules are 
responsible for imparting hair colour. There is now thought to be four types of 
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pigment responsible for the diversity in hair colour namely pheomelanin, 
oxypheomelanin, eumelanin and oxyeumelanin. 76 Oxypheomelanin and 
oxyeumelanin are the oxidative products of pheometanin and eumelanin 
pigments respectively, induced by the presence of hydrogen peroxide. 
A four class system has been proposed for defining hair colour according to its 
melanin content. " The study demonstrated that black to dark brown hair 
contains virtually intact eumelanin whereas brown hair contains more of the 
oxidative breakdown product, oxyeumelanin. Furthermore, blonde hair contains 
large quantities of oxyeumelanin. The study also showed that the traditional 
view of mixed-type melanins in brown/chestnut hair produced from the same 
melanocyte is incorrect since only eumelanin and oxyeumelanin were found. 
The author concluded that the diversity of hair colour results from eumelanin 
and pheomelanin at different degrees of structural integrity. 
2.3 Hair Follicle 
Hair follicles are small sacs surrounding the hair root, embedded in the skin's 
epidermal epithelium and lie approximately 3-4 mm below the surface of the 
skin. They are connected with the sebaceous and apocrine glands and also 
eccrine sweat glands in the axillary and pubic areas. 
The hair follicle consists of several layers of cells. The outer root sheath (ORS) 
is part of the epidermis and surrounds the other layers. The inner root sheath 
(IRS) region encases the growing hair fibre. Hair cells are synthesised in the hair 
follicle bulb by extensive mitotic activity and move upward to form the body of 
the hair fibre and the IRS. The adjacent region (keratogenous zone) is where 
the hair keratinises, hardens and solidifies. The final region is the permanent 
hair where the hair cells have dehydrated to form the hair shaft. 
2.4 Hair Growth 
Hair grows out of the epidermis and is synthesised in the hair follicle. Hair 
growth begins in cells present in a germination centre (matrix) which is found in 
the base of the follicle. As cell division occurs, the cells become larger and 
elongate out of the matrix into the keratogenous zone. They produce melanin 
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pigment in this zone and keratinise into long fibres through the cross-linking of 
amino acid functional groups such as the sulfhydryl group in cysteine. The cells 
gradually die and their decomposition involves the release of cell nuclei and the 
elimination of water. 
Human head hair can be found in one of three growth stages; anagen, catagen or 
telogen (Figure 2-3). The size and the shape of the hair roots differ depending 
on the particular growth stage that the hair is in. Hair growth is an intermittent 
cyclic process which alternates between periods of growth and dormancy. The 
hair growth process and growth rate is different between body regions and even 
within a single region. 12 The different stages and rates of growth are described 
in more detail in sections 2.4.1-2.4.4. 
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Figure 2-3 Different stages of the hair growth cycle13 (© 2007 by Taylor & Francis Group, 
LLC) 
2.4.1 Anagen 
Anagen is the first growth phase in which the follicle develops and the hair is 
produced. Hair grows for varying amounts of time depending on the anatomical 
region, usually continuing between 7 to 94 weeks" but potentially lasting several 
years. In the anagen phase, there is an increase in mitotic activity of the matrix 
cells at the base of the hair follicle. Newly divided cells elongate to form thin 
filaments which grow upwards into the follicular canal. The cells differentiate 
into the cortex, cuticle and medulla and the hair begins to keratinise to produce 
a new hair. After the follicle is fully grown, it is elongated to at least six times 
Catagen Anagen 
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its original length in the resting phase. " Nutrients and drugs, supplied by a 
blood capillary, are incorporated into the hair shaft during this phase. 
Approximately 85 % of hairs in the posterior vertex region of the scalp are in the 
anagen phase at any one time, while the other 15 % are in the resting (tetogen) 
phase. " Hair in the anagen phase has characteristic dark roots as it contains 
pigment granules which extend into the root bulb. It also possesses a follicular 
tag, which is a clear piece of tissue surrounding the hair shaft near the root. 
The presence of the follicular tag can indicate if a hair has been removed by 
unnatural means, for example during a violent attack. As the follicular tag is 
made up of cells, it can provide a source of deoxyribonucleic acid (DNA) for 
testing purposes and can be used to determine the sex of the hair. 
2.4.2 Catagen 
Following the active growth stage of a new hair, mitotic activity of the matrix 
cells suddenly ceases and the catagen phase begins. Catagen is a short 
transitional growth phase between active growth and resting. Hair can remain 
in this phase for approximately 2-3 weeks and grows at a slower rate than hair in 
the anagen phase. A mass of keratin cells forms at the base of the hair shaft, 
which separates from the follicle. During this process, the follicle bulb is 
partially destroyed and the dermal papilla contracts as the follicle approaches 
the resting phase. Hair roots in this phase can possess characteristics of hair in 
either anagen or telogen. 
2.4.3 Telogen 
Telogen is the final phase in the hair growth cycle, in which follicular activity 
ceases and the follicle rests. The hair becomes completely detached from the 
bulb and is retained in the follicular canal. Consequently, the hair can be easily 
pulled out or plucked from the scalp. Roots of telogen hairs are either clear or 
white as they are lacking pigment granules. Telogen hairs do not have follicular 
tags but instead have root sheaths which are pieces of tissue attached to the 
root. 
The length of time the hair cells spend in the telogen phase depends on the body 
area and age of the individual. Scalp hair can be in the resting phase for about 
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3-4 months however this can last 2-6 years, depending on anatomical region. " 
The old hair is forced out through the scalp surface as a new hair shaft grows. 
After the telogen phase, another growth cycle begins. 
2.4.4 Growth Rate 
Hair growth rate is not clearly defined and it can vary greatly between 
individuals and in different and also in the same body regions on a particular 
individual. This is because not all hair is growing at any one given time and the 
percentage of follicles in the anagen phase varies. Human scalp hair is generally 
assumed to grow at a rate of 0.35 mm/day for males and females. However a 
range of 0.07-0.78 mm/day was observed in one study where 82 % of the test 
population had a growth rate in the range of 0.32-0.46 mm/day. 13 
Hair type and anatomical location are most influential in determining growth 
rate however gender, race and age can also affect growth rate. Scalp hair has a 
faster growth rate than axillary and pubic hair, white beard hair has the slowest 
growth rate. Scalp hair growth rate is faster in females than males, is faster in 
Caucasians than Asians and tends to decrease with age. " Growth rate is also 
influenced by seasonal changes, nutrition, genetic make-up, endocrine 
dysfunction and pregnancy. " These factors affecting growth rate must be 
considered in the interpretation of hair results. 
2.5 Drug Incorporation Mechanisms into Hair 
Several studies have been carried out in an attempt to explain the factors that 
influence drug incorporation into hair from the bloodstream. 1809'20'2' However an 
exact mechanism has not yet been established. This is partly due to the limited 
number of controlled drug administration studies in humans that involve the 
collection of plasma, hair and sweat samples. 22 
There are three proposed models for incorporation of drugs entering into the 
hair (Figure 2-4). These are (1) active or passive diffusion from the bloodstream 
into the dermal papilla, (2) diffusion from sweat and other secretions 
surrounding the growing or mature hair fibre, or (3) external drug contamination 
from vapours or powders that diffuse into the mature hair fibre. The most likely 
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model is probably a combination of all of these routes of incorporation however 
the importance of the different routes has not been determined and will vary 
depending on the drug and also between individuals. For interpretation 
purposes, the incorporation route via the bloodstream is the most significant 
when information on for example dose taken or time of drug intake is required. 
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Figure 2-4 Three models of drug incorporation into hair" (© 2007 by Taylor & Francis Group, 
LLC) 
2.5.1 Incorporation from the Bloodstream 
The hair follicle is provided with a good blood supply. Any drugs circulating in 
the bloodstream will also be passed to the hair follicle. Drugs passively diffuse 
through the cell membrane from the bloodstream into matrix cells of the 
growing hair positioned at the base of the follicle. The diffusion rate across the 
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membrane is related to drug Upophilicity and the pH gradient between the 
plasma and the hair cell. This will be discussed later in sections 2.6.1 and 2.6.2. 
This incorporation model, also known as the passive diffusion model, proposes 
that as the hair grows out from the scalp, the drugs form bands in the hair that 
are directly proportional to the concentration present in the bloodstream at the 
time the hair was formed. The passive diffusion model is supported by the 
findings of a study in which the dose of methoxyphenamine ingested by five 
individuals correlated well with the concentration of drug detected in the hair. 
Methoxyphenamine was found to move along the hair shaft with a growth rate of 
0.40-0.46 mm/day and demonstrated no diffusion. " 
The passive diffusion model forms the basis of segmental hair analysis in which 
measured hair segments from the root to the tip are analysed to determine an 
individual's prior drug use. Based on the assumption that hair grows at a 
constant rate of 1.0 cm/month, the position of drugs along the hair shaft can be 
directly linked to the time at which the drug was ingested. 
As mentioned previously, there are other routes of drug incorporation into hair 
and there is evidence supporting the fact that the passive diffusion model is an 
oversimplification of the incorporation process. Although there is a good 
correlation between the dose of drug ingested and the concentration detected in 
hair for some drugs, this is not the case for others. There was a poor correlation 
between the morphine dose and concentration detected in hair of cancer 
patients being administered with therapeutic doses of morphine. " In contrast 
with the predictions of the passive diffusion model, higher morphine 
concentrations were detected in the hair of patients exposed to the lowest doses 
using radioimmunoassay (RIA). Drug concentrations in hair have also been shown 
to vary significantly in individuals receiving the same dose. 25 In addition; there 
is also some evidence to suggest that the position of the drug along the hair 
shaft does not correlate with time of exposure. " 
A further discrepancy with this model is that parent drug to metabolite ratios in 
blood do not correlate with those in hair. Cocaine is for example predominantly 
found in hair, despite its short half-life in blood (0.7-1.5 hr). Although hair, in 
particular the bulb, contains cytochrome P450 enzymes capable of drug 
metabolism, it does so less readily than other organs. 26 
Hair Chapter 2,14 
As a result of the discrepancies associated with the passive diffusion model and 
the apparent complexity involved with drug incorporation into hair, a multi- 
compartment model has been proposed to include incorporation from sweat and 
other secretions and also incorporation from external contamination. 
2.5.2 Incorporation from Sweat, Other Secretions and External 
Contamination 
The multi-compartment model shown in Figure 2-4 includes the incorporation 
route via the bloodstream into the dermal papilla as well as by sweat and sebum 
bathing the mature hair fibre. The model also considers external drug 
contamination through vapours or powders as a route for potential incorporation 
into the mature hair fibre. 
It is widely accepted that drugs and their metabolites are excreted in sweat27'28 
and there are some studies which investigate this in relation to drug 
incorporation into hair. As hair is very porous and can increase its weight by 
18 % by absorption of liquids, drugs can be easily transferred into hair from 
sweat. 29 Deuterated cocaine was detected in multiple segments after a single 
dose, supporting the evidence that sweat or other secretions are a possible route 
for drug incorporation into hair. 30 It has also been proposed that differences in 
drug concentrations found in hair could be attributed to secretion variability 
between individuals. Different concentrations of cocaine were detected in the 
sweat of individuals receiving the same dose. 25 Sebum was shown to deposit 
insignificant quantities of cocaine, flunitrazepam and nicotine onto the hair. 31 
Both in vitro and in vivo experiments have been conducted in an attempt to 
differentiate between drugs deposited in hair from external sources and drugs 
which have been ingested, with markedly different results. Rhodamine dye was 
found to penetrate the hair at the cuticle scale junctions and further along the 
non-keratinous cell membrane complex after soaking in a solution. " In contrast 
an in vivo experiment using mice found that fluorescein and rhodamine were 
deposited mainly in the cortex and the medulla. " The dyes, whether 
incorporated in vitro or in vivo, could not be removed by extensive wash 
procedures making interpretation of analytical results difficult. 
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Several decontamination procedures have been recommended recently for 
differentiation between external drug contamination and ingested drug. These 
will be discussed in section 2.10. Although drugs deposited on the hair from the 
external environment can be removed by a decontamination procedure, it has 
been shown that a small fraction of these drugs are able to penetrate the cuticle 
of the hair shaft, therefore affecting the true results of hair testing. 
2.5.3 Binding Mechanisms 
The mechanisms of drug binding in hair are not fully understood but melanin and 
keratin hair components have been suggested as potential sites of interaction. 
Drug binding to melanin was identified more than four decades ago13 and there 
have since been many studies in this area which have investigated the binding of 
a variety of drugs with different physicochemical properties. 
Melanin pigment is a potyanionic indolequinone based polymer that will 
potentially interact with positively charged (cationic) molecules., ' This 
interaction may explain the preferential incorporation of some basic drugs into 
pigmented hair over non-pigmented hair. 19'34,35,36 Basic drugs exist as cationic 
molecules at physiological pH and could preferentially interact with the melanin 
in pigmented hair by electrostatic forces between the cationic functional groups 
and the anionic carboxylic groups on the surface of the melanin polymer. 
Depending on the structure of the bound drug, the electrostatic binding can be 
strengthened by van der Waals forces, hydrophobic interactions, charge transfer 
reactions and covalent bonding. 
It has been suggested that the most important association of drugs with melanin 
occurs during melanin synthesis at which time the drug molecules become 
entrapped within the melanin polymer. " Therefore drug incorporation into hair 
may relate to melanin content in the melanocyte. 
The in vitro binding of cocaine, benzoylecgonine, amphetamine and 
N-acetylamphetamine to synthetic melanin subtypes has been studied. The 
results indicated that the more basic drugs (cocaine and amphetamine) bind to 
eumelanins and mixed eumelanin /pheomelanins to different degrees but do not 
bind to pure pheomelanin. The net neutral molecules (benzoylecgonine and 
N-acetylamphetamine) did not bind to any melanin subtype. " 
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A number of in vivo experiments using dark-agouti (DA) rats (which have no 
sweat glands) were carried out in Japan and the results demonstrated that the 
plasma concentration was not the major factor affecting drug incorporation into 
hair but rather the physicochemical properties of the drugs. 37'38 Although the 
conclusions of these experiments cannot be directly applied to human hair as it 
is more complex than DA rat hair which only contains eumelanin, the 
relationship between incorporation rate and drug basicity and melanin affinity is 
relevant. Hence these relationships are discussed in section 2.7. 
There are few studies which address the issue of drug binding to keratin in hair. 
Human studies in subjects with grey hair have shown that various drugs can be 
detected in the pigmented and non-pigmented hair shafts of these individuals. 
This supports the proposition that keratin has an important role in drug binding 
to hair. Various studies have detected higher concentrations in the pigmented 
hair shafts compared to the non-pigmented (white) hair shafts. 39i40 This could be 
explained by the presence of a strong ionic interaction between the positively 
charged drugs and the negatively charged melanin polymer which is absent in 
non-pigmented hair. 
2.6 Drug Properties Influencing Incorporation 
There are a number of physicochemical properties which influence drug 
incorporation into hair, the main ones being lipophilicity, basicity and melanin 
affinity. Hair structure and cosmetic treatments also have a significant effect 
on drug binding in hair (discussed in section 2.7). Other factors affecting 
incorporation are bioavailability, the pKa value, plasma elimination half-life, 
volume of distribution and cell membrane permeability. ' 
2.6.1 Lipophilicity 
Due to the chemical nature of the cell membrane, non-polar, more lipophilic 
parent drugs are more likely to pass through from the bloodstream to the hair 
forming cells than polar, more hydrophilic drug metabolites. " This would 
explain why parent drug concentrations in hair are mostly higher than their 
respective metabolites. Greater incorporation of parent drugs can be 
advantageous when trying to distinguish heroin use from prescribed morphine or 
Hair Chapter 2,17 
codeine use for example. A positive correlation of 0.770 was found to exist 
between lipophilicity and incorporation rate into rat hair for nineteen basic 
drugs of abuse. 37 
2.6.2 Basicity 
Drug ionisation at physiological pH influences the extent of incorporation into 
hair. Basic drugs exist as cationic molecules at physiological pH and should 
preferentially bind to melanin in pigmented hair. Codeine which is a weak base 
and cationic at physiological pH was incorporated more into rat hair to a greater 
extent than phenobarbital, which is a weak acid and is not cationic at 
physiological pH. 26 The conclusion from this study was that at a given plasma 
concentration, there is a greater concentration of cationic drugs incorporated 
into hair than anionic drugs. 
Basic drugs were found to have higher incorporation rates into hair compared to 
more acidic and neutral drugs in a study examining the incorporation rate of 
twenty acidic, basic and neutral drugs of abuse into rat hair. 37 Cocaine had the 
highest incorporation rate and THCA had the lowest. There was a 3600 fold 
difference observed between their incorporation rates. 
Amphetamine incorporates into both pigmented and non-pigmented hair to a 
greater extent than its non-basic analogue N-acetylamphetamine. 19 Two basic 
benzodiazepines, flurazepam and medazepam, were shown to have relatively 
high incorporation rates in a study into the rate of incorporation of eight 
benzodiazepines into rat hair. 42 
2.6.3 Melanin Affinity 
Drug incorporation into hair can be influenced by pigmentation i. e. melanin 
content of hair. As discussed in section 2.5.3, melanin polymers possess many 
negatively charged carboxylic acid groups in their structure which attract 
positively charged basic drug molecules under physiological conditions. Melanin 
affinity is therefore associated with drug basicity. 
Experiments were carried out to test the melanin affinity of twenty drugs of 
abuse. Each drug displayed a different affinity for melanin binding, however 
Hair Chapter 2,18 
cocaine had the highest affinity, followed by benzphetamine and phencyclidine. 
The correlation coefficient for a graph of melanin affinity versus cocaine 
incorporation rate into hair was 0.947 and this direct relationship supports the 
evidence that melanin content in hair is strongly related to drug incorporation 
into hair. 37 In controlled oral codeine administration studies, a significantly 
positive relationship (R2 = 0.73) was found to exist between codeine 
concentrations in hair and the total melanin concentration present. 43 This 
contrasts with findings for more neutral and acidic drugs such as 
11-nor-A9-tetrahydrocannabinot- 9-carboxylic acid (THC-COOH) and 
N-acetylamphetamine where a lack of correlation between concentrations of 
these drugs in hair to hair melanin content has been observed. 19; 37 
In an animal study involving Long Evans rats, six phenethylamines were detected 
at relatively high concentrations in black hair however none were detected in 
white hair collected from the same rats. These findings indicate that the 
presence of melanin strongly influences the retention and incorporation of basic 
drugs. " 
2.6.4 Chemical Structure 
Drug-melanin binding is affected by the presence of different para-substituents 
on the benzene ring of methamphetamine. Nitro-, amino-, methytenedioxy-, 
methoxy- and bromo- groups all showed relatively higher melanin affinities than 
the unsubstituted methamphetamine. 45 
A study into the incorporation rates of seven phenethytamine analogues in rat 
hair roots also found different incorporation rates for each analogue, supporting 
the evidence that changes in the drug functional groups greatly affect drug 
incorporation into hair. ' 
2.7 Bias in Hair Testing 
Bias in drug testing can be defined as an increased chance of detecting drugs in 
one group of individuals over another when both groups have been exposed to or 
used the same quantity of drugs. In hair testing, bias can appear in two main 
situations: (1) Two individuals ingest the same quantity of drug but due to 
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biological or genetic reasons, one individual does not incorporate as much drug 
into the hair as the other, producing a false negative result; (2) Two individuals 
who are not drug users are exposed to drugs from their surrounding 
environment. Due to biological, genetic or cultural reasons one individual 
incorporates the drugs more readily into the hair from the environment and 
retains them longer than the other individual, producing a false positive result. 
The effect of hair bias remains an unresolved issue with hair testing. 
Cosmetically treated hair incorporates drugs more readily than untreated hair as 
it has structural damage and residual chemicals. When a drug penetrates the 
hair it can either bind or be removed through normal hygiene practices or 
decontamination as part of the hair testing procedure in the laboratory. Bias is 
associated with melanin content which facilitates drug binding. Different hair 
treatments associated with Africans and other ethnic groups are more prone to 
environmental contamination leading to false positive results. 
Cosmetic treatments such as dyeing, bleaching, chemical straightening and 
permanent waving reduce the binding of drugs in hair as these processes damage 
the hair structure. After these treatments, drug concentrations can decrease by 
50-80 % of their original concentration. " This is an important consideration for 
interpretation of hair analysis results since a change in drug concentration is 
induced by cosmetic treatments. Products used for these treatments are strong 
bases which can cause hair damage. Commonly used bleaching and dyeing 
formulas are combinations of hydrogen peroxide and an agent containing 
ammonium hydroxide. Ethanol and natural pigments are also used for bleaching 
and dyeing respectively. 46 In bleaching formulas, ammonium hydroxide opens 
the cuticle scales which aid the entry of drugs. Hydrogen peroxide is also a 
strong oxidant which attacks the melanin pigment resulting in decolourisation of 
hair. In dyeing formulas, natural pigments dye the hair to a desired colour. 
Chemical straightening and permanent waving causes the hair to become porous 
and permeable as the cuticle is disrupted. 47 In addition, some of the cosmetic 
products that are applied to hair to add shine after chemical straightening can 
aid transfer and binding of drugs. " 
All of the above mentioned cosmetic treatments can change the hair 
ultrastructure, resulting in drugs being lost from the hair matrix, or they can 
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become incorporated more easily into the hair matrix following exposure to 
external contamination. " The increased risk of obtaining false positive hair 
analysis results, due to drug uptake by sweat or sebum, has been demonstrated 
for bleached and permanently waved hair but not to a great extent. 49 
Hair collected from a female drug addict who had brown hair with strands of 
bleached hair was tested. " 3-fold higher concentrations of cocaine and codeine 
were found in the brown hair compared with the bleached hair. A decrease in 
benzodiazepine, cocaine and opiate concentrations was found in hair that had 
been bleached in vitro in another study. " The effect of bleaching and dyeing 
hair on the concentrations of opiates, cocaine, cannabinoids and nicotine has 
also been investigated. ' Bleaching was found to produce lower drug 
concentrations than dyeing. In this study, the degree of hair damage was also 
identified as a factor affecting drug concentrations; the more damaged the hair, 
the greater the loss of drug. 
Several studies have shown that some drugs incorporate into hair with higher 
melanin content and therefore there may be a bias in drug testing in hair from 
different races. Generally, Caucasian hair incorporates smaller quantities of 
drugs compared to African hair. Significantly more cocaine was detected in 
male African American hair than male and female black/brown Caucasian hair. 52 
An animal study found that in cases of high codeine intake by guinea pigs, black 
pigmented hair incorporated the highest concentration compared with white 
non-pigmented hair. 34 Another animal study noted that black pigmented rat hair 
incorporated a higher methadone concentration (21-fold) than white non- 
pigmented hair. 53 
Morphological differences have been identified between black African hair and 
hair from Caucasians and Asians. The African hair samples contained a tightly 
interwoven mat of hair shafts and many hair shafts were knotted, broken and 
inter-locked in comparison with Caucasian and Asian hair samples., ' This 
damage to hair structure through twisting in African hair could explain the 
differential drug binding observed between races since drugs have to first 
penetrate the cuticle which is made easier by the damage. " 
It is important to consider any wash procedures carried out in the laboratory 
which may affect the concentration of drug that is detected in the sample. It is 
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good laboratory practice, on receiving a sample, to note the physical condition 
of the hair and the type of cosmetic treatment, if any. 
An attempt was made to correct for racial bias observed in hair samples, using 
dyes, which can provide additional information on the permeability and binding 
capacity of hair. 55 The authors concluded that although the method was useful, 
it would be difficult to implement this process as part of a production system. 
Other studies have found no bias and have proposed that differences in drug 
levels observed in hair from various races are probably due to different rates of 
drug use. 56,57 A statistical analysis has been conducted on reported drug levels in 
hair where the hair colour was indicated. " There were differences in the drug 
levels detected in the differently coloured hair samples; however, these were 
not significant. The authors of the study propose that although hair colour does 
contribute to drug incorporation in hair, its contribution is yet to be detected 
statistically. 
2.8 Collection of Hair Samples 
It is necessary to consider a number of important factors when analysing hair 
samples. These include the method of collection used: whether the sample was 
collected from a living or deceased subject; any potential contamination which 
may result during the collection of, for example post-mortem samples; the 
sample size; and the anatomical location of the hair. 
2.8.1 Methods of Collection 
In post-mortem cases, hair samples should be collected prior to the post-mortem 
examination to prevent them from getting wet or contaminated with blood. 
Head hair is collected from the posterior vertex region and is either plucked 
from the scalp (in which case the roots will be present) or cut as closely as 
possible to the scalp. General Practitioners or solicitors normally collect hair 
samples from living individuals and in these cases the hair is cut as closely as 
possible to the scalp. 
The results of segmental analysis are meaningless if the collection and handling 
of the sample is inappropriate. Therefore, it is essential to obtain a sample that 
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has been correctly aligned with the root and tip ends clearly labelled. If this is 
not done, each segment will contain different portions of the hair strand 
therefore representing longer and overlapping time periods. 
Plucked hair may be advantageous over cut hair in some instances for example in 
an acute fatal poisoning case resulting in a delayed death. In this situation, a 
period of 2-3 days in a coma may yield negative blood and urine results due to 
elimination and cut hair may also be negative. " 
Plucked or cut hair samples are collected and stored inside hair collection kits at 
ambient temperature. The kits contain a circular piece of aluminium foil which 
has an area labelled "root end". After the "root ends" are aligned, the sample 
is wrapped in the foil and placed in an envelope clearly labelled with the case 
details. The envelope is then placed in a plastic evidence bag and sealed with 
adhesive tape. Figure 2-5 shows a typical hair collection kit. 
Figure 2-5 Typical hair collection kit 
2.8.2 Sample Size 
The sample size required for analysis varies between laboratories. It depends on 
the number of analyses to be carried out using different extraction 
methodologies and also on the sensitivity of the analytical method. A bundle of 
hair from the posterior vertex of approximately "pencil thickness" is normally 
sufficient for testing, but this depends on the amount of hair a particular 
individual possesses. In thin-haired or bald subjects for example, it may be 
necessary to collect the hair further down the head from the posterior vertex. 
ý"ý; 'ý ': ý;, 
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Sample sizes ranging from a single hair to 200 mg hair have been reported in the 
literature. " 
It is generally best to have as large a sample size as possible to ensure the 
detection of low drug concentrations for example in date-rape cases where the 
subject has potentially ingested a single dose of drug. 
2.8.3 Sample Selection 
There are three basic hair types on the human body namely vellus, intermediate 
and terminal hair. Vellus hair is fine, short and non-pigmented and is found on 
eyelids and forehead. Intermediate hair is of medium length and diameter and 
is found on the arms and legs of adults. Terminal hair is coarse, pigmented and 
has a large diameter and is found on the scalp, beard, armpit and pubic region. 
The different hair types form due to differences in the hair follicles. 
Ambosexual hair follicles are influenced by hormones and change during puberty 
e. g. pubic and armpit regions. 
For the purpose of hair analysis, head hair from the posterior vertex region of 
the scalp is normally chosen as it does not grow at such a variable rate 
compared to hair in other body regions and is less affected by differences in age 
and sex. In addition, there is a greater and more constant percentage of hair in 
the anagen growth phase in this region. Beard, axillary and pubic hair have also 
been used for drug analysis59'60 but does not offer any significant advantages over 
head hair testing as hair from these regions are also exposed to sources of 
contamination. The drug concentrations in these hair types vary for an 
individual depending on the location of the hair sample. This has been 
attributed to a number of factors such as the presence of apocrine glands, blood 
supply, telogen/anagen ratios and hair growth rate in different body regions. ' 
The location of the hair sample is an important consideration as the biology of 
hair from different body regions and sources of contamination vary, influencing 
the interpretation of results. 
Hair 
2.8.3.1 Scalp Hair 
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Scalp hair is the easiest, most accessible sample to obtain but as there are hairs 
in various growth phases on the head, the sampling area is crucial. The growth 
rate is highest in scalp hair therefore it displays the greatest variability. The 
ducts of the sebaceous gland empty directly into the hair follicle and so the hair 
shaft gets exposed to sebum before it grows out from the skin. Scalp hair can 
also be contaminated by sweat gland secretions, cosmetic treatments and 
contaminants from the air, water or dust. 
2.8.3.2 Beard Hair 
Beard hair is thick; the follicles are relatively large and grow at the slowest rate. 
Beard follicles are different from other follicles as the ducts of the sebaceous 
glands do not discharge into the follicle but onto the surface of the skin. 
Consequently, beard hair may be less contaminated by sebum than scalp hair 
and hence may be the sample of choice a few days after drug use. Beard hair 
can however become contaminated with pieces of epidermis through shaving and 
by environmental exposure. 
2.8.3.3 Pubic Hair 
Analysis of pubic hair may be necessary when there is no scalp hair available. It 
may be less contaminated from environmental exposure or cosmetic treatment 
but it may however be contaminated with urine and sebaceous, apocrine and 
eccrine gland secretions and is not a convenient sample to collect. 12'15 
Segmental analysis would not be appropriate for the analysis of pubic hair as 
interpretation of results would not be possible due to variable growth rates. 
2.9 Drug Stability in Hair 
The stability of drugs in hair depends on the morphological and physicochemical 
properties of the hair. The concept of diffusion bridges in hair fibres was 
investigated as a potential means of drug molecules entering into and out of the 
hair fibre. " Aqueous solutions of codeine, dihydrocodeine and morphine were 
shown to diffuse. A hypothesis was formed that organic substances may be 
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linked to the non-keratinous (morphological) hair regions and that these regions 
provide diffusion bridges for small molecules when water is present. These 
diffusion bridges could be a route for external contamination to enter the hair or 
loss of endogenous drug from the hair. This phenomenon was further supported 
in another study which used fluorescence microscopy to investigate the diffusion 
of Rhodamine B dye by staining the hair fibres. " 
Various studies on drug stability in hair have investigated the effect of cosmetic 
treatments, such as dyeing, bleaching and permanent waving. ", ", " The results 
are in agreement that drug concentrations decrease in hair that has been 
exposed to these treatments. Repeated shampooing does not have a significant 
effect on the drug concentration of hair. 63 
Opiate concentrations in hair were found to decrease dramatically after 
bleaching, permanent waving and UV exposure. "' UV damages hair as free 
radicals are formed when UV light is absorbed by amino acids such as cysteine, 
phenylalanine, tyrosine and tryptophan and this causes disulfide bonds within 
the hair to break. 14 
Bleaching and exposure to water or soil for six months, as well as exposure to 
tap water for 4 weeks, was found to result in formerly positive hair samples 
producing negative results. 64 
2.10 Decontamination 
As hair grows out of the epidermis, it is exposed to the environment, including 
any potential drug contamination which may be present in the surroundings. 
Sweat and other body secretions could also be regarded as contamination 
although it is not from an external source. The "bathing" of a mature hair in 
sweat could result in the broadening of the drug band previously incorporated 
through the bloodstream. Decontamination or "washing" of hair samples is 
therefore used to allow an accurate interpretation of results, by removing any 
loosely bound external drug contamination as well as gels, mousses, oils and 
everyday dirt which may be present on the hair. This step can help to make the 
hair extract cleaner, reducing potential interferents which may be present. In 
addition to this, it can minimise the number of false positive results. 
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All decontamination procedures are based on the assumption that exogenous 
drugs deposited in hair from the environment are loosely bound to the surface of 
the hair. It is a necessary step in the hair testing procedure since the amount of 
drug present in hair through ingestion is low compared with that in the 
environment. Several authors have however reached the conclusion that no 
washing procedure would be 100 % effective in removing external contamination 
in any contamination situation . 
13,63, ' There are still many more decontamination 
experiments which need to be performed in order to determine the exact set of 
conditions in which a procedure succeeds or fails. An attempt should be made in 
these studies to mimic real-life contamination scenarios but the design of these 
wilt be based on preconceptions. 
There is currently no standard decontamination procedure for hair. It is difficult 
to standardise a decontamination procedure since it is not known if all of the 
external contamination has been removed or if drug incorporated into the hair 
shaft through ingestion is being removed. Several authors have shown that some 
decontamination procedures remove drug present in the hair shaft through 
systemic exposure. ", " In addition, passive drug contamination has been found 
within the hair and not just on the surface. " Furthermore it has been suggested 
that the extent of hair damage may affect the quantity of drug which is lost 
from the hair shaft. Highly damaged hair is more porous and hence is more 
likely to lose a greater quantity of drug present in the shaft through systemic 
exposure. " 
In general the less polar solvents remove less externally bound drug as the 
solvent does not swell the hair as much as more polar solvents. BB Among the 
agents used for decontaminating hair are aqueous media such as phosphate 
buffer" and detergents69 as well as organic solvents such as, ethanol", acetone", 
dichloromethane'Z and methanol. 71 Decontamination with organic solvents is 
currently preferred over washing with aqueous media as it does not result in hair 
swelling however it may not remove all externally incorporated drugs. " 
Dichloromethane has been shown to only remove the loosely adhering cocaine in 
hair. 74 Furthermore it was shown to be as equally effective as phosphate buffer 
in removing loosely bound cocaine, which in contrast was found to remove some 
of the more tightly bound drug. 72 A washing procedure should be a compromise 
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where sufficient external contamination is removed but incorporated drugs are 
not. 
The identification of unique drug metabolites could be used to distinguish 
passive contamination and actual drug ingestion. Careful consideration must be 
given to the interpretation of metabolite data however as cocaine and heroin 
metabolites can be produced during the parent drug degradation. 
Benzoylecgonine has been detected in hair contaminated once with cocaine. 
Hydrolysis of cocaine to form benzoylecgonine can occur in the presence of 
sweat or during personal hygiene practices and also due to the presence of 
enzymes in matrix cells. " Another study found that heroin contaminants can 
enter into the hair matrix and become transformed into significant 
concentrations of 6-monoacetylmorphine (6-MAM), morphine and codeine 
metabolites. 78 In these hydrolysis situations, cut-off values and metabolite to 
drug ratios are of limited use for evaluating passive contamination. It is ideal to 
detect unique drug metabolites which are produced by the body only as a result 
of pharmacological processing of the drugs as these could only be present as a 
result of actual drug use. A negative hair testing result can be used as a means 
of ruling out either drug use or contact with drugs however a positive hair 
testing result cannot be used as a definitive sign of drug use and should be 
confirmed with blood and/or urine results. 
2.11 Sample Preparation 
Sample preparation is one of the most important steps in hair analysis yet this 
varies between laboratories, with some selecting to cut the hair while others 
select to grind it into powder form. 
Powdered hair is thought to be more homogeneous and suitable for comparative 
studies. 75 Hair that was ground using a traditional ball mill at room temperature 
produced better qualitative and quantitative results for drugs of abuse compared 
to cut hair due to the greater surface area in contact with the extraction 
medium. " Another study which used a cryogenic grinding device confirmed 
these findings when ground hair produced better quantitative results. However 
cut hair was shown to be the better preparation method for qualitative results 
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for drugs of abuse. " A common finding with the hair grinding method is that 
there is a significant loss of hair fragments retained in the ball mill. One 
laboratory noted that the differences between cutting and grinding were not 
very large and recommended a fast cutting procedure with a razor, scalpel or 
scissors. " 
2.12 Extraction Methods 
Several different extraction procedures have been reported for the extraction of 
drugs and their metabolites from the hair matrix. Some of these include acidic 
hydrolysis", alkaline hydrolysis82, enzymatic hydrolysis", direct solvent83 or 
buffer extraction84 and other less conventional methods such as supercritical 
fluid extraction8' and subcritical fluid extraction. 86 
Following the removal of the drugs and their metabolites from the hair matrix, 
the extraction procedures used are very similar to those used for blood and urine 
testing. " Solid-phase extraction (SPE) using different kinds of columns 51,73,88,89°82 
and liquid-liquid extraction (LLE)11'91,9' are commonly used but less conventional 
methods such as solid-phase micro-extraction (SPME)92°93 and molecularly 
imprinted solid phase extraction (MISPE)94°95 have also been reported. 
The two main types of extraction involve digestion of the hair matrix and 
extraction of drug from the undigested hair matrix with subsequent extraction 
using SPE or LLE. Extraction conditions cited in the literature differ in pH, 
temperature and duration of extraction. The extraction method chosen for a 
particular drug depends on its chemical properties, such as pKa value, as well as 
its chemical stability. For example, sodium hydroxide is a good solvent for drug 
extraction mainly because of the destruction of the protein hair matrix however 
it is not suitable for 6-MAM which is chemically unstable in sodium hydroxide. 
Enzymatic and direct solvent extractions using methanol for example, are less 
harsh than alkaline hydrolysis methods, which can destroy the drug as mentioned 
above. Extractions using B-glucuronidase and methanol do not completely 
dissolve the hair matrix and are advantageous in drug screening. 96 Alkaline and 
acidic hydrolysis extractions are however very efficient as they completely 
solubilise the hair matrix, producing better drug recoveries than direct 
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extraction with organic solvents. Therefore if a drug is chemically stable, 
hydrolysis extraction methods are preferred. 
A potential problem associated with hydrolysis extraction is that drug 
metabolites may be formed, which could result in false results. An example of 
this is 6-MAM, which can degrade during acidic or alkaline hydrolysis to form 
morphine. The choice of extraction is also influenced by the analytical method 
to be used in the subsequent analysis. 
2.13 Analytical Methods 
Radioimunoassay (RIA) was predominately used for hair testing for drugs of 
abuse before the introduction of mass selective detectors in GC-MS systems. 87 
Opiates were first detected using RIA in the hair of heroin abusers in 1979 and it 
initiated many investigations into drugs of abuse in hair. Since then, various 
methods including other immunoassays such as enzyme linked immunosorbent 
assay (ELISA) or chromatographic techniques have been reported. Immunoassays 
are useful as screening tests due to their sensitivity, speed and simple use. 
However immunoassays are usually semi-quantitative since the kits are specific 
to a group of target drugs or drug metabolites rather than a single target drug. 
Identification and quantification is carried out using chromatographic techniques 
which have been coupled with MS for excellent sensitivity and selectivity. 
Gas chromatography (GC) coupled with mass spectrometry (MS) is the most 
commonly used chromatographic method and has been widely applied in the 
detection of drugs of abuse in hair. ", " 35,37,38' , 51,50 Ion spray liquid 
chromatography-mass spectrometry (LC-MS) is also used now and is becoming 
more popular due to its high sensitivity and shorter analysis time as unlike GC- 
MS, there is no derivatisation step required. 97 Capillary zone electrophoresis has 
also been applied in quantitative hair analysis. 98'99 
2.14 Current International Hair Testing Guidelines 
The role of hair testing in toxicological applications has been widely discussed 
among various scientific bodies such as the Society of Hair Testing (SoHT), 
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Society of Forensic Toxicologists (SOFT) and the Substance Abuse and Mental 
Health Services Administration (SAMHSA). 
In 2004, international representatives of the SoHT published a set of 
recommendations for laboratories carrying out hair testing in forensic cases., " 
The areas agreed upon include; sampling, shipping and storage; 
decontamination; hair disintegration and extraction; screening test; criteria for 
mass spectrometric analysis; analysis of specific drug classes such as opiates, 
cocaine, amphetamines and cannabinoids; cut-off values; and internal and 
external quality control protocols. Higher cut-off values than those 
recommended by the SoHT have been proposed by SAMHSA for amphetamines 
and marijuana after consulting mainly with commercial hair testing companies. "' 
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3 Immunoassay 
3.1 Introduction 
The application of immunoassays as "initial screening tests" for drugs of abuse in 
urine specimens is well established and routinely practiced. Immunoassays have 
also been adapted as "initial screening tests" for detecting the presence of 
drugs and drug metabolites in a variety of other biological matrices. 
Immunoassays are generally defined as analytical systems that depend on 
specific antigen-antibody reactions for detecting target analyte(s) in different 
sample matrices. In drugs of abuse screening, immunoassay serves as a useful 
means of eliminating negative specimens from further confirmatory tests and 
also identifying any drug class that requires confirmation by a second step test. 
International guidelines for substance abuse management, including scientific 
protocols for initial drug screening and confirmatory analysis, have been 
developed by a number of government agencies, professional organisations and 
forensic or clinical societies. Immunoassay systems have mainly been designed 
to meet the guidelines stipulated by the Substance Abuse and Mental Health 
Services Administration (SAMHSA). SAMHSA has provided cut-off values and 
quality control requirements for initial drug screening in workplace testing which 
were published in the Federal Register in 2004.98 A sample containing drugs 
below the cut-off is reported as negative for screening. However, if a sample 
screens in the initial test as positive, a confirmatory test that exploits a 
different chemical principle to immunoassay is used to specifically identify and 
quantify the presence of a drug and/or metabolite. The joint Forensic 
Toxicology Laboratory Guidelines provided by the Society of Forensic 
Toxicologists and American Academy of Forensic Sciences (SOFT/AAFS) specifies 
a minimal requirement for laboratories to perform immunoassay. " A second 
immunoassay can be used to support the initial screening result prior to 
confirmation but cannot be used to confirm the results of another immunoassay 
result. 
Immunoassay 
3.2 General Overview 
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In the last 35 years, analytical methods that rely on specific analyte recognition 
by high affinity binding proteins have been applied in many diverse areas of 
biochemical analysis to the extent that they are now regarded as representing a 
standard analytical principle. Although there are various kinds of naturally 
occurring high affinity specific binding proteins such as hormone receptors, it is 
the unique properties of antibodies including their high affinity, specificity and 
range of antibody-antigen binding reactions that have resulted in their 
widespread use in protein binding assays in routine analyses and also in research. 
Antibodies have some advantages compared with other binding proteins. They 
are stable, soluble and abundant. There are standard procedures for antibody 
preparation, selection, isolation, coupling and immobilisation. They are suitable 
for the detection of antigens and non-antigenic small molecules (molecular 
weight > 150 amu). They are available as a polyclonal mixture (with related 
binding specificities for a variety of analytes) or as a monoclonal mixture (with a 
single binding specificity for a particular analyte). They can be modified and 
systematically improved with recombinant DNA methods. "' 
There are many different immunoassay systems however all commonly rely on 
the specific molecular recognition of antigen-antibody binding interactions to 
detect minute drug quantities in complex biological matrices. The antigen- 
antibody binding pair has been described as "a form of ligand and receptor 
binding pair". 103 Most immunoassays use a label attached to either the antigen 
(ligand) or the antibody (receptor) which is fundamental to the measurement of 
the binding interactions between the pair. Immunoassays are named according 
to the label used in the particular system. A label is any substance which can be 
chemically attached to either an antigen or antibody to enable a measurable 
property necessary for the specific immunoassay. Some examples of the types of 
label chosen for adequate sensitivity include radioisotopes, fluorescence and 
enzymes. 
Immunoassays for small molecules such as drugs of abuse operate as a 
competitive immunoassay. Free drug in the sample competes with drug- 
derivative reagent for the binding sites on a specified amount of antibody. 
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Drugs of abuse molecules are known as `haptens' since they are not naturally 
immunogenic and have to be coupled to an antigenic carrier molecule to induce 
antibody formation. Central to the development of a successful competitive 
immunoassay system is the design and synthesis of two suitable haptens, namely 
one for "immunogen" and the other for drug derivative. 103 The immunogen is 
designed to produce a selective antibody with the required reactivity 
characteristics when introduced into a suitable host animal. The "activated 
drug derivative" possesses a suitable molecular linker to allow coupling to a 
carrier or labelling molecule. The drug derivative has a similar chemical 
structure and immunogenic properties to the analyte(s) of interest and this 
enables successful competition between the free drug in the sample and the 
drug derivative reagent for antibody binding. 
There are two types of competitive immunoassay, heterogeneous and 
homogeneous, depending if there are additional steps in the process to separate 
the "antibody bound" complexes from the "free" drug in the sample and/or 
"free" drug derivative in the reaction mixture. Heterogeneous immunoassays 
such as enzyme linked immunosorbent assay (ELISA) use washing for example to 
remove the unbound labels, leading to an increase in the signal to noise ratio as 
the background noise from the labels has been removed as well as potential 
sample matrix effects. Heterogeneous assays can therefore achieve lower 
sensitivity levels compared with homogeneous assays. 
3.3 Enzyme Linked Immunosorbent Assay (ELISA) 
ELISA has become the most widely used immunoassay technology since its 
development in 1971-1972.103 An array of commercially available ELISA kits has 
been developed specifically for the purposes of drug testing in the forensic 
toxicology field. These have been applied in the detection of drugs of abuse in a 
variety of biological matrices including blood104'105, urine 'ob,, 07'108,, 09, serum, 
hair 84,108'109,,, 0,,,,,,,:,, 13' oral fluid 108,109,114,115, meconium, sweat and vitreous 
humor. 103,116 
ELISA is a solid phase, heterogeneous, competitive immunoassay system used for 
the highly sensitive detection of small drug molecules. The amount of bound 
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antigen or antibody is measured by a signal change produced by enzymatic 
catalysis. 
The ELISA tests are performed using microtitre plates coated with antibodies 
with a high affinity to the target drug. ELISA kits are supplied as microtitre 
plates (normally supplied as 12 x8 well strips), enzyme labelled drug derivative, 
substrate and stop reagent (Figure 3-1). 
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Figure 3-1 Typical contents of an ELISA kit as supplied by manufacturer 
A suitable aliquot of sample, standard or control is added to the corresponding 
well, usually in duplicate, followed by the enzyme conjugate. The reaction 
mixture is then left to incubate for typically 45-60 minutes to allow adequate 
time for drug binding, enhancing assay sensitivity. During the incubation period, 
the enzyme conjugate competes with the drug in the sample for the antibody 
binding sites on the wells. The most commonly used enzyme for drug ELISA is 
horseradish peroxidase (HRP). Azide buffer preservatives should be avoided as 
they affect ELISA performance by inhibiting the HRP enzyme. 
The wells are washed with deionised water or phosphate buffer in order to 
remove any unbound drug that may be present in the sample or any residual 
enzyme conjugate remaining in the wells. Blood samples with high haemoglobin 
levels can react with 3,3', 5,5'-tetramethylbenzidine (TMB) substrate used for 
the final colour development, resulting in high background noise. This washing 
step removes any background noise, effectively improving the assay sensitivity. 
Immunoassay 
Labeling Reagents 
TMB, a chromogenic substrate containing hydrogen peroxide, is then added to 
the wells and develops a blue colour with any bound enzyme conjugate. The 
colour development is a result of the enzyme label catalysing the oxidation of 
TMB in the presence of hydrogen peroxide. The darker the blue colour, the 
greater the amount of bound enzyme conjugate present and the lesser the 
amount of bound drug. The addition of dilute acid, such as hydrochloric acid, 
ends the catalytic reaction and hence the blue colour development. The well 
contents are turned yellow which allows greater sensitivity and a better 
separation of absorbance values compared with the blue colour produced by the 
TMB substrate, resulting in better discrimination between positive and negative 
results. A spectrophotometer is used to calculate the result by measuring the 
absorbance value at 450 nm. The various steps forming part of the ELISA 
procedure are illustrated in Figure 3-2. 
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Figure 3-2 General schematic of ELISA procedure' 17 
The absorbance value is inversely proportional to the concentration of drug in 
the sample. A sample producing an absorbance value less than that produced by 
the relevant cut-off standard is considered a presumptive positive whereas a 
sample producing an absorbance value greater than or equal to the cut-off 
standard is considered negative. The result is regarded as "qualitative" or 
"semi-quantitative" and the quantity of drug and/or metabolite in any sample 
Chapter 3,35 
Enzyme 
jfs Subfite 
Second Antibody la Product 
or 
Tarnet Analste 
w 
ti° 
Immunoassay Chapter 3,36 
cannot be determined by immunoassay. The assay is "semi-quantitative" since 
the result represents the total contribution of all the compounds in the sample 
that can compete for antibody binding sites and is normally not a definitive 
measurement resulting from binding of the target analyte. 
3.4 Antibodies 
3.4.1 Action and Structure 
In immunoassay systems, the antibodies are the active components derived from 
animal blood. Antigens are the specific part of the immunogen that are 
recognised by and react with antibodies. Antibodies are proteins which are 
produced by the B-lymphocytes of the immune system. The body manufactures 
antibodies in an attempt to destroy the antigen molecule. The antibodies bind 
to and block antigen activity. 
Antibodies make up a group of globular serum proteins called immunoglobulins 
(Igs). There are five main classes of immunoglobulins namely IgM, IgG, IgA, IgD 
and IgE. IgG is a 150,000 Dalton glycoprotein and the predominant fraction in 
serum which contains the antibodies and hence is mainly used in drug screening 
tests. 102 The antibody reagent must be of high purity for the purposes of binding 
affinity, specificity and cross-reactivity and so IgG fractions are purified by 
affinity chromatography. 
A typical antibody molecule has two identical antigen binding sites which are 
specific to the antigen which caused the immune response. The structure of an 
antibody molecule consists of four protein chains, two of which are heavy (H) 
identical chains and two of which are light (L) identical chains. The H and L 
chains in IgG for example are 420 and 215 residues respectively. "' They are held 
together by disulfide bridges to form a Y-shape. Each antibody molecule can 
bind 2 molecules at one time, on each `arm' of the Y-shape. There are variable 
(V) regions of the H and L chains positioned at the tips of the Y `arms'. The 
amino acid sequence in these regions varies significantly between antibodies. 
An H chain variable region and an L chain variable region together form a unique 
binding site, which accounts for the high antibody specificity. The "tail" of the 
Y-shaped antibody molecule is formed by the constant (C) regions of the H 
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chains which are responsible for distribution in the body and for the mechanisms 
involved in antigen disposal, show very little variation in amino acid sequence 
between antibodies. "' Immunoglobulin molecules demonstrate flexibility, 
particularly at the "hinge regions" of the H chains as this aids their binding to 
adjacent specific antigens and also allows the aggregation of soluble antigens. "' 
A typical two-dimensional structure of an antibody is illustrated in Figure 3.3. 
The H chains are represented in blue while the L chains are in red. 
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Figure 3-3 Typical two-dimensional antibody structure' 18 
3.4.2 Immune Response 
Antibody production is stimulated by introducing an antigen into a host animal 
such as a rabbit. The primary immune response is the selective proliferation and 
differentiation of B and T lymphocyte cells that occurs the first time the body is 
exposed to a given antigen. During this phase, there is a time lag of about 7 
days before antibody-secreting cells are produced. It takes about 10-17 days 
following the initial exposure to antigen to generate the maximum response to 
antibody production, which is relatively small compared to the secondary 
response. "' The secondary immune response is specific and occurs when the 
body has had at least one prior exposure to the same antigen. A faster, larger 
and more prolonged response is produced due to the presence of long-lived 
memory cells. Figure 3-4 shows the differences between the primary and 
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secondary immune responses for antibody concentrations in blood serum over 
time. 
Second exposure . ndarý 
104 to antigen A, : »ºnniºne 
first exposure )ý. ne to 
ti f 
to antigen B antigen A 
1#)' First exposure 
to antigen A 
X X, 
loll 
100 
ý4f 
7 14 21 28 33 42 49 36 
Time (days) 
Figure 3-4 Primary and secondary immune responses for antibody concentrations in blood 
serum over time19 
IgM specific antibodies are initially produced in the primary immune response 
followed later by IgG. IgG is produced during the late primary immune response 
and also during the secondary immune response. It is used in protein binding 
assays for routine analyses and research since it is the predominant fraction in 
serum and also because IgG antibodies bind to antigen with a higher affinity than 
IgM antibodies. "' 
3.4.3 Antigen-Antibody Binding 
Antigen-antibody binding is a reversible process. In high-affinity binding 
interactions, the ease of association outweighs the ease of dissociation. During 
association, repulsive forces between atoms on the antibody-binding site 
(paratope) and the antigenic determinant region (epitope) of the specific 
protein antigen are overcome so that subsequently, attractive interactions such 
as hydrogen bonds, ionic bonds and van der Waals forces can occur. 
A collision between the antigen and antibody must take place before an 
interaction is established. The collision rate depends on the diffusion rate, 
which, in turn, is affected by molecular shape and mass, reactant mobility and 
temperature. Hence, haptens generally associate more readily with their 
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specific antibodies than large antigens. As well as temperature, other 
physicochemical conditions which influence antigen-antibody binding in an 
aqueous environment include pH, ionic strength and the presence of other ionic 
species in the sample that could also potentially bind. The effects of these 
conditions are discussed in section 3.5. 
Antigen-antibody interactions reach equilibrium slower when the antigen or 
antibody is immobilised to a solid phase surface, such as microtitre wells, 
compared to when both are free to diffuse. This is because the potential for 
interactions in microtitre wells is reduced since the area is small and the antigen 
or antibody is localised. Consequently, many automated immunoassays requiring 
short incubation times exploit either the use of microparticulate solid phase 
material or binding reactions occurring in the liquid phase. 
Antibodies bind strongly to antigens in a similar way to enzyme-substrate 
binding, via a "lock and key" mechanism (Figure 3-5). They do not bind via 
covalent chemical bonds but via electrostatic forces, van der Waals forces, 
hydrogen bonds and hydrophobic bonds. Binding therefore depends upon short 
range factors hence the need for a highly specific association between antibody 
and antigen. Antigen binding can be reversed by high salt concentration, low 
pH, denaturing agents such as urea, organic solvents, heat and competitive 
antigens. 
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Immunoassays can be designed using polyclonat or monoclonal antibodies 
depending on how the antibodies are manufactured. Polyctonal antibodies bind 
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less specifically and so are useful for screening for a group of related drugs such 
as opiates. Monoclonal antibodies on the other hand are highly specific for a 
particular drug such as morphine. 
3.5 Variables Influencing Evaluation of Results 
3.5.1 Inter-Individual Variations 
Inter-individual variations, diet and medication are some of the contributing 
variables that can influence the outcome and interpretation of immunoassay 
results. Pharmacogenetic and physiological variations exist between every 
individual and these ultimately affect the drug metabolism and excretion 
profile. Ingestion of certain foods or medication can result in the need for more 
complex interpretation of drug screening results. "', "' 
3.5.2 Sample Adulteration 
There are many readily available adulterants and urine substitutes that are 
designed to defeat drugs tests. Some of these are produced specifically for 
"passing" a urine drug test, while others are common household products. 
These can be easily researched or purchased via the Internet. A recent search 
using the Internet and psychiatric and medical literature identified a 
comprehensive list of products, compounds and tampering methods, including 
data on their efficacy. "' Methods for tampering with a sample can be associated 
with three basic categories: in vivo adulteration which is the ingestion of a 
chemical prior to sample collection such as sample dilution by excessive water 
consumption; in vitro adulteration which is the addition of a foreign substance to 
a sample after collection; and urine substitution which occurs when a sample 
negative for drugs is substituted for a drug positive sample during sampling. 
SAMHSA (2004) guidelines recommend that a number of validity checks are 
carried out for urine drug screens, including temperature, pH, creatinine, 
specific gravity (when creatinine < 20 mg/100 ml-) and tests for oxidising 
adulterants. "' 
In vitro adulteration can pose a problem in immunoassay; particularly in urine 
testing since it can potentially interfere with the immunoassay detection system 
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by decreasing absorbance rates124 or convert a target drug into a compound that 
is not detected by screening or confirmation methods. "' The commercially 
available in vitro products are marketed under a variety of brand names but are 
essentially limited to the same active ingredients including: glutaraldehyde, 
sodium or potassium nitrate, pyridinium chlorochromate (PCC) and 
peroxide/peroxidase. There is conflicting results in terms of the tampering 
effectiveness of these adulterants in producing false negative immunoassay 
results. The discrepancy in effectiveness is probably due to differences in the 
urine drug concentrations and/or the concentration of adulterant. "' Both 
AdultaCheck 6 and Intect 7 urine test strips were shown to successfully detect 
the presence of glutaraldehyde, nitrite and PCC in urine and could be used as a 
means of checking sample integrity. 126 The presence of some in vitro household 
products such as sodium chloride, bleach, vinegar, Visin& eye drops, 
detergent/soap, ammonia, aspirin, ibuprofen, riboflavin (vitamin B2) and golden 
seal tea have been shown to interfere with immunoassay by affecting drug 
binding. 121,122'123,, 240250279128 
3.5.3 Cross Reactants 
Antibodies developed for a particular drug can cross-react with other 
structurally related or unrelated drugs or even endogenous compounds present 
in the sample matrix. Cross reactivity is a measurement of antibody response to 
substances that are not the target analyte. An understanding of assay cross 
reactivity and potential interference is crucial in the interpretation of 
immunoassay results. Some structurally unrelated medications can possess three 
dimensional conformations that have a weak but sufficient binding affinity for 
some particular antibodies. ` 
The presence of over the counter sympathomimetic amines, pseudoephedrine 
and diphenhydramine, in blood samples taken from non-decomposed bodies, 
produced a large proportion of false positive screening results using an 
amphetamines ELISA system. 12' It was proposed that ingestion of over the 
counter medication, pholcodine, was the cause of four false positive hair results 
for samples that had been screened using an opiates ELISA system. "' This 
finding was supported in another study where pholcodine, rifampicin and 
ofloxacin were found to cross react with an opiates ELISA system. "' Some 
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examples of other published cases include the cross reactivity of oxaprozin with 
a benzodiazepines assay and ranitidine with a methamphetamine assay. "', "I 
Some sample pretreatment procedures have been proposed to reduce the effects 
of immunoassay cross reactivity such as the use of glucuronidase hydrolysis to 
enhance the sensitivity of the benzodiazepines assay. "' 
As well as the potential presence of drugs and/or adulterants in a sample, there 
may be cross reactive endogenous sample components present such as 
putrefactive amines. Phenethylamine could be present in decomposed blood 
and it has been reported to contribute to a large proportion of false positive 
results due to its cross-reactivity with an amphetamines ELISA system. "" 
Phenethylamine is structurally very similar to amphetamine, differing only by a 
methyl group (Figure 3-6). Furthermore, the sensitivity of the ELISA screening 
was shown to increase from 87.2 % to 93.6 % when the known decomposed blood 
samples were removed from the analysis. 127 
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Figure 3-6 Molecular structures of amphetamine and phenethylamine 
3.6 Coupling 
In order to be immunogenic, molecules have to have a molecular weight 
> 5000 amu. Drugs of abuse molecules are known as `haptens' since they have 
relatively low molecular weights of 100-500 amu and are not naturally 
immunogenic. Haptens are transformed to immunogens by coupling to a 
macromolecule such as bovine serum albumin (BSA), for example 20-30 hapten 
molecules per BSA molecule. 102'132'133 Coupling produces an immunogen capable 
of manufacturing antibodies specific to free hapten which binds with high 
affinity. When a particular hapten complexes with an antibody-binding site, or 
paratope, it is generally located in a cavity which possesses functional groups of 
the peptide residues and backbone that are complementary in structure to the 
binding regions of the hapten molecule. High affinity paratopes often produce 
complexes in which the hapten is buried by 80-90 % or more. 102 
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The site of coupling is a crucial consideration as it determines the antibody 
specificity. The coupling site affects the cross-reactivity of the antibody and 
can be altered to increase or decrease the cross-reactivity as required. An 
example is the coupling site on morphine. When the morphine molecule is 
coupled through the 3-position, the antibody demonstrates a higher cross- 
reactivity with codeine than morphine. This is because codeine has a greater 
structural similarity with the immunising group coupled to the 3-position 
compared to morphine itself. In contrast, if the morphine is coupled through 
the nitrogen, the cross reactivity of morphine is higher than codeine as morphine 
has a greater structural similarity to the molecule coupled through the nitrogen 
compared to codeine. Figure 3.7 shows the molecular structure of morphine and 
codeine with the two potential coupling sites indicated on morphine. 
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Figure 3.7 Molecular structures of morphine and codeine with potential coupling sites 
indicated on morphine 
3.7 Advantages of ELISA 
Radioimmunoassay (RIA) has been used in the past as a screening technique due 
to its reliability and its ability to detect low drug levels in a wide range of 
biological samples whilst remaining relatively unaffected by sample matrix 
effects. The use of radioactively labelled material does however prevent its 
performance out with safe areas and consequently a non-radioactive technique 
such as ELISA is a safer and highly sensitive alternative. ELISA and RIA were 
evaluated as screening procedures for post-mortem samples for nine major drug 
classes and ELISA was found to be a suitable alternative to RIA. 134 
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From a practical viewpoint, the reagents used in ELISA have a longer shelf life 
than RIA reagents which are limited due to radioactive decay. ELISA lends itself 
well to automation and high throughput while RIA does not. In addition, RIA 
screening takes a longer time than ELISA screening, is more labour intensive and 
presents a higher risk of carry-over. "' 
ELISA is a fast and sensitive technique which can be used to screen large 
numbers of unknown samples. There is no need to extract blood and urine 
samples, which only require dilution with phosphate buffer. Although an 
extraction is required for hair screening, this takes a relatively short time. 
Small sample sizes are used in ELISA so matrix effects are minimised as there is 
less background interference with the developing colour. 
ELISA systems show varying degrees of cross-reactivity for the detection of drugs 
within a class. It is useful to detect the presence of a variety of drugs within the 
same drug class. ELISA kits have been adapted for specific use for drug 
detection in a variety of biological matrices. The cocaine ELISA system for urine 
for example targets benzoylecgonine, while the cocaine ELISA system for hair 
targets cocaine. 
3.8 Disadvantages of ELISA 
Drug immunoassays produce "semi-quantitative" results since the assay result 
represents the summative contribution of all drugs from a particular drug class 
in a sample that can compete for antibody binding and is generally not 
representative of a single target analyte. 
Absolute specificity, based solely on a binding reaction, is not achievable and 
this might be interpreted as a limitation of ELISA. Irrespective of the type of 
binding protein assay, there is a possibility that structurally related or unrelated 
drugs or even endogenous compounds present in the sample matrix could cross- 
react with the binding protein in the assay. Due to the increasing availability of 
many new over the counter and prescription medications, it is essential that the 
manufacturers of ELISA kits continually update the cross reactivity studies to 
allow accurate evaluation of immunoassay results. 
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A major limitation of using immunoassay in forensic toxicology is that antibodies 
are commercially available for a relatively small number of drugs, mainly for 
drugs of abuse as there is a large market for these kits. New kits are being 
manufactured to try to meet requirements however this is a huge task and is 
continually changing with the availability of new drugs. ELISA assays for new 
drugs of abuse such as methylphenidate (Ritalin®), fluoxetine (Prozac®), 
zolpidem (Ambien®), sertraline (Zoloft®) as well as other drugs such as 
paracetamol have recently been introduced onto the market. 136 
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4 Liquid Chromatography-Mass Spectrometry 
4.1 Introduction 
A combination of liquid chromatography and mass spectrometry (LC-MS) is a 
valuable analytical tool in various fields. The development of a suitable LC-MS 
interface that allows the LC mobile phase to pass into the mass spectrometer, 
which is held under vacuum, is central to the increasing number of published LC- 
MS applications over the last few decades. LC-MS has established itself as a 
complementary technique to gas chromatography-mass spectrometry (GC-MS) in 
the analysis of less volatile compounds and/or high molecular weight 
compounds. "' It has been estimated that almost 70 % of routine samples in the 
toxicology laboratory can be analysed by LC. 133 A clear advantage of LC is that 
unlike GC, time-consuming derivatisation steps are not generally required. An 
important practical advantage of LC-MS over GC-MS is that the optimisation of 
ionisation and MS parameters can be performed by the continuous infusion of a 
dilute solution of the analyte into the ion source, without the involvement of 
chromatography. 
Since the amount of energy transferred to the molecule during the ionisation 
process is small, electrospray ionisation (ESI) is known as a soft ionisation 
technique. As a result, pseudo molecular ions [M + H] ' or [M - H] "are readily 
formed, generally with little or no molecular fragmentation resulting in limited 
structural information. It is however suitable for quantitative analysis and 
benefits the sensitivity of MS-MS analysis as most of the total ion count (TIC) 
relates to one precursor ion in MS-MS mode. The formation of other charged 
species such as clusters with solvents such as acetonitrite ACN [M + 42] + and 
methanol [M + 32] + or adducts with sodium [M + 23] ', ammonium [M + 18] + or 
potassium [M + 39] + have been described for some compounds under the soft 
ionisation ESI technique. The use of cluster ions or adducts as precursor ions can 
lead to poor reproducibility so the protonated or deprotonated pseudo molecular 
ions should be used where possible. 
LC-ESI-MS/MS has been used to analyse various drugs of abuse including 
opioids134,135,136,137,138,139,140 benzodiazepineSl4lol42,143,144,145,146,147 amphetamines2,137,148,149 
and cocaine and its metabolites134,135,137P 139P 150P 151 as in this thesis, as well as 
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other drugs of abuse such as cannabinoids139''s'''58 and LSD'59''6o in a variety of 
biological matrices. Some studies have developed ESI methods for screening and 
quantifying drugs from multiple drug classes. 
97,141,143,161,162 
In this thesis, a Thermo Finnigan LCQTM' Deca XP Plus instrument was used for 
method development and validation. The instrument has three main 
components namely an LC system, ESI interface and a mass spectrometer 
detection system; hence these will be discussed in subsequent sections of this 
chapter. 
4.1.1 Liquid Chromatography 
LC is a powerful separation technique that can be operated in both normal- 
phase (NP) and reverse-phase (RP) mode. Both modes of chromatography rely 
on two phases, namely the stationary phase and mobile phase. Generally, the 
separation is achieved by differential migration of analytes through a 
microparticulate solid stationary phase. A liquid mobile phase consisting of a 
single solvent or buffer/solvent mixture is degassed, filtered and blended (if a 
mixture is required) before flowing through the stationary phase to elute the 
analytes. All analytes differ in polarity and are therefore retained on the 
stationary phase for different amounts of time. Furthermore, analytes will 
respond differently depending on the type of stationary phase and mobile phase 
system used. 
In NP chromatography (NPC), the stationary phase is of higher polarity than that 
of the mobile phase hence is commonly used for the analysis of relatively non- 
polar analytes. Silica is used as the stationary phase in combination with non- 
polar solvents such as dichloromethane and hexane. Since these solvents are 
hazardous to health and the environment, NPC is avoided in most Laboratories. "' 
In LC-MS applications however, RP chromatography (RPC) using aqueous mobile 
phases has been the most widely applied. RPC is suitable for the analysis of 
polar analytes since the polarity of the mobile phase is higher than that of the 
stationary phase. There is a range of non-polar silica-bonded stationary phases 
available, with C18 being the most popular. The solvents typically used for the 
mobile phase, in combination with an aqueous buffer are acetonitrile and 
methanol, which are less hazardous and easier to handle compared with the 
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solvents used in NPC. NPC may however be more suited in the analysis of drug 
enantiomers, for example, which require chiral stationary phases. 
4.2 Liquid Chromatography-Mass Spectrometry 
4.2.1 Mobile Phase Composition and Flow Rate 
The composition of the mobile phase, type and concentration of buffer and 
organic modifier are extremely significant as they affect the separation and 
ionisation of analytes. 1 One study demonstrated that formic acid produced a 
response that was 10 times higher than trifluoroacetic acid using a low buffer 
strength of 2-3 mmol/L. 765 The separation ability however decreases as the 
buffer strength decreases. A high organic percentage of the mobile phase 
favours ion formation as solvent evaporation efficiency is improved and hence 
the ion yield passing into the mass analyser is increased. "' Therefore, a 
compromise between chromatographic separation and ion signal intensity has to 
be reached. 
Usually, the LC-MS mobile phase is comprised of an aqueous buffer and an 
organic solvent. Buffer selection is important not only to achieve and control 
the pH of the LC mobile phase but also because of some practical 
considerations. In LC-MS, non-volatile buffers should be avoided as they wilt 
precipitate in the ion source, resulting in clogging and impaired instrument 
performance i. e. reduction in signal intensity due to competition between 
analyte ions and electrolyte ions for conversion to gas phase ions. Therefore 
volatile buffers such as ammonium formate, ammonium acetate, acetic acid and 
ammonia must be used. Low buffer concentrations should be used to prevent 
saturation of the surface of the droplet, preventing the analyte from passing 
into the gaseous phase and ultimately lowering its response. At high buffer 
concentrations (> 10 mM), the ionisation efficiency is affected and the 
relationship between detector response and concentration is not linear. 166 
Liquid chromatography-mass spectrometry 
AH- OAc- 
A NH4- ° h 
NH4+OAc- AH+ """" 
AH+ 
A NH4+ 2 
AH+ NH4+ A AH+ ° 
A AH+ OA c- NH4+ 
NH4+OAc- 
A 
Figure 4-1 Surface competition between 
analyte and electrolytes 
Electrolyte concentration 
Chapter 4,49 
Figure 4-2 Decrease in analyte 
response with increasing electrolytes 167 
A pre-requisite of ESI is that the analyte exists as an ion in solution therefore the 
pH of the mobile phase should be carefully selected depending on the pKa of the 
analytes of interest and usually contains a small amount of volatile acid or base. 
A general rule of thumb is `basic analyte, acidic mobile phase and vice versa'. 163 
This is because an acidic mobile phase contains an excess of H+ ions which would 
ionise basic analytes by the addition of a proton. Conversely, a basic mobile 
phase contains an excess of OH' ions which would cause deprotonation of acidic 
analytes. The mobile phase carrying the analytes of interest is passed into the 
atmospheric pressure ionisation (API) source (typically in pL/min) through a 
fused silica inner capillary which is inserted through the sample inlet and ESI 
needle (Figure 4-3). 
As well as the composition of the mobile phase, the flow rate also affects 
ionisation. Higher signal to noise (S/N) ratios are achieved at lower flow rates 
since solvent evaporation is more efficient and ultimately the transmission of gas 
phase ions into the vacuum region is improved. 163 This explains why a drying gas 
(nitrogen) and a high probe temperature e. g. 300 °C are used to assist droplet 
formation and solvent evaporation. 
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Figure 4-3 Cross-sectional view of ESI probe assembly168 
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There are a wide variety of LC columns available to the analyst but one 
important consideration in selecting an appropriate column is that a higher 
organic concentration in the mobile phase improves the ionisation efficiency. If 
a more retentive column is used, the organic content can be increased in the 
mobile phase without losing chromatographic retention. "' Analyte retention on 
a column depends on the polarity of the analyte and stationary phase. The most 
widely used columns contain a chemically modified silica stationary phase, the 
most popular stationary phase being one in which a C18 alkyl group is bonded to 
the silica surface. 
The two basic types of stationary phase have been discussed in section 4.1.1, 
however, the binding sites on the stationary phase can be end-capped to 
improve chromatographic performance and increase column stability. An 
example is the use of polar end-capping with bonding of C18 alkyl chains, is a 
successful approach for the reproducible retention of polar analytes such as 
quaternary ammonium compounds under highly aqueous conditions. "' 
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The nature of the ESI interface is such that lower mobile phase flow rates are 
necessary for more efficient mobile phase evaporation and improved ionisation 
of analytes. Narrow-bore columns are therefore favourable for ESI. Typical 
dimensions are 150 mm in length with a 2.1 mm internal diameter. A reduction 
in the column bore size results in a decrease in the column volume. Since ESI is 
a concentration dependent process, this will result in a higher concentration of 
analyte per unit volume of mobile phase, thereby increasing the analyte signal. 
The choice of column dimensions and particle size dictates the maximum load on 
the column and the flow rate that can be used. Small particles in narrow-bore 
columns allow a shorter analysis time and improved selectivity but the 
backpressure of the column has to be compensated for by a lower flow rate. 
4.3 Electrospray Ionisation 
ESI and atmospheric pressure chemical ionisation (APCI) are regarded as the 
golden standards of LC-MS. 1° They are complementary techniques, with most 
analytes being sufficiently ionised by either or both ion sources. "' Furthermore, 
the two ion sources are usually interchangeable within the same instrument. In 
recent years however the family of API sources has expanded to include 
atmospheric pressure photo-ionisation (APPI), atmospheric pressure laser 
ionisation (APLI) and sonic spray ionisation (SSI), which have all contributed to 
the analytical potential of LC-MS. Other ion sources include thermospray 
ionisation (TSI), particle beam ionisation (PBI), fast atom bombardment (FAB), 
desorption electrospray ionisation (DESI) and matrix-assisted laser desorption 
ionisation (MALDI). 
Electrospray ionisation (ESI) was the first developed API source and to date is the 
most frequently used ionisation mode used in analytical toxicology. "' A 
literature review of metabolism studies for drugs of abuse and prescription drugs 
published in 2000 reported that ESI was used in 73 % of methods, with APCI being 
used in 23 % of methods. 71 ES! allows the determination of thermolabile, high 
molecular weight compounds such as proteins'"' and/or highly polar compounds 
such as quaternary ammonium compounds and herbicides. 169 
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The general ESI process involves four stages; droplet formation from the LC 
mobile phase, charging of droplets, desolvation of droplets and formation of 
analyte ions (Figure 4-4). A high voltage (typically 3-5 kV) is applied to the ESI 
needle which is sufficient to nebulise the liquid into highly charged droplets on 
exiting the needle. Depending on the voltage polarity, nebulised droplets 
containing the ionised analytes can be positively or negatively charged. For 
example, if a positive voltage is used then the droplets will be positively 
charged. These charged droplets are subsequently desolvated before passing 
through the ion sweep cone and into the analyser. Analyte ions are obtained 
directly from the liquid mobile phase droplets so thermally labile compounds do 
not suffer from degradation. 
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Figure 4-4 ESI process in positive ion mode168 
As droplet size decreases, the charged species move closer together and are 
repulsed. When this repulsion on the droplet surface is overcome by the 
cohesive forces of the surface tension, a coulombic explosion results where 
micro droplets with radii of -10 % those of the parent droplets are formed. 166 A 
series of these explosions occur until gas phase ions are produced from direct 
emission of the micro droplets then the sample ions enter into the API stack via 
an ion transfer capillary (Figure 4-5). 
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The ESI needle is orthogonal to the axis of the ion transfer capillary that carries 
the ions to the mass analyser. The reason for this is to keep the ion transfer 
capillary clean. The ion sweep cone is a mechanical barrier that prevents large 
droplets and particulates from entering the ion transfer capillary. 
Ions from the ion transfer capillary pass through the tube lens which has a 
voltage applied to it to focus the ions towards the opening of the skimmer. 
From the skimmer, ions move towards the ion optics assembly which focuses ions 
from the API source to the mass analyser. 
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Figure 4-5 Cross-sectional view of the API stack168 
4.4 Ion Optics 
sKW r1ER 
ti 
In the LCQTM' Deca XP Plus system, the ion optics consists of one quadrupole, one 
octapole, separated by an interoctapole lens which helps with ion focusing. The 
quadrupole and octapole are an array of square and cylindrical rods respectively, 
which act as ion transmission devices. An RF voltage and DC offset voltage is 
applied to the rods to create an electric field that guides the selected ions of 
particular m/z along the axis of the quadrupole/octapole into the mass analyser. 
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4.5 Ion Trap Mass Analyser 
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The ion trap mass analyser is also known as the quadrupole ion trap mass 
analyser and has been described as a three-dimensional quadrupole. 1 It 
consists of three stainless steel electrodes: the entrance endcap electrode, the 
exit endcap electrode; and the ring or `doughnut' electrode (Figure 4-6). The 
two endcap electrodes are hemispherical and are positioned above and below 
the ring electrode, to form a hyperbolic cavity. They each have a small hole in 
their centres to permit the passage of ions into and out of the ion trap. 
When sample ions of a specified m/z are held in a static position or `trapped', a 
radiofrequency (RF) voltage is applied to the endcap electrodes and the 
amplitude of the RF voltage applied to the ring electrode is ramped in order to 
facilitate ion ejection from the trap. As the voltage on the ring electrode is 
increased, trapped ions are selectively ejected out through the exit lens by 
increasing m/z into the ion detection system. Following the completed scan 
cycle, other ions are admitted into the trap and the process is repeated. As the 
ion trap operates in this mode, it is defined as a pulsed mass analyser. 166 Ion 
trap mass analysers allow MS-MS analysis by isolating specific product ions and 
fragmenting them by collision induced dissociation. 
Helium is present within the ion trap and is used as a damping gas and collision 
activation partner to greatly enhance sensitivity and mass spectral resolution. 
When sample ions enter the trap, they collide with helium atoms therefore 
reducing their kinetic energy and the amplitude of their oscillations. As a result, 
the ions migrate to the centre of the cavity where they are tightly focused in a 
long, narrow cloud. Helium atoms are also used in tandem mass spectrometry 
(MS-MS) for collision induced dissociation of precursor ions to product ions. 
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Figure 4-6 Cross-sectional view of the mass analyser 168 
4.6 Detector 
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Selected ions are passed from the ion trap mass analyser to the detector system. 
This system contains a conversion dynode and an electron multiplier. An ion 
strikes the surface of the conversion dynode, readily emitting secondary 
particles (Figure 4-7). These secondary particles are then focused by the curved 
surface of the conversion dynode and are accelerated into the electron 
multiplier by means of a voltage gradient. The electron multiplier contains a 
cathode and an anode. If the secondary particles from the conversion dynode 
strike the inner walls of the electron multiplier cathode with sufficient energy, 
electrons will be ejected. These electrons are accelerated further into the 
cathode by a potential gradient. As the cathode is funnel-shaped, the electrons 
continue to strike the inner walls of the cathode, creating an electron cascade 
which results in a measurable electric signal (current) and typically a signal gain 
of 106-107.166 The current is then converted to a voltage by an electrometer 
circuit for processing and recorded by the MS data system. 
; 
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Figure 4-7 Cross sectional view of the ion detection system showing the electron multiplier 
and conversion dynode168 
4.7 Matrix Effects 
A major problem with generating ions using API techniques is matrix effects 
(MEs) from biological matrices such as blood, urine and hair. Ion suppression or 
enhancement of analyte ionisation by co-eluting compounds is known as matrix 
effects. MEs depend mainly on the sample matrix, sample preparation method, 
quality of chromatographic separation, mobile phase additives and type of 
ionisation used. The exact mechanism of MEs is yet to be established but it is 
generally believed to originate from the competition between an analyte and 
the co-eluting matrix component in the ion source. ESI is particularly prone to 
matrix effects, more so than APCI. This is because of the presence of excess 
reagent ions which produce charged species in APCI; hence the APCI ionisation 
process is less susceptible to MEs. 163 
Since analyte ionisation depends on the matrix constituents present, this can 
pose problems when the matrix is not consistent between individuals. As a 
result, validation parameters such as limit of detection (LOD), limit of 
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quantitation (LOQ), linearity, precision and accuracy will be affected. 
Therefore an evaluation of MEs should form a central part of the validation of 
any LC-MS procedure. The use of deuterated internal standards helps to 
minimise MEs since they elute close to the analyte and are therefore affected by 
matrix constituents in the same way as the analyte. 
Two different approaches have been described in the literature for assessing 
MEs. The first approach involves the continuous infusion of a solution of the 
analyte into the mobile phase from the column via a post-column T-connection 
and a syringe pump. 13'"4 Simultaneously, an injection of extracted blank matrix 
is performed. A constant signal in the detector is produced unless compounds 
are present which suppress or enhance ionisation. Such compounds would result 
in a decreased or increased signal respectively. Potential MEs and their 
retention times can be identified by monitoring the detector response following 
the injection of blank extracted matrix components. A strategy for assessing the 
MEs quantitatively is to determine the peak areas of analyte in two different 
sets of samples. The first set consists of standards prepared in neat mobile 
phase (set A). The second set are extracts using blank matrix from different 
sources which are spiked after extraction (set B). From this data, the ME (%) can 
be calculated by dividing set B by set A and multiplying by 100.15 Values greater 
than 100 % are indicative of ion enhancement while values less than 100 % are 
indicative of ion suppression. 
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5 Buprenorphine in Urine 
5.1 Buprenorphine 
Buprenorphine is a semi-synthetic opioid derivative of thebaine. It has a 
chemical structure which is closely related to morphine (Figure 5-1) and at low 
doses (typically 0.3-0.6 mg intravenous or intramuscular) is a powerful analgesic, 
with 25 - 40 times the potency of morphine. "' The binding potential of opioids 
to brain receptors is related to analgesia therefore buprenorphine binds tightly 
to the p- and K-opioid brain receptors, acting as a partial agonist and antagonist 
when bound to the respective receptor types. "' In nave users, buprenorphine 
demonstrates agonist activity, similar to morphine while in addicts it acts as an 
antagonist, producing withdrawal symptoms. The kinetics of the opioid 
receptors is slow; hence the duration of action is long-lived. "' 
Buprenorphine was developed by Reckitt Et Colman Products with a view to 
producing a useful analgesic with greater safety and a lower chance of abuse 
compared with other opiate agonists. 13 Buprenorphine has been prescribed in 
the United States since the early 1980s under the tradename Buprenex® and in 
most European countries as Temgesic® as a treatment for pain relief (especially 
for surgical purposes) and in anaesthesiology. More recently, it has been 
identified as an alternative medication to methadone for the treatment of 
heroin addiction. Under the tradename Subutex®, high dose tablets (0.4,2 and 
8 mg) are administered sublingually for this purpose. 
In Scotland from 2006-2007, the number of buprenorphine prescriptions for use 
in drug dependence was 9,100 compared to 457,045 methadone prescriptions. ` 
Buprenorphine has not been identified as a contributor in either drug-related 
deaths or impaired driving in the Strathclyde region of Scotland in 1995- 
2007.1 . 576.177 Another study into drug-related deaths in Edinburgh and Glasgow in 
1990-1992 found buprenorphine to be present in one case M The authors 
concluded that the small number of positive samples implied that the drug is 
very unlikely to cause death. However it is more likely that buprenorphine was 
not commonly prescribed at that time for the treatment of heroin addiction. 
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In contrast, buprenorphine is used widely in France for the treatment of 90,000 
heroin addicts184 where, in fact, a black market has developed with frequent 
misuse by intravenous injection. "' Furthermore, buprenorphine abuse by 
intravenous injection of crushed tablets meant for sublingual use contributed to 
the deaths of 20 heroin addicts. "' A study in the Nord-Pas-de-Calais region of 
France in 2003-2004 which tested for drugs of abuse in 1000 urine samples 
collected from truck drivers confirmed the presence of buprenorphine in 1.8 % of 
positive samples. "' 
5.2 Pharmacokinetics, Metabolism and Excretion 
The pharmacokinetic and physicochemical data for buprenorphine are shown in 
Table 5-1. 
Table 5-1 Pharmacokinetic and physicochemical data for buprenorphine176 
Half Life (hr) Vd (L/kg) Protein Binding (%) p' 
Buprenorphine 2-4 2.5 96 8.5,10.0 
Buprenorphine is rapidly metabolised in the liver by the cytochrome P450 
CYP3A4 system. During metabolism, it becomes N-dealkylated to form 
norbuprenorphine, which is also pharmacologically active (Figure 5-1). 
Buprenorphine is predominantly cleared from plasma by biliary excretion 
following conjugation with glucuronic acid or N-dealkylation and conjugation. 
However a small amount of drug and metabolites is cleared slowly by the 
kidney. "' Within 144 hours of a single intramuscular dose of radiolabelled 
buprenorphine, 95 % is eliminated with 68 % radioactivity measured in the faeces 
and 27 % in the urine. 176 
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Blood concentrations of buprenorphine can be very low since only low doses are 
required in the treatment of pain due to its high potency. A2 mg sublingual 
dose of buprenorphine administered to 6 healthy adults produced an average 
peak plasma concentration of 1.6 ng/mL after 1.3 hours. 116 Opiate-dependent 
subjects taking an 8 mg sublingual dose of buprenorphine each day as part of 
their maintenance therapy were shown to have a plasma drug concentration 
range of 1-8 ng/mL. 187 Therapeutic concentrations of free buprenorphine in 
urine can also be low (less than 1 ng/mL), requiring sensitive methods of 
detection. "6, t76,184 In contrast, free buprenorphine and norbuprenorphine 
concentrations greater than 20 ng/mL urine have been observed in cases of 
abuse. 106'184'188 
5.3 Toxicity 
Symptoms associated with buprenorphine overdose include confusion, dizziness, 
pinpoint pupils, hallucinations, hypotension, respiratory difficulty, seizures and 
coma. Concentrations found in the blood and urine of a drug addict who had 
died following intravenous injection of buprenorphine were 3.0 and 616 ng/mL 
buprenorphine and 3.1 and 48 ng/mL norbuprenorphine respectively. ", Average 
post-mortem concentrations found in the blood and urine of 20 heroin addicts 
who had intravenously injected buprenorphine meant for sublingual use were 8.4 
and 172 ng/mL buprenorphine and 2.6 and 67 ng/mL norbuprenorphine. 185 
More than 150 fatal overdoses involving the combined use of buprenorphine and 
psychotropic drugs (in particular benzodiazepines and neuroleptics) have been 
reported in France. "" A study in Singapore also highlighted that concurrent 
HO---r-tBu 
Me 
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administration of buprenorphine and benzodiazepines was potentially fatal. "' 
Interestingly, an Australian study reported a greater number of opioid toxicity 
symptoms in relation to methadone consumption compared to buprenorphine in 
concurrent benzodiazepine users. 192 
5.4 Previously Reported Methods of Analysis 
Buprenorphine detection in urine has been reported using 
immunoassay106'107,, 84,193,194, thin layer chromatography195, high performance liquid 
chromatography (HPLC)193,196' 
GC_MS194,197,198 and LC_! S. 106,107,184,186'191'199 
ELISA has been widely used for the determination of buprenorphine in urine for a 
number of different purposes. It has proved useful in the rapid screening of 
large numbers of post-mortem samples184i191 and also in a clinical setting for the 
rapid measurement of urine concentrations in maintainence programmes. 107084,194 
ELISA has also been applied in the urine testing of truck drivers in France in the 
interests of road safety. 181 
As discussed in chapter 3, this method of detection is highly sensitive but is not 
specific due to the potential antibody cross reactivity with drug metabolites and 
other structurally similar compounds other than the target drug. A 
buprenorphine ELISA system by the International Diagnostics Systems 
Corporation showed no cross-reactivity with dihydrocodeine, ethylmorphine, 6- 
monoacetylmorphine, pholcodine, propoxyphene, dextromoramide, 
dextrometorphan, codeine, morphine, methadone and EDDP. 184 Another 
buprenorphine ELISA system by the Immunalysis Corporation demonstrated no 
cross-reactivity with dihydrocodeine, codeine, morphine, methadone, EDDP, 
tramadol and propoxyphene. 107 Standard buprenorphine immunoassays cross- 
react with the major metabolite, norbuprenorphine to a relatively high extent 
depending on the concentration of norbuprenorphine that is present. This is an 
advantage since norbuprenorphine concentrations are generally higher than 
buprenorphine concentrations. 116,107097099 
A recently published HPLC method describes the combined use of solid-phase 
extraction and an HPLC system using diode array detection (DAD) to detect 
buprenorphine and norbuprenorphine in urine samples obtained from drug 
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addicts on a therapy programme. 197 The advantages of using this method include 
the use of small sample volumes, high extraction efficiencies for both 
compounds (>_ 97 %) as well as good levels of precision (<_ 4.9 %) and highly 
purified extracts. The LOD was determined to be 0.5 ng/mL and 0.2 ng/mL for 
buprenorphine and norbuprenorphine respectively. One urine sample taken from 
a patient who was receiving 16 mg/day buprenorphine contained 51.7 ng/mL 
buprenorphine and 50.4 ng/mL norbuprenorphine. A disadvantage of using this 
method is that the linearity range for both compounds was 10.0-1500 ng/mL 
which is acceptable for quantification of the sample concentrations in this study 
but would need to be extended to include lower concentrations if lower doses 
were being administered. As mentioned previously, therapeutic urine 
concentrations as low as 1 ng/mL free buprenorphine have been observed. 106 
The first HPLC method with electrochemical detection for the detection of 
buprenorphine and norbuprenorphine in urine samples was published 15 years 
ago. 793 The extraction involved a three-step alkaline toluene extraction and 
reported limits of detection were 0.2 ng/mL buprenorphine and 0.15 ng/mL 
norbuprenorphine. The HPLC results in this study were compared to RIA which 
was only able to detect buprenorphine concentrations higher than 1 ng/mL. 
A GC-MS method involving solid-phase extraction has been reported to analyse 
buprenorphine and norbuprenorphine in urine after therapeutic doses, which 
was linear from 1-100 ng/mL. 198 Urine samples were hydrolysed using B- 
glucuronidase and subsequently converted to their methyl derivatives by 
extractive alkylation. The LOD for both compounds was determined to be 
0.2 ng/mL, with high recovery values of 92 % and 104 % for buprenorphine and 
norbuprenorphine respectively. Free norbuprenorphine was detected in urine in 
the range of 0.4-1.7 ng/mL following a single 0.2 mg sublingual dose of 
Temgesic®. Buprenorphine levels were however below the method's detection 
limit. A more recent GC-MS method involving liquid-liquid extraction of urine 
was developed for the purposes of monitoring buprenorphine withdrawal 
protocols, which was linear up to 2000 ng/mL for buprenorphine and 
norbuprenorphine. 197 Like the previously mentioned GC-MS method, urine 
samples were hydrolysed using B-glucuronidase to cleave the conjugates but a 
different derivatisation method involving bis (trimethylsilyl) trifluoroacetamide 
(BSTFA) containing trimethylchlorosilane (TMCS) was used. A higher LOD was 
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found for buprenorphine and norbuprenorphine (1 ng/mL for both) compared to 
the other method mentioned, with lower recovery values of 59 % and 58 % 
respectively. Buprenorphine and norbuprenorphine concentration ranges were 
28-1458 ng/mL and 28-1843 ng/mL respectively. 
There have been several LC-MS methods published over the last decade for the 
determination of buprenorphine and norbuprenorphine in urine. This is mainly 
because of easier sample pre-treatment required for LC-MS compared to GC-MS 
which requires a derivatisation step. 
LC-ESI-MS with a single quadrupole mass spectrometer was used to detect both 
compounds using a linear LC gradient system in a variety of matrices including 
urine, blood and hair. "' Urine samples were hydrolysed overnight with 6- 
glucuronidase and the analytes isolated using a single liquid-liquid extraction 
step with a mixture of chloroform /propan-2-of/heptane (25: 10: 65, v/v/v). 
Extraction recovery for buprenorphine was greater than 80 % and the LOQ was 
0.2 ng/mL, which is more sensitive than the GC-MS methods discussed 
previously. The LC-ESI-MS method was used for confirmation after ELISA 
screening and was shown to be more sensitive than ELISA, detecting 
buprenorphine in 7 urine samples which screened as negative using ELISA at a 
cut-off value of 0.5 ng/mL. 
Another reported LC-ESI-MS method for buprenorphine and norbuprenorphine 
detection in urine used a single quadrupole mass spectrometer supplied from a 
different manufacturer. Both compounds were separated by gradient elution 
following liquid-liquid extraction with 1-chlorobutane and pH alteration to 
alkaline conditions. "' The LOQvalue for buprenorphine was higher (0.5 ng/mL) 
and extraction recovery similar (average 87 %) using this method compared to 
the LC-ESI-MS method described previously. 
An LC-ESI-MS-MS method has been developed for the rapid screening and 
quantification of buprenorphine and its metabolites. 199 The authors evaluated 
three approaches in the study including: the direct injection of diluted urine to 
measure conjugated metabolites; the direct injection of diluted urine after 
enzymatic hydrolysis for quantification of buprenorphine and norbuprenorphine; 
and the quantification of buprenorphine and norbuprenorphine after enzymatic 
hydrolysis and SPE clean-up. It was concluded that the direct analysis of 
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glucuronide conjugates was an acceptable screening method but that the direct 
analysis of free drug sometimes required SPE clean-up to improve the LC-MS 
sensitivity 20-fold, especially in cases where both buprenorphine and 
norbuprenorphine were below the cut-off value. 
5.5 Aim of Study 
At the time of this study, the Immunalysis® ELISA kit had just become 
commercially available for the detection of buprenorphine in urine. The aim of 
the work was to validate the ELISA test and to apply it in the analysis of real 
samples. The screening results were compared with an in-house LC-MS-MS 
method. 
5.6 Experimental 
5.6.1 Samples 
A total of 69 urine samples were tested in the study. 7 of these samples were 
obtained from volunteers on the Subutex® treatment programme at the Turning 
Point Drugs Crisis Centre, Glasgow while the other 62 samples were routine 
samples which had been submitted to the University laboratory for 
buprenorphine testing. 
5.6.2 Chemicals 
Buprenorphine, norbuprenorphine, buprenorphine-d4 and norbuprenorphine-d3, 
dihydrocodeine, codeine, morphine, tramadot, propoxyphene, methadone and 
2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) were obtained from 
LGC Promochem (Teddington, UK). Buprenorphine Direct ELISA kits were 
obtained from the Immunalysis Corporation (Pomona, CA, USA). The kits 
contained a 96-well antibody-coated microplate, buprenorphine conjugate 
labelled with horseradish peroxidase (HRP), substrate solution containing 
3,3', 5,5'-tetramethylbenzidine (TMB) and hydrogen peroxide and stop solution 
containing 1N hydrochloric acid. Phosphate buffer saline (0.1 M, pH 7.0) was 
used to dilute urine samples in the ELISA test and this was also obtained from 
the Immunalysis Corporation. Disposable 75 x 12 mm borosilicate glass culture 
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tubes for ELISA were obtained from VWR International, UK. HPLC grade 
methanol, acetonitrile, acetone, dichloromethane, glacial acetic acid, 
ammonium hydroxide, formic acid and potassium dihydrogen phosphate were 
obtained from BDH (Poole, UK). Ammonium formate and B-glucuronidase crude 
solution were obtained from Sigma-Aldrich (Dorset, UK). Bond Elut Certify® LRC 
SPE columns (130 mg, 10 mL) were obtained from Crawford Scientific 
(Strathaven, UK). 
5.6.3 Standard Solutions 
Individual drug stock standard solutions and deuterated drug standards were 
obtained as 100 pg/mL prepared in methanol. A combined working drug solution 
of buprenorphine and norbuprenorphine was prepared at 1 pg/mL by 100-fold 
dilution with methanol. This was achieved by adding 25 pL of 100 pg/mL drug 
solution into a 25 mL volumetric flask and making up the volume to the 25 mL 
mark with methanol. A combined working deuterated standard solution of the 
buprenorphine-d4 and norbuprenorphine-d3 standards was also prepared at 
1 pg/mL in the same way as the working drug solution. 
5.6.4 Extraction Solutions and Mobile Phase 
5.6.4.1 Preparation of 1 M, pH 5 Sodium Acetate Buffer 
42.9 g of sodium acetate trihydrate and 10.4 mL of concentrated (17 M) glacial 
acetic acid was dissolved in 400 mL of deionised water, the pH was adjusted to 
5.0 with 1M acetic acid and the solution made up to 500 mL with deionised 
water. 
5.6.4.2 Preparation of 0.01 M, pH 3.0 Acetic Acid 
286 µL of concentrated (17 M) glacial acetic acid was placed in a 500 mL 
volumetric flask and this was made up to volume with deionised water. 
5.6.4.3 Preparation of 0.1 M, pH 6.0 Phosphate Buffer 
1.70 g of potassium hydrogen phosphate and 12.14 g of potassium dihydrogen 
phosphate were weighed into a1L beaker. 800 mL deionised water was added 
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and the solid was dissolved by stirring. After the solid had dissolved, the pH of 
the solution was adjusted to 6.0 using IM potassium hydroxide solution. The 
solution was then transferred into a1L volumetric flask and was made up to the 
1L mark with deionised water. 
5.6.4.4 Preparation of Mobile Phase 
The mobile phase consisted of a mixture of aqueous buffer and acetonitrile. To 
prepare the 3 mM ammonium formate + 0.001 % formic acid aqueous buffer, 
0.189 g of ammonium formate and 10 µL of concentrated formic acid were 
added to a1L volumetric flask and made up to the mark with deionised water. 
5.6.5 Instrumentation 
ELISA analysis of urine samples was carried out using a MiniPrep 75 automatic 
pipettor purchased from Tecan (San Jose, CA). The microplate wells were 
washed and read using a Columbus Plus washer system and a Sunrise Remote EIA 
autoreader from Tecan (Grödlg, Austria). 
LC-MS-MS analysis was carried out using a Surveyor HPLC system with an LCQ 
Advantage ion trap mass spectrometer (Thermo Finnigan, San Jose, CA, USA). 
Chromatographic separation was performed using a Gemini Cis column (150 mm 
x 2.0 mm ID, 5 µm particle size), fitted with a guard column with identical 
packing material (4 mm x 2.0 mm, 5 pm particle size) (Phenomenex, Torrance, 
. CA, USA). 
5.6.6 ELISA and LC-MS-MS Methods 
5.6.6.1 ELISA 
Each ELISA run contained a set of calibrators consisting of a blank and spiked 
urine samples at a concentration of 0.5,1 and 5 ng/mL buprenorphine (cut-off 
value 0.5 ng/mL). This cut-off value was also used in another ELISA study which 
screened 93 buprenorphine positive urine samples and produced no FN results 
when compared to a validated LC-ESI-MS method. "' 
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A high positive control (10 ng/mL) and a negative control provided with the kit 
were used to check kit performance. These controls were distributed to wells at 
the beginning and end of the plate to check instrument drift. Each calibrator, 
control and sample was vortex mixed after 10-fold dilution with phosphate 
buffer. The on-line dilution was achieved by adding 100 pL of urine to 900 pL 
phosphate buffer saline (pH 7.0). 
20 pL of diluted calibrator, control or sample was added to the wells in duplicate 
followed by 100 pL of enzyme conjugate. The plate was then left in the dark at 
room temperature for an incubation period of 1 hour. After incubation, the 
wells were washed 6 times with deionised water in order to remove any unbound 
sample or residual enzyme conjugate which may be left in the wells. 100 pL of 
TMB substrate reagent was then added and the plate was left to incubate in the 
dark at room temperature for a further 30 minutes. After 30 minutes, the 
catalytic reaction was stopped by adding 100 pL of stop reagent (containing 1N 
hydrochloric acid) to each well. The contents of the wells turned yellow 
following addition of the stop reagent to enable the chromophore to be detected 
at 450 nm. A reference wavelength of 620 nm was used. The absorbance 
readings were inversely proportional to the concentration of buprenorphine 
and/or norbuprenorphine present in the sample. 
5.6.6.2 LC-MS-MS 
The LC-MS-MS method was an in-house method that had already been developed 
and validated by Dr Hazel Torrance within the forensic toxicology laboratory at 
the University of Glasgow. 
5.6.6.2.1 Sample Preparation 
The calibration graph was constructed from spiked urine samples in the 
concentration range 5-200 ng/mL for buprenorphine and norbuprenorphine. To 
achieve this, the appropriate amount of working drug solution at 1 pg/mL (5,10, 
25,50,100 and 200 pL) was added to 1 mL blank urine. 100 ng (100 NL) of 
working deuterated standard solution at I pg/mL was also added to each test 
tube. A blank urine sample was prepared without any drugs or deuterated 
standards, as well as another blank urine sample with only deuterated standards 
to assess any contamination which may be present. 1 mL of acetate buffer 
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(pH 5.0,1 M) was added to each test tube along with 40 pL of B-glucuronidase 
crude solution (helix pomatia). The samples were placed in an oven for 3 hours 
at 60 °C and after cooling, 3 mL of phosphate buffer (pH 6.0,0.1 M) was added 
to each sample, followed by vortex mixing. The pH of each sample was adjusted 
to pH 6.0 using 1M potassium hydroxide. The samples were then centrifuged at 
2500 rpm for 10 minutes. 
5.6.6.2.2 Extraction Procedure 
Bond Elut Certify® LRC cartridges were conditioned with 2 mL methanol, 
followed by 2 mL phosphate buffer (0.1 M, pH 6.0). The samples were then 
applied to the cartridges and allowed to drip through without a vacuum to allow 
maximum time for analyte-sorbent interactions. The cartridges were washed 
with 1 mL deionised water followed by 0.5 mL acetic acid (0.01 M, pH 3.3) and 
dried under full vacuum for 10 minutes. 50 pL of methanol was added to each 
cartridge and the cartridges dried under full vacuum for 2 minutes. 4 mL 
acetone/dichloromethane (1: 1 v/v) was then added to further wash the 
cartridges. The basic analytes were eluted with 2x1.5 mL ethyl acetate with 2 
% ammonia. The extracts were blown down under nitrogen at 30 °C and 
reconstituted in 80 pL mobile phase (initial conditions 3 mM ammonium formate 
+ 0.001 % formic acid: acetonitrile (75: 25 v/v)). 
5.6.6.2.3 Analysis 
The column temperature was maintained at 35 °C. LC was carried out using a 
mixture of 3 mM ammonium formate + 0.001% formic acid in water (solvent A) 
and acetonitrile (solvent B) at a flow rate of 0.3 mL/min. The gradient elution 
programme was 75 %-20 % solvent A within 15 minutes. The % of solvent A was 
decreased to 10 % between 15-17 minutes and was held at 10 % solvent A for 17- 
22 minutes. After this time, initial mobile phase conditions were restored for 5 
minutes. A divert valve taking LC flow to waste was used for the first 3 minutes 
and for the last 7 minutes of the programme in order to preserve the MS source. 
All MS data was collected in electrospray positive ion mode. The capillary 
temperature, sheath and auxiliary gas flow rates and collision energies were 
optimised for each analyte. The following settings were applied throughout the 
analysis: capillary temperature 280 °C; sheath and auxiliary gas flow rates were 
set to 20 and 15 units on the data system arbitrary scale and collision energies 
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were 36 % for buprenorphine and 32 % for norbuprenorphine. The probe voltage 
used was 4.5 W. Internal standard data was collected in selected ion 
monitoring (SIM) mode and anaLytes were identified on the basis of their full 
MS-MS spectra. Buprenorphine produced a pseudo-molecular ion of m/z 468, 
with a major product ion of m/z 414 while norbuprenorphine produced a pseudo- 
molecular ion of m/z 414, with a major daughter ion of m/z 396. Quantification 
was carried out using the major product ion to deuterated drug standard ratio. 
5.7 ELISA Method Validation 
In the method validation, all spiked samples were analysed according to the 
ELISA procedure described in section 5.6.6.1. 
5.7.1 Dose Response Curve 
A dose response curve was produced over the concentration range 0.5 ng/mL- 
100 ng/mL buprenorphine. This was achieved by spiking 1 mL blank urine with 
the appropriate volume of buprenorphine solution at 0.1 pg/mL (5,10,100 pL) 
for the lower concentrations and 1 pg/mL (25,50,100 NL) for the higher 
concentrations. The spiked urine standards were 0.5,1,10,25,50 and 
100 ng/mL buprenorphine. 
5.7.2 LOD and Assay Precision 
The LOD was calculated from the mean B/Bo (%) value (A0) and standard 
deviation (s) of the B/Bo (%) values for 48 confirmed negative post-mortem urine 
samples. "' The use of post-mortem urine negatives in the determination of the 
assay LOD is more accurate than using blank urine collected from a living 
individual. The possible presence of interfering compounds in post-mortem 
urine may affect the assay LOD. Spiked urine standards were prepared at low 
concentrations (0.25,0.5 and 1 ng/mL buprenorphine) and the B/Bo (%) value 
calculated for the LOD was matched to the B/Bo (%) value of the spiked 
calibrator to determine the LOD in ng/mL. 
Equation 5-1: LOD = AO -3s 
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Assay precision was tested at the cut-off value of 0.5 ng/mL buprenorphine. To 
achieve this concentration, 5 pL of 0.1 pg/mL buprenorphine solution was added 
to 1 mL blank urine. 
Within-sample precision (n=10) was calculated from 10 readings of the same 
spiked urine sample. Intra-day precision (n=20) of the absorbance readings was 
calculated from duplicate readings of 10 spiked urine samples. The intra-day 
precision experiment was carried out on five separate days to calculate the 
inter-day precision (n=100). 
5.7.3 Cross Reactivity 
A buprenorphine and norbuprenorphine dose response graph was produced to 
calculate norbuprenorphine cross reactivity. The buprenorphine dose response 
curve consisted of 4 spiked urine samples at 0.5,1,5 and 10 ng/mL 
buprenorphine. This was achieved by spiking I mL blank urine with 5,10,50 and 
100 pL of 0.1 pg/mL buprenorphine solution. The norbuprenorphine dose 
response graph consisted of 3 spiked urine samples at 1,5 and 10 ng/mL 
norbuprenorphine. This was achieved by spiking 1 mL blank urine with 10,50 
and 100 pL of 0.1 pg/mL norbuprenorphine solution. 
Graphs of B/Bo (%) vs Concentration (ng/mL) were plotted manually on log-log 
graph paper. The best fit line was drawn through the points for the 
buprenorphine and norbuprenorphine graphs. The concentration of 
buprenorphine producing the same B/Bo (%) value as 1 ng/mL and 10 ng/mL 
norbuprenorphine was identified from reading off the graphs. Cross reactivity 
was then calculated by dividing this buprenorphine concentration by the 
norbuprenorphine concentration and multiplying by 100 to express as a 
percentage. Cross reactivity was calculated at 1 ng/mL and 10 ng/mL 
norbuprenorphine for comparison with the manufacturer's results which were 
provided at these concentrations. 
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5.8 ELISA Results and Discussion 
5.8.1 Dose Response Curve 
A dose response curve was generated for blank urine spiked at buprenorphine 
concentrations of 0.5,1,10,25,50 and 100 ng/mL (Figure 5-2). The B/Bo (%) 
values were calculated where B is the absorbance value of the bound calibrator 
and Bo is the absorbance value of the blank calibrator. The results were 
obtained in duplicate and an average B/Bo (%) value was calculated. The optical 
density values showed a hyperbolic decrease with increasing buprenorphine 
concentration. This is because at higher concentrations, more buprenorphine is 
bound to the antibody sites compared to enzyme conjugate, producing lower 
optical density values. 
Figure 5-2 Buprenorphine dose response curve (linear scale) 
The same set of data is shown in Figure 5-3 only plotted on log scale for both 
axes. The graph is an S-shaped ligand reaction curve. 200 As seen from this 
graph, the immunoassay has a short linearity range and low precision at both 
ends of the range. Usually a cut-off value is chosen in the linear range, which 
would be 10-50 ng/mL in this graph. This is the optimum region for 
discriminating between true positive (TP) and true negative (TN) samples. 
However a cut-off < 10 ng/mL is required for buprenorphine screening due to its 
potentially low levels and therefore 0.5 ng/mL was chosen as the cut-off value. 
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Figure 5-3 Buprenorphine dose response curve (log-log scale) 
5.8.2 LOD and Assay Precision 
The LOD was calculated as 0.5 ng/mL buprenorphine using Equation 5-1. 
Within-sample precision (n=10) was calculated as 5.3 % from 10 readings of the 
same spiked urine sample. Intra-day precision (n=20) of the absorbance readings 
was calculated as 6.4 % from duplicate readings of 10 spiked urine samples. The 
intra-day precision experiment was carried out on five separate days to 
calculate the inter-day precision (n=100) of 12.9 %. 
5.8.3 Cross Reactivity 
A high degree of cross reactivity was observed for norbuprenorphine at low and 
high concentrations, although this was greater at the higher concentration. The 
results were comparable to the manufacturer's values (Table 5-2). As 
mentioned previously in section 5.4, this high degree of norbuprenorphine cross 
reactivity is advantageous in an ELISA screening assay as norbuprenorphine 
concentrations detected in urine are generally higher than buprenorphine 
concentrations. 
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Table 5-2 Cross reactivity of buprenorphine ELISA 
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Analyte Concentration % Cross Reactivity 
% Cross Reactivity 
Quoted by (ng/mL) Found Manufacturer 
1 78 80 
Norbuprenorphine 
10 116 120 
A high concentration of dihydrocodeine, codeine, morphine, propoxyphene, 
tramadol, methadone and EDDP (10,000 ng/mL) did not cross react with the 
assay. This concentration was also tested by the kit manufacturers. The 
average absorbance values observed for these drugs are given in Table 5-3. 
None of these were equal to or less than the average absorbance value of 1.58 
observed for the assay sensitivity level of 0.5 ng/mL buprenorphine. Although 
the average values are relatively close to the average value for the cut-off, the 
concentration of drugs tested would not usually be as high in actual case 
samples. 
Table 5-3 Absorbance values for opiate drugs at 10,000 ng/mL 
Analyte Absorbance Value (n=2) 
Dihydrocodeine 1.67 
Codeine 1.75 
Morphine 1.66 
6-MAM 1.67 
Propoxyphene 1.71 
Tramadol 1.74 
Methadone 1.63 
EDDP 1.76 
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5.8.4 Sensitivity and Specificity 
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The number of true positive (TP), true negative (TN), false positive (FP) and 
false negative (FN) results are usually tallied and applied to Equation 5-2 and 
Equation 5-3 to determine the sensitivity and specificity of an analytical system. 
A TP result is defined as one where both the screening and confirmation result 
are positive. Conversely, a TN result is one in which the screening and 
confirmation result are both negative. The greatest number of TP and TN results 
can be obtained by choosing the optimum cut-off concentration for a particular 
system. Although there were no FP or FN results found in this particular study, a 
FP result is one in which screening is positive and confirmation negative and a 
FN is where screening is negative and confirmation is positive. It is essential 
that cut-off levels are low enough to eliminate FN screening results. 
Furthermore, this is more important than the elimination of FP screening results. 
Equation 5-2 Sensitivity = (TP x 100 /(TP + FN) 
Equation 5-3 Specificity = (TN x 100)/(TN + FP) 
Of the 69 urine samples screened as part of this study, there were 21 TP and 48 
TN results. Therefore the sensitivity and specificity of the ELISA system as 
calculated using Equation 5-2 and Equation 5-3 were both 100 % using a cut-off 
value of 0.5 ng/mL buprenorphine. This cut-off value was recommended by the 
manufacturers and was found in this study to be the optimum concentration for 
achieving the highest number of TP and TN results compared to higher cut-off 
concentrations. 
In a review on hair analysis by immunological methods up until the year 2000, it 
was recommended that the cut-off is not set at the limit of detection due to the 
very large incidence of false positive results. 20° It was also pointed out that the 
precision at both ends of the dose response curve is low due to the S-shaped 
graph. In this study the assay sensitivity level of 0.5 ng/mL buprenorphine was 
selected as the cut-off as it produced 100 % TP and TN results, it was 
recommended as the cut-off by the manufacturer and the precision of the 
system was well within the published acceptance criteria of 10 % for intra-day 
precision and 20 % for inter-day precision. 201 
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5.8.5 Case Samples 
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The ELISA and LC-MS-MS results for the case samples are provided in Table 5-4. 
5.8.5.1 ELISA 
14 out of 21 samples screened as positive at levels greater than the highest 
calibrator (> 5 ng/mL buprenorphine). However the ELISA concentration 
detected in 5 out of 21 samples were in the range 0.61-0.93 ng/mL 
buprenorphine equivalents. These samples contained low levels of 
buprenorphine in some cases levels < LOQ of the LC-MS-MS method and did not 
contain norbuprenorphine. This finding supports the use of a low cut-off level of 
0.5 ng/mL buprenorphine as the samples would have screened as negative at 
higher cut-off levels. 
The buprenorphine equivalent concentrations obtained by the ELISA test for 
samples 5,7,17 and 18 were lower than those obtained by LC-MS-MS. Apart 
from ELISA being a semi-quantitative test, a possible reason for this could be 
that the ELISA kit does not cross-react with buprenorphine and norbuprenorphine 
glucuronide conjugates which may have been present in these particular urine 
samples. The ELISA extraction, unlike the LC-MS-MS extraction did not involve a 
hydrolysis step in order to reduce the time required for sample preparation prior 
to screening. 
5.8.5.2 LC-MS-MS 
Buprenorphine and norbuprenorphine concentrations in the urine case samples, 
as determined by LC-MS-MS, ranged from 1- 1931 ng/mL and 7- 7550 ng/mL 
respectively. Most concentrations detected were in the ranges reported in the 
literature. "'''" However the concentrations determined for sample 20 are higher 
than reported concentrations. This sample was collected from a patient on a 
Subutex® treatment programme. 
Buprenorphine concentrations in samples 2,6,9 and 11 could not be quantified 
by LC-MS-MS. The LC-MS-MS concentrations found for these samples were higher 
than the LOD (0.4 ng/mL) but lower than the LOQ (1.3 ng/mL). As 
buprenorphine was detected in these samples, they were counted as TPs. 
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5.8.5.3 ELISA vs LC-MS-MS 
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The excellent qualitative agreement between the ELISA and LC-MS-MS results is 
demonstrated in Table 5-4. As mentioned in section 5.8.4, the sensitivity and 
specificity of the ELISA kit tested in this study were both found to be 100 %. 
Another study which tested 138 urine samples using the same cut-off value but a 
different ELISA kit (One Step") to the one used in this work detected 26.5 % FP 
results. "' The One StepTM' ELISA kit demonstrated a low cross reactivity (< 1 %) 
with norbuprenorphine at 50 ng/mL buprenorphine. This cannot be compared 
directly to the cross reactivity observed with the Immunalysis® kit tested in this 
study as the cross reactivity varies with concentration. No cross reactivity was 
observed with the drugs shown in Table 5-3 using this kit. 
5.9 Conclusion 
The Buprenorphine Direct ELISA kit from Immunalysis® is a highly sensitive and 
specific screening procedure for detecting buprenorphine in urine using a cut-off 
value of 0.5 ng/mL buprenorphine. The method has been validated and applied 
successfully in the semi-quantitative analysis of 21 TP case samples. The assay 
is capable of detecting buprenorphine concentrations in both therapeutic and 
abuse situations. The assay also demonstrated a high degree of cross reactivity 
with norbuprenorphine which is advantageous as it is usually present at higher 
levels than buprenorphine. 
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Table 5-4 ELISA vs LC-MS-MS results for positive buprenorphine case samples 
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ELISA LC-MS-MS 
Sample 
Number 
BUP Equivalents 
(ng/mL) 
BUP (ng/mL) NBUP (ng/mL) Source 
1 >5 40 48 Routine 
2 >5 < LOQ 7 Routine 
3 >5 12 125 Routine 
4 >5 8 34 Routine 
5 2.50 1 22 Routine 
6 0.61 < LOQ NEG Routine 
7 0.93 8 NEG Routine 
8 >5 31 131 Routine 
9 0.63 <LOQ NEG Routine 
10 >5 12 NEG Routine 
11 0.77 <LOQ NEG Routine 
12 >5 179 97 Routine 
13 >5 246 2288 
Crisis 
Centre 
14 >5 130 1001 
Crisis 
Centre 
15 >5 146 2195 
Crisis 
Centre 
16 >5 123 1835 
Crisis 
Centre 
17 0.63 6 NEG Routine 
18 2.15 21 82 Routine 
19 >5 531 5730 
Crisis 
Centre 
20 >5 1931 7550 
Crisis 
Centre 
21 >5 167 2255 
Crisis 
Centre 
"BUP"=Buprenorphine, "NBUP"=Norbuprenorpmne, "*Nt(i-=Negative 
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6 Drugs of Abuse in Hair by ELISA 
6.1 Introduction 
Historically radioimmunoassay (RIA) was used for screening drugs of abuse in 
hair. The first report was the detection of opiates in 197910 and since this initial 
study, there has been many more publications in this area. 61'197'198'199 In the last 
decade, several groups have used RIA to detect opiates and cocaine in hair for 
the purposes of proving the illegal consumption of heroin and cocaine. "', ", 
Another more recent publication used RIA to screen for amphetamines in the 
hair of known users and workplace subjects. ' Benzodiazepine detection in hair 
by RIA has also been reported. "' Although RIA is a sensitive and robust method, 
the use of radioactive materials has imposed strict safety regulations and has 
limited its application out with safe areas. It is therefore only cost effective 
when used for a large number of samples. For these reasons, there is currently 
an increasing trend towards non-radioactive alternatives such as ELISA. 
ELISA is now being routinely applied as a screening method for the detection of 
drugs of abuse in hair81'105'106'107'108,109,110,179,203 as it is safe, simple, highly sensitive, 
uses relatively small sample sizes and can be automated. Other immunoassay 
systems including enzyme multiplied immunoassay technique (EMIT)204,205 and 
fluorescence polarisation immunoassays (FPIA)205,206 have also been used for this 
purpose. One group developed an LC-MS-MS screening method for drugs of abuse 
as an alternative to immunoassay before confirming any positive screens with 
GC-MS. 94 
ELISA kits have been specifically designed for detecting drugs of abuse in hair. 
As mentioned previously, conventional urinary immunoassays are targeted 
towards the detection of hydrophilic metabolites whereas it is usually the parent 
drug which is found in higher concentrations in hair. A hair immunoassay test 
should have a sensitivity and specificity greater than 90 % at the selected cut- 
off. 195 Some urinary ELISA kits, when applied for the purposes of hair testing, 
have been shown to lack the required specificity. ", "' This is in contrast to other 
reports which found excellent ELISA sensitivity and specificity of greater than 
90 %. 107009 
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There are three main requirements for immunoassays used for hair testing: they 
cross react with the drugs actually present in hair; they are not affected by 
sample matrix interference; and they must be capable of detecting the drug 
concentrations in hair. 200 
ELISA kits for hair usually demonstrate cross reactivity with the parent drug and 
lipophilic metabolites actually found in hair. A comparison of EIA and FPIA for 
the detection of cocaine in hair found that EIA was more sensitive, specific and 
efficient. "' The authors proposed that the differences in results were due to the 
cross reactivity towards the parent drug, cocaine. The EIA kit was designed for 
oral fluid testing and had a high cross reactivity with cocaine of 100 %, while the 
FPIA was designed for urinary analysis and had a very low cocaine cross 
reactivity of 1 %. Only kits with relatively high cross reactivity with the parent 
drug should be validated for hair screening. However the exception is the ELISA 
screening test for cannabis in hair. This kit cross reacts 100 % with the 
11-nor-delta(9)-tetrahydrocannabinolcarboxylic acid (09THC-COOH) metabolite 
instead of the delta (9)-tetrahydrocannibinol (19THC) parent drug to avoid 
screening false positive hair samples that have been contaminated through 
exposure to cannabis smoke. 
ELISA demonstrates minimal matrix interference because of the wash step after 
the competitive incubation. This removes the sample matrix and any unbound 
label before the addition of the substrate and subsequent colour development. 
The use of an enzyme label amplifies the signal during catalysis and this reduces 
the limits of detection to the extremely low levels (pg/mg range) required for 
hair testing. The sensitivity required for the immunoassay screening test for 
opiates, cocaine and amphetamines has been stipulated in the most recent 
publication by the SoHT. 10° The following cut-off concentrations must result in a 
positive screening result: 0.2 ng/mg morphine or 6-MAM; 0.5 ng/mg cocaine; 
0.2 ng/mg MDMA, MDEA, MDA, methamphetamine or amphetamine; and 
0.1 ng/mg THC. 
6.2 Alm 
The aim of this to study was to validate an ELISA method for the detection of 
drugs of abuse in hair and apply it in the analysis of case samples. 
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6.3 Experimental 
6.3.1 Samples 
The post-mortem scalp hair samples screened for amphetamine, 
benzodiazepines, cocaine, opiates and methadone were routine samples 
submitted to the laboratory at the University of Glasgow. They were tested for 
diagnostic purposes and the results were reported to the Procurator Fiscal. 
The hair samples screened for methamphetamine as part of a collaboration with 
the National Institute of Scientific Investigation in Seoul, South Korea were 
routine samples submitted to the Korean lab which had been collected from 
living individuals suspected of drug abuse. 
6.3.2 Chemicals 
Amphetamine (AMP), benzodiazepine, cocaine, methamphetamine (MAMP) and 
opiate direct ELISA kits were obtained from the Immunalysis Corporation 
(Pomona, CA, USA). The kits contained a 96-well antibody-coated microplate, 
enzyme conjugate labelled with horseradish peroxidase (HRP), substrate solution 
containing 3,3', 5,5'-tetramethylbenzidine (TMB) and hydrogen peroxide and stop 
solution containing 1N hydrochloric acid. Hair extraction buffer (0.025 M 
mondbasic phosphate buffer pH 2.7), neutralising buffer (0.5 M dibasic 
phosphate buffer pH 9.0) and phosphate buffer saline (0.1 M, pH 7.0) used to 
dilute hair extracts in the ELISA test were also obtained from the Immunalysis 
Corporation. Disposable borosilicate glass culture tubes (75 x 12 mm) were 
obtained from VWR International, UK. The drug standards used to assess kit 
cross reactivity were purchased from LGC Promochem (Teddington, UK). 
6.3.3 Instrumentation 
A Mint Prep 75 automatic pipettor from Tecan (San Jose, CA) was used. The 
microplate wells were washed and read using a Columbus Plus washer system 
and a Sunrise Remote EIA autoreader also from Tecan (Grödlg, Austria). 
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6.4 ELISA Method 
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The post-mortem hair samples were firstly analysed by LC-MS-MS as described in 
chapters 7 and 8. Only samples which had a sufficient amount of sample left 
were analysed by ELISA. 
6.4.1 Sample Preparation 
The root-0.5 cm segment was removed from each hair sample and the remaining 
hair segmented depending on the length. The decontamination procedure used 
was the same as the LC-MS-MS procedure for the purposes of method 
comparison. Each section was washed once with 0.1 % sodium dodecyl sulfate 
with a 10 minute ultrasonication, twice with deionised water with a 10 minute 
uttrasonication and twice with dichloromethane with a 10 minute 
ultrasonication. Dichloromethane was chosen for the organic washes since it 
was demonstrated that no more than 10 % of cocaine, opiates and 
benzodiazepines were extracted when dichloromethane was used to wash real 
hair samples. "' It was not however known if the drugs detected in the 
dichloromethane washes were incorporated through use or passive exposure. 
After decontamination, the hair segments were cut into smaller segments of 2-3 
mm in length using a pair of clean scissors. A previously published aqueous 
extraction method was used which had been applied in the ELISA screening of 
cocaine and amphetamine in hair. 108,119 Spiked hair calibrators were prepared for 
each assay at the cut-off value, 2x cut-off value and 5x cut-off value by adding 
the appropriate concentration of target drug to 10 mg blank decontaminated 
hair. The concentrations used for the calibrators are given in Table 6-1. A blank 
calibrator was also prepared. Negative and positive spiked controls were 
prepared in-house and these were distributed across the plate to ensure 
consistent system performance. 
The cut-off values used for cocaine and opiates were recommended by the 
Society of Hair Testing (SoHT) and SAMHSA. 10°'101 The cut-off values used for the 
amphetamines was the GC-MS cut-off used by the toxicology laboratory in Seoul" 
and had to be the same for the purposes of comparing the ELISA and GC-MS 
methods as discussed in section 6.6.4.4. The same screening cut-off was 
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proposed for amphetamines by SAMHSA. 101 ELISA cut-off values have not yet 
been recommended for methadone or benzodiazepine screening in hair by the 
SoHT or SAMHSA. 
The methadone cut-off selected was therefore the same as the opiates 
(0.2 ng/mg). This concentration produced a B/Bo (%) value just above 70 % but 
was still in the linear portion of the dose response curve. The benzodiazepine 
cut-off was 0.1 ng/mg as this concentration produced the optimum sensitivity 
and specificity for 13 positive hair samples compared with a validated LC-MS-MS 
reference method as discussed later in section 7.6.4.11' 
Table 6-1 ELISA cut-off values 
ELISA kit Cut-off (ng/mg) 
2x Cut-off 
(ng/mg) 
5x Cut-off 
(ng/mg) 
Amphetamines 0.5 1 2.5 
Benzodiazepines 0.1 0.2 0.5 
Cocaine 0.5 1 2.5 
Methamphetamine 0.5 1 2.5 
Methadone 0.2 0.4 1.0 
Opiates 0.2 0.4 1.0 
0.5 mL of monobasic phosphate buffer was added to each sample, calibrator and 
control then the vials were capped and incubated at 60 °C for 1 hour in an oven. 
After cooling, 50 pL of dibasic phosphate buffer was added to neutralise the 
acidic buffer and the extracts were transferred to labelled EIA glass culture 
tubes. ALL extracts were then diluted 1: 5 on-Line by adding 800 pL phosphate 
buffer saline to 200 pL hair extract. The diluted extracts were then vortex 
mixed. 
6.4.2 ELISA Assay 
An aliquot of the diluted extract was added to the individual micro-plate well 
coated with the target drug specific antibody, depending on the ELISA kit used. 
The aliquot volume used was dependent on the ELISA test for a particular drug 
class and the sensitivity required. The sample volumes used for each drug class 
(Table 6-2) gave good separation of absorbance values between the blank 
calibrator and the spiked cut-off calibrator. 
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After adding the aliquots of diluted extract, 100 pL of HRP enzyme labelled 
target drug derivative (specific to the ELISA test) was added to each well. After 
a1 hour incubation period at room temperature, the micro-plate wells were 
washed 6 times with deionised water (6 x 300 pL). 100 pL TMB was added to 
each well and the plate incubated in the dark at room temperature for a further 
30 minutes. The reaction was stopped using 100 pL 1N hydrochloric acid and 
the plate read at 450 nm with a reference wavelength of 650 nm. The case 
samples were considered to be presumptively positive if the B/Bo (%) value was 
lower than the B/Bo (%) value of the cut-off calibrator. 
Table 6-2 Aliquot volumes used in each ELISA test 
ELISA Test Aliquot volume (NL) 
AMP 25 
Benzodiazepines 50 
Cocaine 20 
Methadone 50 
MAMP 25 
Opiates 25 
6.5 ELISA Method Validation 
6.5.1 Dose Response Graph 
Dose response curves were generated for all drugs of abuse assays over the 
concentration range 0.05-5 ng/mg target drug (dependent on the assay). The 
target drug demonstrated 100 % cross reactivity with a particular assay according 
to the ELISA kit manufacturers and these are named in Table 6-3 for each kit. A 
blank was also prepared as a reference for calculating the B/Bo (%) values. The 
B/Bo (%) values were calculated where Bo is the absorbance value of the blank 
calibrator and B is the absorbance value of the bound calibrator. Although the 
methadone assay cross reacts 100 % with I-methadone, d, 1-methadone was used 
to spike calibrators since methadone is usually consumed in the racemic form. 
As discussed in section 6.6.2, an acceptable sensitivity level was achieved using 
d, (-methadone. 
The curves were generated by spiking 10 mg of blank decontaminated hair with 
the appropriate volume of target drug solution at 0.1 lag/mL (5,10,25,50 pL) 
for the lower concentrations and 1 pg/mL (10,25,50 NL) for the higher 
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concentrations. The spiked hair standards were 0.05,0.1,0.25,0.5,1.0,2.5 
and 5.0 ng/mg target drug. 
Table 6-3 Target drugs for particular ELISA kits 
ELISA kit Target drug 
AMP d-Amphetamine 
Benzodiazepine Oxazepam 
Cocaine Cocaine 
Methadone l-Methadone 
MAMP d-Methamphetamine 
Opiate Morphine 
6.5.2 LOD and Assay Precision 
The LOD was calculated from the mean B/Bo (%) value (Ao) and standard 
deviation(s) of the B/Bo (%) values for 10 x 10 mg confirmed negative hair 
samples. This has been recommended as the minimum number of blank wells 
that should be run when estimating the LOD. 102 10 mg spiked blank hair samples 
were prepared at low concentrations (0.025,0.05,0.075 and 0.1 ng/mg target 
drug) and the B/Bo (%) value calculated for the LOD for each assay was matched 
with the B/Bo (%) value of the spiked calibrator to determine the LOD in ng/mg. 
The precision was tested at' x cut-off, the cut-off and 2x cut-off as the SOFT 
guidelines state that the precision of a screening assay must be demonstrated at 
and around the cut-off value. " The cut-off concentrations are provided in Table 
6-1. Within-sample precision (n=10) was calculated from 10 B/Bo (%) readings of 
the same spiked hair sample. Intra-day precision (n=20) of the B/Bo (%) was 
calculated from duplicate readings of 10 spiked hair samples. The intra-day 
precision experiment was carried out on five separate days to calculate the 
inter-day precision (n=100). 
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6.5.3 Cross Reactivity 
Chapter 6,85 
The cross-reactivity of the ELISA kits was tested and the results compared with 
those provided by the manufacturers. The drugs tested were considered 
analogues of the target drug and were included in the validated LC-MS-MS 
method described in chapter 8. Other common drugs of abuse with no obvious 
structural similarity to the target drug were also tested. The list of drug 
analogues tested for each assay is given in Table 6-7-6-12. 
Cross reactivity was calculated by constructing a target drug dose response curve 
and a dose response curve for the drug to be tested. The drugs were spiked into 
phosphate buffer saline (pH 7.0) for testing. The concentration of target drug 
producing the same B/Bo (%) value as the drug being tested was determined at a 
given concentration. The cross reactivity was then calculated by dividing this 
target drug concentration by the concentration of drug being tested and 
multiplying by 100 to express as a percentage. 
6.6 ELISA Validation Results and Discussion 
6.6.1 Dose Response Curves 
Dose response curves were generated for all drugs of abuse assays (Figure 6-1 - 
Figure 6-6). The results were obtained in duplicate for each concentration and 
an average B/Bo (%) value was calculated. The B/Bo (%) values showed a 
hyperbolic decrease for all assays with increasing target drug concentration. As 
discussed in chapter 5, this is because of the inverse relationship that exists 
between absorbance and drug concentration when using ELISA. From the dose 
response curves, the B/Bo (%) values for the cut-off calibrators were all below 70 
% and were in the linear portion of the curve. The ELISA kit manufacturers 
recommend that the selected cut-off concentration produces a B/Bo (%) below 
70 % to ensure the highest number of true results. 
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Figure 6-3 Cocaine dose response curve 
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Figure 6-6 Morphine dose response curve 
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6.6.2 LOD and Assay Precision 
Chapter 6,88 
The LOD values for the drugs of abuse assays are shown in Table 6-4. With the 
exception of the benzodiazepines assay, the LOD values were lower than the 
cut-off concentrations used for screening. Although the cut-off concentration 
used for the benzodiazepine assay was the same as the LOD, the B/Bo (%) was 
70 %. Furthermore this cut-off concentration was found to produce the greatest 
number of true results when compared to a validated LC-MS-MS method as 
discussed later in section 7.6.4.11' 
Precision data is shown in Table 6-5 and Table 6-6. There are currently no 
published guidelines on acceptable levels of precision for drug screening by 
ELISA however all within sample and intra-day data was <9% at all levels 
tested, which is accepted as good precision in chromatographic methods 
according to SOFT guidelines. " Inter-day precision was higher as expected due 
to the greater number of results and the fact that the tests were carried out on 
five separate days. 
Table 6-4 ELISA LOD values 
ELISA Assay LOD (ng/mg) 
AMP 0.05 
Benzodiazepine 0.1 
Cocaine 0.05 
Methadone 0.1* 
MAMP 0.05 
Opiate 0.05 
*n=8 for blank samples 
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Table 6-5 ELISA within-sample precision 
Chapter 6,89 
ELISA A 
Within-sample Precision (% RSD for n=10) 
ssay 
/x Cut-Off Cut-Off 2x Cut-Off 
AMP 4.9 3.1 4.1 
Benzodiazepine 4.1 3.9 3.1 
Cocaine 6.5 5.5 4.3 
Methadone 6.0 4.0 6.9 
MAMP 3.0 4.0 3.6 
Opiate 6.4 6.9 6.1 
Table 6-6 ELISA intra-day and inter-day Precision 
Intra-day Precision (n=20) Inter-day Precision (n=100) 
ELISA Assay Yx 
Cut-Off Cut-Off 
2x 
Cut-Off 
fix 
Cut-Off Cut-Off 
2x 
Cut-Off 
AMP 8.0 8.3 7.4 8.7 9.7 11.9 
Benzodiazepine 6.9 4.6 2.3 8.6 8.2 5.9 
Cocaine 7.7 6.9 5.9 10.5 11.9 13.5 
Methadone 8.3 7.3 6.5 10.9 13.2 17.4 
MAMP 8.8 7.4 5.7 6.6 7.6 6.7 
Opiate 8.7 8.4 7.6 11.9 10.9 14.1 
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6.6.3 Cross Reactivity 
Table 6-7 Cross reactivity of amphetamine analogues with amphetamine ELISA kit 
Compound 
Approx. ng/mL 
equivalent to 
25 ng d-AMP 
% Cross Reactivity 
quoted by 
Immunalysis® 
% Cross Reactivity 
Found 
1-AMP 1700 2.5 1.5 
d-MAMP > 1000 6.5 < 1.0 
1-MAMP > 2000 2.0 < 1.0 
d, 1-MDA 11 250 263 
d, (-MDMA > 2500 < 1.0 < 1.0 
d, 1-MDEA >2500 <1.0 <1.0 
Overall, the cross reactivity values determined for the amphetamine specific kit 
were comparable to the values quoted by the manufacturers. A relatively high 
cross reactivity was demonstrated for MDA however the kit had less than 1% 
cross reactivity with d- and 1-methamphetamine, d, 1-MDMA and d, 1-MDEA. The 
kit manufacturers have two different ELISA kits to accommodate regional 
differences in amphetamine abuse which are the amphetamine specific and the 
methamphetamine specific kits. As mentioned previously, the amphetamine 
specific ELISA is 100 % cross reactive with d-amphetamine, which is the illicit 
form. As the cross reactivity of the licit 1-AMP enantiomer is very low, this ELISA 
test is an excellent means of distinguishing between illegal amphetamine use 
and medication. Furthermore it could eliminate the need for chiral separation 
of the amphetamine enantiomers in the confirmation method. The 
methamphetamine specific ELISA kit which is 100 % cross reactive with the illicit 
d-methamphetamine should be used in tandem with the d-amphetamine specific 
kit. 
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Table 6-8 Cross reactivity of oxazepam analogues with benzodiazepine ELISA kit 
Compound 
Approx. ng/mL 
equivalent to 
100 ng oxazepam 
% Cross Reactivity 
quoted by 
Immunalysis® 
% Cross Reactivity 
Found 
7-aminoflunitrazepam 
(7-AF) 1300 Not given 8 
Chtordiazepoxide 750 17 13 
Diazepam 125 91 80 
Ftunitrazepam 310 31 32 
Lorazepam 860 13 12 
Nitrazepam 320 33 31 
Nordiazepam 70 150 143 
Temazepam 130 83 77 
The experimental cross reactivity values were comparable with the 
manufacturer's values for the benzodiazepine ELISA kit. As shown in chapters 7 
and 8, the majority of hair samples tested positive for diazepam and its 
metabolites by LC-MS-MS so this kit is ideally suited for screening. 
The kit may not be suitable for screening hair samples positive for 
chlordiazepoxide, flunitrazepam and its metabolite, lorazepam or nitrazepam as 
they cross-react to a relatively lower extent than diazepam and its metabolites. 
This study did not investigate this potential problem due to a lack of positive 
samples for these drugs atone. 
There is a commercially available flunitrazepam ELISA kit which should ideally 
be used in tandem with the benzodiazepine ELISA kit for screening. These kits 
cross react 100 % with the 7-aminoflunitrazepam (7-AF) metabolite which has 
generally been found in higher concentrations in hair, due to its higher basicity. 
The kit was not tested for the purposes of this study since there were no LC-MS- 
MS positives for flunitrazepam or 7-AF as shown in chapters 7 and 8. 
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Table 6-9 Cross reactivity of cocaine metabolites with cocaine ELISA kit 
Chapter 6,92 
Approx. ng/mL % Cross Reactivity % Cross Reactivity Compound equivalent to quoted by Found 50 ng cocaine Immunalysis® 
Benzoylecgonine 960 7.6 5.2 
Cocaethylene 40 110 125 
Ecgonine methyl , 5000 < 1.0 < 1.0 ester (EME) 
This cocaine specific ELISA kit was developed for the detection of cocaine in 
hair. It is well known that parent drug concentrations are higher than 
metabolite concentrations in hair so it is more appropriate for a screening test 
to be calibrated towards the parent drug. Cocaine and cocaethylene are the 
primary analytes found in hair after cocaine ingestion hence the high % cross 
reactivity for cocaethylene. Benzoylecgonine is present at lower levels but has 
been shown to be an artefact of some sample treatment and extraction 
procedures involving acidic and alkaline hydrolysis. Cocaethylene is only present 
when the individual has used both cocaine and alcohol at the same time and is a 
useful marker of cocaine use. EME levels have not been widely reported in hair. 
In this study as discussed in chapter 8, it was detected in a very small number of 
samples at low levels. 
Table 6-10 Cross reactivity of methadone analogue with methadone ELISA kit 
Approx. ng/mL % Cross Reactivity 
Compound equivalent to quoted by 
% Cross Reactivity 
300 ng Immunalysis® Found 
methadone 
EDDP 13,000 < 5.0 2.3 
Like other drugs of abuse, methadone is found in hair at higher levels in hair 
than EDDP. In fact, EDDP is not detected in some cases where methadone is 
present. "' Reported concentration ratios of the EDDP metabolite and 
methadone parent drug are 0.05-0.67.9° 
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Table 6-11 Cross reactivity of MAMP analogues with MAMP ELISA kit 
Chapter 6,93 
Compound 
Approx. ng/mL 
equivalent to 
50 ng d-MAMP 
% Cross 
Reactivity quoted 
by Immunalysis® 
% Cross 
Reactivity Found 
d, 1-MAMP 80 65 63 
1-MAMP > 2000 8.0 <1.0 
d, 1-MDMA 38 135 132 
d-AMP > 10,000 2.0 < 1.0 
1-AMP > 2000 3.4 < 1.0 
d, 1-MDA > 10,000 < 1.0 < 1.0 
d, 1-MDEA 1500 10 3.3 
As shown in Table 6-11, the methamphetamine specific ELISA kits cross reacts 
with the racemic mixture of methamphetamine and MDMA to a relatively high 
extent but to a low extent with the other designer drugs MDA and MDEA and 
amphetamine enantiomers. The experimental values were mostly comparable 
to those provided by the manufacturer. However there was a greater difference 
in the value obtained for l-methamphetamine. The cross reactivity determined 
experimentally was lower than the cross reactivity quoted by the manufacturers. 
This is an advantage when screening samples for illicit methamphetamine as it is 
unlikely that the licit form would be detected in the screen due to its low cross 
reactivity. 
Table 6-12 Cross reactivity of morphine analogues with opiate ELISA kit 
Approx. ng/mL % Cross Reactivity % Cross Reactivity Compound equivalent to quoted by Found 25 ng morphine Immunalysis® 
Codeine 11 200 227 
Dihydrocodeine 58 Not given 43 
6-MAM 320 83 69 
After heroin use, hair often contains primarily 6-MAM, with smaller quantities of 
diamorphine and morphine. Therefore this opiates ELISA is suited to hair 
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screening due to its relatively high cross reactivity with 6-MAM. The kit is also 
highly cross reactive with codeine which can be present in the hair of heroin 
abusers. Morphine and codeine which are extracted from the Papaver 
Somniferum poppy are acetylated during the production of illicit heroin. 
Acetylcodeine is metabolised to codeine after heroin use. 
Dihydrocodeine was tested as it is commonly prescribed as a narcotic analgesic 
in Scotland and is frequently detected in blood and urine samples submitted to 
the laboratory for routine testing. 
6.6.3.1 Cross Reactivity of Structurally Unrelated Drugs 
Various drugs of abuse, which are not structurally related to the target drug in a 
particular assay, were tested at 10,000 ng/mL. This included amitriptyline, 
d-amphetamine, buprenorphine, cocaine, codeine, 6-MAM, MDMA, methadone, 
morphine, A9THC-COON and tramadol. All of the compounds tested for a 
particular assay were tested in duplicate and did not produce a B/Bo (%) value 
that was less than that produced from the assay sensitivity levels shown in Table 
6-4. 
6.6.4 Case Samples 
ELISA results are provided for post-mortem hair samples submitted to the 
laboratory for opiates, cocaine and methadone testing. These were initially 
compared to GC-MS results obtained by in-house methods used within the 
Forensic Medicine and Science Section at the University of Glasgow. In brief, 
this involved incubating the hair in methanol overnight at 45 °C, removing the 
methanol then incubating the hair overnight in 0.1 M hydrochloric acid at 45 °C. 
The combined extracts were cleaned up using Bond Elut Certify"' SPE cartridges. 
Opiates were derivatised using N, O-Bis (Trimethylsilyl) trifluoroacetamide 
(BSTFA) with 1% trimethytchlorosilane (TMCS). Cocaine and its metabolites 
were derivatised using pentaftuoropropionic anhydride (PFPA) and pentaftuoro-1- 
propanot (PFPOH) prior to GC-MS analysis. 
Methamphetamine ELISA results for the collaboration with the Korean laboratory 
are provided in section 6.6.4.4. Results for other post-mortem samples screened 
for amphetamines, benzodiazepines, cocaine and opiates are provided in 
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chapters 7 and 8 respectively as these were compared to LC-MS-MS methods 
which were developed and validated as part of the work for this thesis. 
6.6.4.1 Opiates 
The results for opiate screening in 20 post-mortem hair samples are provided in 
Table 6-13.10 drug-free samples collected from volunteers working in the 
laboratory were also screened. The root-0.5 cm section was removed in each 
case and was not analysed as the sample weight was generally less than 5 mg. 
The remaining hair sample was decontaminated using the procedure described in 
section 6.4.1, cut up into 2-3 mm segments, extracted and analysed by ELISA. 
Table 6-13 ELISA vs in-house GC-MS method for opiates 
ELISA GC-MS 
Sample 
Number 
Weight 
(mg) 
MOR 
Equivalents 
(ng/mg) 
Weight 
(mg) MOR 6-MAM COD DHC 
1 7.50 > 1.0 17.89 17.9 39.9 3.2 0.2 
2 5.21 < 0.2 39.71 - - - 0.4 
3 13.98 0.25 34.20 0.5 1.1 - - 
4 15.60 > 1.0 31.00 0.7 0.4 3.4 4.6 
5 2.93 > 1.0 15.42 5.2 7.3 1.8 - 
6 10.40 > 1.0 82.96 3.8 6.5 7.6 4.2 
7 10.46 > 1.0 19.62 18.8 18.8 5.0 4.0 
8 6.04 > 1.0 14.52 13.5 23.3 2.5 - 
9 8.83 < 0.2 10.04 - - - - 
10 18.66 > 1.0 38.42 3.8 9.2 0.8 - 
11 7.18 0.38 58.08 0.7 1.7 - - 
12 1.98 > 1.0 5.99 6.8 7.5 1.8 1.7 
13 10.03 > 1.0 13.83 0.2 0.6 
14 6.36 > 1.0 12.07 0.3 1.4 0.8 1.6 
15 10.45 > 1.0 47.66 35.4 38.5 17.1 0.4 
16 20.74 > 1.0 67.73 10.9 23.3 4.7 0.2 
17 10.23 > 1.0 25.43 - - 4.55 - 
18 6.68 0.37 10.55 - - - 0.6 
19 5.51 > 1.0 9.56 0.7 1.9 - - 
20 9.05 0.24 9.52 1.5 2.7 0.4 - 
"MOR"=Morphine, "6-MAM"=6-Monoacetylmorphine, "COD "=Codeine, "DHC"= Dihydrocodeine 
The ELISA sensitivity and specificity were 95 % and 100 % respectively using the 
SoHT cut-off of 0.2 ng/mg morphine. Sample 2 produced a FN ELISA result 
however the sample weight and the dihydrocodeine level detected by GC-MS 
were both low. The cross reactivity of dihydrocodeine with the opiates kit was 
found to be 43 %, further explaining this result. 
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6.6.4.2 Cocaine 
Chapter 6,96 
The results for cocaine screening of 16 post-mortem hair samples tested in 
section 6.6.4.1 are presented in Table 6-14. The sample numbers correspond to 
the ones given in Table 6-13. 
Table 6-14 ELISA vs in-house GC-MS method for cocaine 
ELISA GC-MS-MS 
Sample 
Number 
Weight 
(mg) Ecoc quivalents (ng/mg) 
Weight 
(mg) COC BZE COCAETH 
1 7.50 < 0.5 17.89 - - - 
2 5.21 < 0.5 39.71 - - - 
4 15.60 0.57 31.00 0.7 - - 
5 2.93 < 0.5 15.42 - - - 
6 10.40 > 2.5 82.96 32.5 14.1 - 
7 10.46 < 0.5 19.62 0.2 0.03 - 
8 6.04 > 2.5 14.52 172.0 17.1 - 
10 18.66 < 0.5 38.42 - - - 
11 7.18 < 0.5 58.08 - - - 
12 1.98 < 0.5 5.99 - - - 
13 10.03 > 2.5 13.83 1.2 - 0.2 
14 6.36 > 2.5 12.07 0.5 - - 
15 10.45 < 0.5 47.66 0.4 - - 
17 10.23 > 2.5 25.43 2.0 - 0.1 
18 6.68 < 0.5 10.55 - - - 
19 5.51 < 0.5 9.56 - - - 
"COC"=Cocaine, "BZE"=Benzoylecgonine, "COCAETH "=Cocaethylene 
There were a smaller number of cocaine positive samples (n=8) compared to the 
number of opiate positive samples (n=19). All of the cocaine positive samples 
were also positive for opiates. The ELISA sensitivity and specificity for this small 
number of positive cocaine samples compared to the in-house validated GC-M5 
method was 75 % and 100 % using the recommended SoHT and SAMHSA cut-off of 
0.5 ng/mg cocaine. A greater number of positive cocaine samples need to be 
screened to determine if a lower cut-off value is required for future screenings. 
However from the GC-MS results for the 2 FN samples (samples 7 and 15), it 
would appear that this was necessary. 
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6.6.4.3 Methadone 
Chapter 6,97 
The results for methadone screening for 20 post-mortem hair samples tested in 
6.6.4.1 and 6.6.4.2 are presented in Table 6-15. The sample numbers 
correspond to the ones given in Table 6-13 and Table 6-14. 
Table 6-15 ELISA vs in-house GC-MS method for methadone 
ELISA GC-MS-MS 
Sample 
Number 
Weight 
(mg) 
d, l-MD 
Equivalents 
(ng/mg) 
Weight 
(mg) MD EDDP 
1 7.50 > 1.0 17.89 70.6 10.9 
2 5.21 < 0.2 39.71 - - 
3 13.98 < 0.2 34.20 - - 
4 15.60 < 0.2 31.00 - - 
6 9.89 0.27 82.96 2.8 0.6 
7 10.46 0.82 19.62 11.5 2.2 
8 1.03 < 0.2 14.52 3.7 0.4 
9 8.83 < 0.2 10.04 - - 
10 18.66 0.51 38.42 7.7 0.7 
11 7.18 < 0.2 58.08 - - 
14 6.36 < 0.2 12.07 - - 
15 10.45 < 0.2 47.66 - - 
16 20.74 > 1.0 67.73 25.6 6.4 
17 10.23 < 0.2 25.43 - - 
18 6.68 < 0.2 10.55 - - 
19 5.51 < 0.2 9.56 - - 
20 9.05 < 0.2 9.52 - - 
"MD"=Methadone, "EDDP"=2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine 
There was a small number of hair samples which tested positive for methadone 
(n=6). 5 out of 6 of these tested positive by ELISA and GC-MS to give an ELISA 
sensitivity of 83 % at a cut-off of 0.2 ng/mg d, l-methadone. The FN result 
produced by sample 8 is due to an insufficient sample weight for ELISA. All of 
the methadone positive samples also tested positive for opiates. 
6.6.4.4 Methamphetamine: Korean Collaboration 
29 hair samples were screened for methamphetamine using ELISA as part of a 
collaboration with the National Institute of Scientific Investigation in Seoul, 
South Korea. The samples had been submitted to the laboratory in Seoul by the 
police force. The reason for the collaboration was that there is currently an 
insufficient number of methamphetamine positive hair samples in Scotland as it 
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is not a common drug of abuse. In addition, 9 drug free samples were collected 
from laboratory personnel and these were all screened and confirmed as 
negative. 
The ELISA results obtained within the Forensic Medicine and Science Section at 
the University of Glasgow were compared with a validated GC-MS method that is 
currently used in the in the National Institute of Scientific Investigation in Seoul 
(Table 6-16). 12 
Table 6-16 ELISA vs GC-MS methamphetamine positive hair results 
ELISA GC-MS 
Sample 
Number 
Weight 
(mg) 
d-MAMP 
Equivalents 
(ng/mg) 
Weight 
(mg) 
d, I-MAMP 
(ng/mg) 
d, 1-AMP 
(ng/mg) 
1 7.01 > 5.0 4.6 19.5 0.9 
2 9.00 < 0.5 12.7 1.2 0.1 
3 7.08 0.7 7.0 2.2 0.0 
4 8.10 > 5.0 12.7 9.4 1.1 
5 7.04 > 5.0 2.0 22.7 0.9 
6 9.57 > 5.0 17.2 12.7 0.3 
7 9.51 > 5.0 19.0 2.4 0.2 
8 9.37 1.6 6.5 20.4 0.8 
9 9.50 2.7 18.5 3.3 0.2 
10 7.73 > 5.0 4.4 8.0 0.4 
11 9.86 2.9 19.3 6.6 1.0 
12 8.05 > 5.0 10.2 11.9 0.8 
13 7.18 > 5.0 9.9 45.3 2.5 
14 8.13 1.6 12.2 4.1 0.3 
15 9.28 3.0 19.2 7.2 0.5 
16 8.51 2.8 14.5 4.4 0.2 
17 8.10 > 5.0 7.8 9.3 0.9 
18 9.09 > 5.0 12.8 10.6 0.4 
19 9.73 3.0 19.0 12.7 0.4 
20 9.06 > 5.0 19.8 27.5 2.4 
21 10.40 2.4 20.1 2.7 0.2 
22 9.83 1.5 19.4 8.1 1.0 
23 7.11 > 5.0 16.6 12.5 0.4 
24 10.15 > 5.0 16.5 10.2 0.3 
25 9.27 > 5.0 16.6 11.7 0.6 
26 10.21 > 5.0 18.8 20.4 0.9 
27 6.68 > 5.0 14.0 8.1 0.60 
28 10.77 0.6 19.0 1.8 0.1 
29 10.89 > 5.0 19.5 6.9 1.1 
"MAMP"=Metamphetamine, "AMP"=Amphetamine 
Drugs of abuse in Hair by ELISA Chapter 6,99 
The ELISA method is described previously in section 6.4.1 and section 6.4.2. The 
same decontamination method was used by the Korean tab to enable accurate 
ELISA and GC-MS comparison. In brief for the GC-MS analysis, the samples were 
incubated in methanol containing I% v/v hydrochloric acid for 20 hours at 45 °C. 
The methanol extracts were blown down under nitrogen and derivatised with 
trifluoroacetic acid (TFA) for 15 minutes at 65 °C. 
The ELISA sensitivity and specificity were 97 % and 100 % respectively, which are 
in the accepted range of values200 however the FN sample (sample 2) would have 
screened as positive at a lower cut-off value and this supports the 
recommendation by the SoHT. 28 out of 29 samples were screened and 
confirmed as positive using the cut-off in place in the Korean lab of 0.5 ng/mg 
d, 1-methamphetamine. GC-MS analysis found that this sample contained the 
lowest quantity of methamphetamine of all the samples tested (1.2 ng/mg). 
Average ELISA absorbance values for this sample and the cut-off calibrator were 
very close to each other (1.30 and 1.25 respectively). Furthermore, one of the 
duplicate sample absorbance values was 1.22 (a positive result) but the average 
absorbance value meant the screening result was negative. The sample was re- 
run on another day with similar results. Samples that screen at or near the 
ELISA cut-off should be further tested by confirmation. ' The FN result may be a 
result of using different ELISA and GC-MS extraction methods. 
A study published by the National Institute of Scientific Investigation in 2006 
determined criteria for obtaining positive results using the metabolite-to- parent 
drug ratios for methamphetamine in scalp hair. "' 2389 positive scalp hair 
samples collected from methamphetamine abusers were examined in the study. 
Amphetamine to methamphetamine drug ratios ranged from 0.04-1.16 (mean 
0.09). The hair samples were washed twice with water for 5 minutes and twice 
with methanol for 5 minutes. The authors propose that the detection of 
metabolites and parent drug within this ratio range is a useful means of 
distinguishing between external contamination and drug incorporation through 
ingestion. 
In the collaborative work presented in this thesis, the amphetamine to 
methamphetamine ratios ranged from 0.02-0.159 (mean 0.07). As the same GC- 
MS extraction method was used, the difference in the ratio range is probably due 
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to the different decontamination procedure used. I sample only contained 
methamphetamine. 
SAMHSA guidelines stipulate that a hair sample which has been confirmed as 
positive for methamphetamine using a cut-off concentration of 0.3 ng/mg should 
also contain amphetamine levels >_ LOD of the method. "' 
6.6.5 Conclusion 
An aqueous extraction method was validated for the purposes of ELISA screening 
of amphetamine, benzodiazepines, cocaine, methadone, methamphetamine and 
opiates in hair. The assays demonstrated high sensitivity, good precision and 
appropriate cross reactivity with the analytes found in hair. The ELISA method 
was applied successfully for the screening of post-mortem samples for cocaine, 
methadone and opiates in this chapter. There was an excellent correlation 
observed between the ELISA and in-house GC-MS method for opiates, with a 
sensitivity and specificity of 95 % and 100 % respectively. There was a small 
number of cocaine (n=8) and methadone (n=6) positive samples. This 
preliminary study suggested that a lower cut-off value may be required for 
cocaine screening as 2 FN results were produced using the SoHT and SAMHSA 
currently recommended cut-off of 0.5 ng/mg. A cut-off value of 0.2 ng/mg 
appears to be suitable for methadone screening. The 1 FN result was probably a 
result of a very low sample weight of approximately 1 mg. However more data 
is required to determine if the cut-off values recommended by the SoHT and 
SAMHSA for opiates and cocaine are suitable for screening hair samples. 
Hair samples collected from living methamphetamine abusers were also 
screened successfully using this ELISA method. Excellent correlation was 
observed between the ELISA and GC-MS methods, with a sensitivity and 
specificity of 97 % and 100 % respectively. The amphetamine to 
methamphetamine ratios ranged from 0.02-0.159 (mean 0.07). 
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7 Benzodiazepines in Hair 
7.1 Benzodiazeplnes 
Benzodiazepines are the most frequently prescribed drugs for the treatment of 
anxiety and insomnia. "* They are also used as sedatives, muscle relaxants and 
anticonvulsants prior to surgery and other medical procedures. Drug abusers 
take benzodiazepines as illicit replacement drugs, sometimes simultaneously 
with alcohol and other drugs such as opiates, sedatives, antidepressants and 
neuroleptics21 to either calm themselves down or amplify the drug induced high. 
Benzodiazepines are highly addictive, cheap and widely available and are 
therefore widely abused. "' One study in the west of Scotland in 1995-1998 
found that 45 % of drug related deaths tested positive for diazepam while 33 % 
of these cases tested positive for temazepam. '' An assessment of drug 
prevalence in the same region during the same time period found 
benzodiazepines to be present in 82 % of cases. "' A more recent evaluation of 
drug-related deaths in the Greater Glasgow National Health Board Area in 2006 
found benzodiazepines to be present in 79 % of cases21', a figure which is similar 
to the findings of the earlier study in the west of Scotland in 1995-1998. A 
study in Denmark, Iceland, Finland, Norway and Sweden in 2002 frequently 
detected benzodiazepines in addition to the main intoxicant., " Diazepam and 
flunitrazepam were most commonly associated with drug-related deaths. 
Ch lord iazepoxide is the prototype of the benzodiazepine drug class and was the 
first commercially available benzodiazepine which was approved for human use 
in 1960.17' The Scottish Health Statistics for 2006-2007 show that diazepam is 
currently the most commonly prescribed benzodiazepine in Scotland. " Newer 
and shorter-acting benzodiazepine drugs included in this study such as 
temazepam, oxazepam, lorazepam, nitrazepam and flunitrazepam are also 
prescribed in the UK and in many other countries worldwide. 
7.2 Pharmacokinetics, Metabolism and Excretion 
The molecular structures are given for the nine benzodiazepines included in this 
study in Figure 7-1. The pharmacokinetic and physicochemical data are also 
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provided for these benzodiazepines. No data is available for 7-AF however the 
data can be assumed to be similar to that for flunitrazepam. 
H, C 
Ct 
Diazepam 
H, C 
Cl 
Temazepam 
N 
1O 
Cl 
Nordlazepam 
02N' N Cl 
Nitrazepam 
H3C 
7-AF 
H 
Lorazepam 
Figure 7.1 Molecular structures of benzodiazepines 
Oxazepam 
Flunitrazepam Chlordiazepoxide 
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Table 7.1 Pharmacokinetic and physicochemical data for benzodiazepines176 
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Half Life (hr) Vd (L/kg) Protein Binding (96) pK. 
Ch lordiazepoxide 6.27 0.3.0.5 94 4.8 
Diazepam 21-37 0.7-2.6 96 3.4 
Flunitrazepam 9-25 3.4-5.5 78 1.8 
Lorazepam 9.16 0.9-1.3 80 1.3,11.5 
Nitrazepam 17-48 2-5 87 3.2,10.8 
Nordiazepam 31.97 - 97 3.5,12.0 
Oxazepam 4-11 0.7-1.6 87-94 1.7,11.6 
Temazepam 3.13 0.8.1.0 97 1.3 
Chlord iazepoxide is metabolised by N-demethylation to form 
norchlordiazepoxide, which is then further metabolised to demoxepam by 
deamination. These 2 major metabolites are as pharmacologically active as the 
parent drug. The reduction of demoxepam will produce nordiazepam which is 
also an active metabolite and is found in the plasma of patients undergoing long- 
term therapy treatment. Oxazepam is produced by the hydroxylation of 
nordiazepam but has not been detected in plasma. Less than 1% of a dose is 
excreted as the parent drug; about 6% is excreted as demoxepam while most is 
excreted as glucuronide conjugates of oxazepam. "b 
Diazepam is converted to nordiazepam by N-demethylation in the liver. Both of 
these compounds are further converted to oxazepam and temazepam by 
hydroxylation. The 3-hydroxy derivatives oxazepam and temazepam do not 
accumulate in plasma or blood to any significant extent. Trace amounts of 
diazepam and nordiazepam are found in urine; about 33 % of the dose is 
excreted as oxazepam glucuronide conjugates and about 20 % as conjugates of 
nordiazepam, 4'-hydroxydiazepam and temazepam. "b 
Flunitrazepam and nitrazepam are both metabolised by reduction of the nitro 
group to form 7-amino metabolites. A single 2 mg dose of flunitrazepam 
produces a 7-AF concentration of 50-500 ng/mL within 6-24 hours. 16 
Lorazepam is rapidly conjugated with glucuronic acid following ingestion to form 
an inactive metabolite. This accumulates in plasma to a greater extent than the 
parent drug. "' Trace amounts of unchanged lorazepam are found in urine. Most 
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of the dose is eliminated as lorazepam gtucuronide with the rest being 
conjugates of minor hydroxylation metabolites. 
Oxazepam conjugates are also rapidly formed following ingestion but is found to 
a limited extent in serum. Most of the excreted drug in urine after 48 hours is 
oxazepam glucuronide. Temazepam is converted to oxazepam during 
metabolism. Both compounds form glucuronide conjugates. The majority of 
excreted drug in urine is temazepam glucuronide. 
7.3 Previously Reported Methods of Analysis 
The detection of benzodiazepines in hair is relatively difficult due to the low 
levels which incorporate in the hair. Sramek first reported the detection of 
diazepam in hair by RIA In 1992.202 This work was followed by the analysis of 
benzodiazepines in hair using highly sensitive analytical methods. 
Benzodiazepines have been detected in the hair of living and deceased users by 
GC-/viS214,215 216,2t7,2t1, HPLCZ19,220, and LC. M5. MS. 91,94,108, "2, "5,147,221 Various extraction 
methods have been reported including alkaline digestionu", acid hydrolysis223, 
enzymatic treatments40'2" and Soerensens buffer. 224,217.219 
There have been a number of studies using gas chromatography-negative ion 
chemical ionisation-mass spectrometry (GC-NCI-MS) for the detection of 
benzodiazepines in hair as it is more sensitive than positive-ion chemical 
ionisation (PCI). 21e. m. 224.5,226 These were published in the mid to late 1990s prior 
to the increasing trend towards using LC-MS-MS for this purpose. One group 
achieved very low LOD values in the range 1-20 pg/mg for alprazolam, 
bromazepam, diazepam, flunitrazepam, lorazepam, nordiazepam, oxazepam and 
triazolam using a Soerensens buffer extraction. =1° A study by another group 
investigating alprazolam in rat hair also used a very sensitive method achieving 
an LOD of 25 pg/mg. =u An overnight alkaline digestion with sodium hydroxide at 
40 °C was used to extract the alprazolam. 
A GC-MS method was reported for the detection of benzodiazepines and other 
psychotropic drugs in hair. 114 The LOD values ranged from 0.01-2 ng/mg and the 
authors proposed that this method could be used for screening. 
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The use of an on-line restricted access extraction column coupled with an HPLC- 
diode array detector (DAD) has been reported. 226 Ammoniated methanol was 
found to produce optimum extraction recoveries from hair spiked with 
clonazepam, diazepam, flunitrazepam, midazolam and oxazepam. The LOD was 
0.2 ng/mg for all benzodiazepines in the study and acceptable recovery values (> 
90 %) were achieved using spiked hair. The validated method was applied to 2 
case samples. In one of the cases, flunitrazepam (Rohypnole) was detected in 3 
hair segments with the concentration ranging from 3.2-3.9 ng/mg. The other 
case sample was collected from an individual who sometimes used oxazepam 
(Semesta®). Two segments were analysed in this case and no oxazepam was 
detected. It was proposed that this was because oxazepam has a shorter half 
life compared to other benzodiazepines and is a polar compound which would 
not readily incorporate into hair. The simultaneous determination of these 
benzodiazepines using this HPLC method was rapid and therefore suitable for 
routine analyses. It was proposed that the use of a MS detector would improve 
the results. Seven extraction methods were compared for the extraction of 
incorporated benzodiazepines from rat hair by HPLC and GC-M5. '2 The method 
which produced the highest recovery for diazepam, flurazepam and medazepam 
was an overnight extraction in methanol-TFA (50: 1 v/v) followed by LLE with 
dichloromethane. 
Another HPLC method for the detection of psychotropic drugs in hair (including 
benzodiazepines) found that the method was not sensitive enough to detect 
diazepam, nitrazepam and oxazepam in post-mortem samples collected from 
individuals who were known to be taking psychotropic drugs prior to death. u' 
This study compared extraction techniques from post-mortem hair samples and 
found that alkaline digestion with sodium hydroxide was more effective at 
recovering benzodiazepines from case hair than acidic (dilute hydrochloric acid), 
methanolic or enzymatic (Subtilisin) treatments. This is in agreement with the 
findings of another study. 116 The authors did however recommend the use of 
alternative procedures to sodium hydroxide digestion for the optimal detection 
of benzodiazepines in hair since all benzodiazepines were degraded under 
alkaline conditions. 
As discussed in chapter 4, LC-MS is becoming increasingly popular due to simpler 
sample preparation requirements, its ability to analyse compounds not suitable 
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for GC and its excellent sensitivity and specificity. Reports on benzodiazepine 
detection in hair using LC-MS have recently become more common than GC-MS. 
An LC-MS-MS method was reported for the detection of sedatives (including 
benzodiazepines) in hair and nail samples. Dichloromethane was used as the 
organic solvent in the LLE. The hair samples were initially incubated overnight 
in methanol/TFA (50: 1 v/v) at room temperature. The LOD values for the 
selected benzodiazepines were very low; in the range of 0.20-6.00 pg/mg. 227 A 
mixture of diethyl ether/dichloromethane (10: 90 v/v) was used by another group 
as the organic phase in a LLE for 16 benzodiazepines following incubation of the 
hair in Soerensens buffer. "' The LOD values in this study were in the range of 
0.5-5 pg/mg. It was proposed that this method would be suitable for screening 
purposes and is capable of monitoring single dose exposures. 
SPE methods have also been reported for extraction of benzodiazepines from 
hair. 9192'108"41 One group reported an extraction method using Bond Elut Certify' 
SPE columns for sample clean-up after enzymatic digestion with proteinase K. 141 
The method was applied to hair samples collected from forensic and clinical 
psychiatric patients. The LOD values ranged from 0.025-0.125 ng/mg. Recent 
work carried out within the Forensic Medicine and Science Section at the 
University of Glasgow has involved the use of molecularly imprinted solid phase 
extraction (MISPE) for extracting benzodiazepines from hair. 91'92 The results were 
compared with a classical SPE method as discussed in section 7.6.6 of this 
chapter. 
7.4 Aim 
There were two aims of this study. The first was to develop and validate an 
ELISA and LC-MS-MS method to screen and confirm 9 benzodiazepines in post- 
mortem hair samples. The second aim was to compare this validated SPE 
method with a novel MISPE method for the detection of benzodiazepines in 10 
post-mortem samples. The MISPE method was developed and validated by Dr 
Marinah Ariffin, a colleague within the Forensic Medicine and Science Section at 
the University of Glasgow at the time of the study. " 
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All samples were post-mortem scalp hair samples submitted to the toxicology 
laboratory of the Forensic Medicine and Science Section at the University of 
Glasgow for routine testing. The samples were tested for diagnostic purposes 
and the results were reported to the Procurator Fiscal. 
7.5.2 Chemicals 
Methanol, acetonitrile, acetic acid, ammonium hydroxide, cyclohexane, ethyl 
acetate, formic acid, dichloromethane, toluene and propan-2-ol were purchased 
from BDH (Poole, UK) and were of analytical grade. Ammonium formate and 
sodium dodecyl sulfate were purchased from Sigma-Aldrich (Dorset, UK). 7-AF, 
flunitrazepam, oxazepam, lorazepam, ch lord iazepoxide, temazepam, diazepam, 
nordiazepam and nitrazepam, 7-AF-d7, flunitrazepam-d7, oxazepam-d5, 
lorazepam-d4i temazepam-d5, diazepam-d5 and nordiazepam-d5 used in the LC- 
MS-MS confirmation were obtained from Promochem (Teddington, England). 
Clean Screen® (ZSDAU 020) mixed mode SPE columns were purchased from 
United Chemical Technologies Incorporation (Pennsylvania, US). 
Benzodiazepine Direct ELISA kits were purchased from Immunalysis (Pomona, CA, 
USA). The kits contained a 96-well antibody-coated microplate, benzodiazepine 
conjugate labelled with horseradish peroxidase (HRP), substrate solution 
containing 3,3', 5,5'- tetra methyl benzidine (TMB) and stop solution containing 
1N hydrochloric acid. Hair extraction buffer (0.025 M monobasic phosphate 
buffer pH 2.7), neutralising buffer (0.5 M dibasic phosphate buffer pH 9.0) and 
phosphate buffer saline (0.1 M, pH 7.0) used to dilute hair extracts in the ELISA 
test were also obtained from the Immunalysis Corporation. Disposable 
borosilicate glass culture tubes (75 x 12 mm) were obtained from VWR 
International, UK. 
Diazepam for polymer synthesis in the MISPE work was obtained from Roche 
(Hertfordshire, UK). Methacrylic acid (MAA) and ethylene glycol dimethacrylate 
(EGDMA) were from Aldrich (Steinheim, Germany), chloroform was from 
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Rathburn (Peebles, UK) and 2,2'-azobisisobutyronitrile (AIBN) was from Acros 
Organics (Gee[, Belgium). 1 mL polyethylene SPE cartridges without sorbent and 
frits (20 pm mean pore size) for diazepam MISPE were purchased from 
International Sorbent Technology Limited (Mid Glamorgan, UK). 
7.5.3 Standard Solutions 
Individual drug stock standard solutions and deuterated drug standards were 
obtained as 100 pg/mL prepared in methanol. For LC-MS-MS confirmation, a 
combined working drug solution of 7-AF, chlordiazepoxide, diazepam, 
flunitrazepam, lorazepam, nitrazepam, nordiazepam, oxazepam and temazepam 
was prepared at 1 pg/mL by 100-fold dilution with methanol. This was achieved 
by adding 25 pL of each 100 pg/mL drug solution into a 25 mL volumetric flask 
and making up the volume to the 25 mL mark with methanol. A combined 
working deuterated standard solution of the 7-AF-d7, diazepam-d5, 
flunitrazepam-d7, lorazepam-d4i nordiazepam-d5, oxazepam-d5 and temazepam- 
d5 was also prepared at 1 pg/mL in the same way as the working drug solution. 
It was not financially viable to use chlordiazepoxide-d5 therefore oxazepam-d5 
was selected for ch lord iazepoxide quantitation since its retention time (tR) was 
close to the tR for chlordiazepoxide (5.1 and 6.2 minutes respectively). The m/z 
of the nitrazepam-d5 precursor ion is the same m/z of the oxazepam precursor 
ion (m/z = 287) and both have a similar tR of 5.8 minutes, resulting in co-elution. 
Therefore oxazepam-d5 was used for nitrazepam quantitation. 
7.5.4 Extraction Solutions and Mobile Phase 
7.5.4.1 Preparation of 0.1 M, pH 6.0 Phosphate Buffer 
The solution was prepared as described in section 5.6.4.3. 
7.5.4.2 Preparation of Mobile Phase 
The mobile phase consisted of a mixture of aqueous buffer and acetonitrile. To 
prepare the 3 mM ammonium formate + 0.001 % formic acid aqueous buffer, 
0.189 g of ammonium formate and 10 µL of concentrated formic acid were 
added to a1L volumetric flask and made up to the mark with deionised water. 
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A MiniPrep 75 automatic pipettor from Tecan (San Jose, CA) was used. The 
microplate wells were washed using a Columbus Plus washer system and read 
with a Sunrise Remote EIA autoreader also from Tecan (Grödlg, Austria). 
7.5.5.2 LC-MS-MS 
LC-MS-MS analysis was carried out using a Surveyor HPLC system with an LCQ 
Deca XP Pluslm ion trap mass spectrometer (Thermo Finnigan, San Jose, CA, USA). 
Chromatographic separation was performed using a Gemini C18 column (150 mm 
x 2.0 mm ID, 5 µm particle size), fitted with a guard column with identical 
packing material (4 mm x 2.0 mm, 5 pm particle size) (Phenomenex, Torrance, 
CA, USA). 
7.5.6 ELISA and LC-MS-MS Methods 
7.5.6.1 ELISA Development 
As there are generally low levels of benzodiazepines detected in hair, the 
benzodiazepines assay was optimised to achieve maximum sensitivity. Sample 
volumes (25,50 NL) and pre-incubation times (30,60,120 minutes) were 
optimised. The parameters which produced the best separation of absorbance 
values between blank hair and the cut-off calibrator of 0.1 ng/mg oxazepam 
were used for analysis (Table 7-2). 
Table 7-2 Sample volume and pre-incubation optimisation results 
Sample Volume (NL) Pre-incubation time (min) 
Average B/BO (%) 
for n=5 
25 30 88.6 
25 60 86.9 
25 120 82.0 
50 30 74.3 
50 60 71.9 
50 120 70.8 
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As shown in Table 7-2,50 pL sample volume with a pre-incubation time of 2 
hours produced the best separation of absorbance values between the blank and 
cut-off calibrator. However 50 pL sample volume with a pre-incubation time of 
1 hour produced a marginally smaller difference and this was selected for 
validation due to the shorter analysis time. The optimised ELISA procedure for 
benzodiazepine screening in hair is described below. This method was used to 
validate the assay and was applied in the screening of post-mortem hair 
samples. The sample preparation method was described in section 6.4.1. 
50 pL of diluted extract of calibrator, control or sample was added to the 
microplate wells in duplicate and left to infiltrate the antibodies at room 
temperature for 1 hour. Subsequently, 100 pL of enzyme conjugate was added 
to each well and the plate was left to incubate for a further hour at room 
temperature. After this time, the wells were washed 6 times with deionised 
water (6 x 300 pL). 100 pL TMB was added to each well and the plate incubated 
in the dark at room temperature for 30 minutes. The reaction was stopped using 
100 pL 1N hydrochloric acid and the plate was read at 450 nm with a reference 
wavelength of 650 nm. 
The case samples were considered to be presumptively positive if the B/Bo (%) 
value was lower than the B/Bo (%) value of the 0.1 ng/mg oxazepam cut-off 
calibrator. 
7.5.6.2 LC-MS-MS 
7.5.6.2.1 Sample Preparation 
The decontamination, segmentation and cutting up of the hair samples was 
described previously in section 6.4.1. After cutting, each sample was split into 3 
separate vials for ELISA, SPE and MISPE procedures. As the likelihood of 
benzodiazepine contamination is low, the dichloromethane washings were not 
analysed. 
An alkaline incubation using methanol with 25 % ammonium hydroxide was used 
prior to benzodiazepine extraction by solid phase. 42 Furthermore, ammoniated 
methanol was found to produce slightly higher recoveries than just methanol for 
diazepam, oxazepam and flunitrazepam in another study. 226 1.5 mL of methanol: 
25 % ammonium hydroxide solution (20: 1 v/v) was added to each calibrator and 
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sample, left to sonicate for one hour and stored at room temperature overnight. 
The solvent was removed from the vials and transferred to a test tube. The hair 
was washed twice with 0.75 mL solvent and the washings removed and 
transferred to a test tube. The contents of the test tubes were evaporated to 
dryness under nitrogen and reconstituted in I mL of phosphate buffer. 
7.5.6.2.2 SPE 
The solid phase extraction method for this study operates by a mixed-mode 
cationic exchange mechanism. The sorbent is composed of C8 chains and 
benzene sulfonic acid. The benzodiazepines adsorb onto the column via both 
hydrophobic and ionic attraction. 
Clean Screen® columns (ZSDAU 020) were conditioned sequentially with 3 mL 
methanol, 3 mL distilled water and 1 mL of phosphate buffer. The vortexed 
samples were loaded onto the columns and allowed to drip through without the 
presence of a vacuum. The columns were washed sequentially with 2 mL 
distilled water, 2 mL phosphate buffer: acetonitrile (80: 20 v/v), 2 mL 
cyclohexane and 2 mL distilled water. The columns were dried under full 
vacuum for 5 minutes after the second wash step, for 1 minute after the third 
wash step and for 5 minutes after the final wash step. The benzodiazepines 
were eluted using 1.5 mL 2% ammoniated ethyl acetate (followed by a2 minute 
drying step under full vacuum) and 1.5 mL dichloromethane: isopropanol: 
ammonium hydroxide (78: 20: 2 v/v). The eluted samples were blown down to 
dryness under a stream of nitrogen and reconstituted in 100 pL of the mobile 
phase (initial conditions 3 mM ammonium formate (65 %) and acetonitrile (35 
%)). 20 pL of the reconstituted extract was injected for analysis. 
7.5.6.2.3 MISPE 
The molecularly imprinted polymer (MIP) is synthesised in the presence of a 
template molecule (in this study diazepam) and consists of a highly cross-Linked 
porous polymer network. After the polymerisation, the template is removed, 
leaving a polymer network with strategically positioned functional groups in 
binding sites that are complementary in size and shape to the template 
molecule. These binding sites have the potential to re-bind with the template 
molecule or other molecules, which have a similar molecular structure to the 
template molecule, in a strong and selective way. 
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Diazepam MIP cartridges were prepared as detailed in another study. 94 The 
cartridges were conditioned using 0.5 mL toluene. The vortexed samples were 
added to the columns and allowed to drip through without the application of a 
vacuum. The columns were washed with 0.3 mL toluene and eluted using 0.5 mL 
15 % (v/v) acetic acid in acetonitrile. The eluted samples were blown down 
under nitrogen and reconstituted with 100 pL of the mobile phase (initial 
conditions 3 mM ammonium formate (65 %) and acetonitrile (35 %)). 20 pL of the 
reconstituted extract was injected for analysis. 
7.5.7 LC-MS-MS Analysis 
The C18 column was maintained at 25 °C. The mobile phase consisted of 3 mM 
ammonium formate + 0.001 % formic acid (A) and acetonitrile (B) at a flow rate 
of 0.3 mL/min. The initial gradient conditions were 65 % A, decreasing to 20 %A 
after 13 minutes. The mobile phase composition was 10 %A from 13.5 to 16.5 
minutes. Initial gradient conditions were restored from 16.5 to 20 minutes as 
this was sufficient time to allow the system to equilibrate. The total run time 
was 20 minutes. A divert valve taking LC flow to waste was used for the last 7 
minutes of the run to preserve the MS source. 
All mass spectral data was acquired in electrospray positive ion mode. The 
capillary temperature, sheath and auxiliary gas flow rates and collision energies 
were optimised for each analyte. The probe voltage used was 4.5 W. Internal 
standard data was acquired in selective ion monitoring (SIM) mode and analytes 
were identified on the basis of their full MS-MS spectra. 2 product ions were 
monitored where possible, to gain qualitative identification data. The major 
product ion was used for quantitation. Optimum tuning parameters, precursor 
and product ions are shown in Table 7-3. 
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Table 7-3 Optimum tuning parameters, precursor and product ions 
NT. 090-e00 SM. 50 
Analyte 
Sheath 
Gas 
(AU) 
Auxiliary 
Gas 
(AU) 
Capillary 
Temp 
(°C) 
Collision 
Energy 
(ý) 
Precursor 
m/z 
Product 
m/z 
7-AF 20 20 280 40 284 264,256 
Chlordiazepoxide 20 20 300 29 300 283*, 241 
Diazepam 20 20 300 42 285 257*, 222 
Ftunitrazepam 20 20 280 43 314 286*, 268 
Lorazepam 30 20 290 30 321 303*, 275 
Nitrazepam 30 20 300 42 282 254,236* 
Nordiazepam 20 15 300 41 271 243*, 140 
Oxazepam 20 20 300 29 287 269*, 241 
Temazepam 20 20 300 29 301 283*, 255 
`= quantitation ion 
LC-MS-MS chromatograms of the product quantitation ions are shown in Figure 
7-2 for the lowest standard concentration (2 ng/ 30 mg blank hair). 
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Figure 7-2 Chromatograms of product quantitation ions for 2 ng/ 30 mg standard 
7.6 Method Validation 
7.6.1 ELISA 
The ELISA method was validated for the benzodiazepines assay as described in 
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mc2 
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2o. OO. 3O "°i IL62ro etýmue 
section 6.5. 
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7.6.2 LC-MS-MS 
7.6.2.1 Linearity 
Chapter 7,114 
Linearity was established over the concentration range of 2-100 ng/30 mg of 
blank hair to produce a regression line for each analyte. This was achieved by 
adding 2,5,10,25,50 and 100 pL of 1 pg/mL working drug solution to 30 mg 
blank decontaminated hair. 100 ng of deuterated internal standard was also 
added by adding 100 pL of 1 pg/mL working deuterated standard solution. A 
blank containing only internal standard and a blank containing no standards were 
also extracted and analysed. 
7.6.2.2 Recovery 
Recovery was calculated for each benzodiazepine at 10 ng/30 mg and 
50 ng/30 mg. Each concentration was extracted five times without the internal 
standard present. Two unextracted standards were also prepared at each 
concentration without internal standard and were kept in the fridge throughout 
the extraction. Before evaporating the samples to dryness with nitrogen, 100 ng 
of internal standard was added to each tube, including the unextracted 
standards. After the samples were dry, they were reconstituted in 100 pL of 
mobile phase and 20 pL was injected for analysis. 
The recovery was expressed as a percentage by dividing the average peak area 
ratio of five extracted standards with the average peak area ratio of two 
unextracted standards and multiplying by 100. 
An additional recovery experiment was carried out for one post-mortem hair 
sample to determine the efficiency of the extraction. The sample was cut up 
into four portions. Each portion was left to incubate in the alkaline extraction 
medium for 1,2,4 and 16 hours and subsequently extracted using the SPE 
method described in section 7.5.6.2.2. 
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7.6.2.3 Stability 
Chapter 7,115 
The stability of the benzodiazepines was assessed during the alkaline overnight 
incubation by comparing the average peak area ratio of four extracted samples 
at 50 ng/30 mg with the average peak area ratio of two unextracted samples. 
The stability during evaporation was also determined. The total extraction 
recovery of benzodiazepine amino metabolites was found to be at least 25 % 
lower than the extraction recovery of their respective parent drugs. 235 This was 
attributed to loss of the 7-amino metabolites during evaporation and the authors 
added tartaric acid to prevent this. In this current study, evaporation of the SPE 
eluant was investigated as a potential means of lowering analyte recovery. Four 
tubes containing SPE eluant were spiked at 50 ng and evaporated under nitrogen 
at 40 °C. The peak area ratio results were compared with two samples spiked at 
the same concentration which were not prepared in eluant and were left to 
evaporate at room temperature. 
7.6.2.4 Intra-Day Precision between Extracts 
Five extracted standards were prepared at 10 ng/30 mg and 50 ng/30 mg. 
Standards were prepared at 2,5,10,25 50 and 100 ng/30 mg to produce 
linearity data. A blank was prepared containing no standards as well as a blank 
containing only internal standard. The extracts were reconstituted in 100 pL of 
mobile phase and 20 pL was injected for analysis. 
Intra-day precision for each extracted standard (n=5) was calculated by 
substituting the average peak area ratio value into the regression equation for a 
particular drug. The mean concentration and % RSD were calculated. 
7.6.2.5 Inter-Day Precision 
The inter-day precision was calculated at 10 ng/30 mg and 50 ng/30 mg using 
five sets of linearity data acquired on five different days (n=25). The average 
peak area ratio value for the five days was substituted into the regression 
equation for a particular drug. The mean concentration and % RSD was 
calculated. 
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7.6.2.6 LOD and LOQ 
Chapter 7,116 
The LOD for each drug was calculated statistically as the intercept of the 
calibration graph plus three times the standard error of the line as shown in 
Equation 7-1 and Equation 7-2.236 The LOQ was calculated statistically as the 
intercept of the calibration graph plus five times the standard error of the line 
as shown in Equation 7-3 and Equation 7-4.236 The values were calculated where 
YB is the intercept, s6 is the standard error of the regression line and m is the 
gradient. 30 mg blank hair portions were spiked with 0.1,0.2,0.3,0.4,0.5, 
0.75,1,2 and 5 ng to produce the regression lines used to calculate the LOD and 
LOQ. 
Equation 7-1 YLOD = YB + 3s 
Equation 7-2 LOD = 
(YLOD 
-Ya) 
m 
Equation 7-3 YLOQ = YB + 5s 
Equation 7-4 LOQ = "' 
LOQ -Ya 
m 
7.6.2.7 Matrix Effect 
A previously published quantitative assessment of the hair matrix effect (ME) 
was carried out for the LC-MS-MS method-` The aim of the experiment was to 
obtain more accurate data on the extent of the hair ME between individuals. 
Drug free hair was collected from five individuals. Each sample was 
decontaminated according to the procedure described in section 6.4.1. 
An unextracted set of five 50 ng standards containing 100 ng internal standards 
was prepared to assess the MS-MS response for neat standards of the analytes of 
interest (set 1). The contents of the vials were evaporated to dryness using 
nitrogen and reconstituted in 100 pL of mobile phase initial conditions. An 
extracted set of five 50 ng standards containing 100 ng internal standards was 
also prepared in hair extracts obtained from five individuals (set 2). For set 2, 
approximately 30 mg of blank, decontaminated hair was weighed out and taken 
through the extraction process. The analytes and internal standards were spiked 
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into these after the SPE. The eluants were evaporated to dryness using nitrogen 
and reconstituted in 100 pL of mobile phase (initial conditions 3 mM ammonium 
formate (65 %) and acetonitrile (35 %)). 20 pL of the reconstituted extract was 
injected for analysis. 
The average peak area ratio was compared between the two data sets to assess 
the absence or presence of ME. The absolute ME (% ME) was calculated using 
Equation 7-5 where A is the standard response obtained from neat solutions in 
set 1 and B is the corresponding response for standards spiked into hair extracts 
after SPE. 
Equation 7-5 ME(%) =Äx 100 
The absolute ME calculated in this way takes into account ion suppression and 
ion enhancement. It is described as the "absolute" ME as it compares the 
response of standard present in the hair extract to the response of a standard 
prepared in neat solutions without the presence of the matrix. A value of 100 % 
indicates that the standard response from the neat solution was the same as the 
standard response in the hair extracts and no absolute ME was observed. A value 
<100 % indicates ion suppression while a value >100 % indicates ion 
enhancement. 
The relative ME (% RME) was also calculated as it is very important to compare 
ME values between hairs collected from different individuals to assess any inter- 
individual variations that may exist. Hair collected from different individuals 
may contain different endogenous compounds that may not necessarily have 
been present in the hair used to validate the method. If these compounds are 
undetected and co-elute with the analytes of interest, the efficiency of analyte 
ionisation could be affected, resulting in a decreased or increased MS-MS 
response. 
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7.6.3 Results 
7.6.3.1 Linearity 
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The gradient and intercept values are shown in Table 7-4 along with the 
correlation coefficient (R2) values for the regression lines. All regression lines 
had an RI > 0.99. 
Table 7-4 Gradient, intercept and R2 values for regression lines 
Analyte Equation of line R 
7-AF y=0.0017x-0.0028 0.9981 
Chlordiazepoxide y=0.0129x-0.0156 0.9994 
Diazepam y=0.0016x-0.0032 0.9984 
Flunitrazepam y=0.0019x-0.0011 0.9992 
Lorazepam y=0.0092+0.0106 0.9974 
Nitrazepam y=0.0036x+0.0082 0.9977 
Nordiazepam y=0.0012x-0.0009 0.9995 
Oxazepam y=0.0093x-0.0122 0.9996 
Temazepam y=0.01 13x-0.0323 0.9985 
7.6.3.2 Recovery 
The recovery for each analyte is given in Table 7-5 for 10 ng/30 mg and 50 ng/30 
mg and ranged from 53-98 %. Generally the analytes had recoveries > 70 % at 
both concentrations. 7-AF and chtordiazepoxide recoveries were lower than the 
other analytes. 
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Table 7-5 Recovery in spiked hair 
Chapter 7,119 
Analyte 
Average % Recovery for n=5 (% RSD) 
10 ng/30 mg 50 ng/30 mg 
7-AF 53 (13) 55 (10) 
Chlordiazepoxide 59 (19) 63 (5) 
Diazepam 77 (13) 69 (2) 
Flunitrazepam 90 (11) 89 (6) 
Lorazepam 76(11) 94(10) 
Nitrazepam 98 (10) 91 (9) 
Nordiazepam 88 (12) 82 (5) 
Oxazepam 71 (10) 83 (8) 
Temazepam 73 (16) 88 (8) 
The experiment carried out on the post-mortem hair sample to assess the 
efficiency of the extraction found that the greatest concentration of diazepam 
and nordiazepam was detected following 16 hour incubation (4.26 and 1.67 
ng/mg respectively). The diazepam and nordiazepam concentrations detected 
after 1,2 and 4 hour incubation were similar and were within a small range 
(2.40-2.70 ng/mg and 0.90-1.16 ng/mg respectively). This incubation time of 16 
hours was selected for method validation. 
7.6.3.3 Stability 
The recovery for all benzodiazepines following the alkaline overnight extraction 
ranged from 89-103 % as shown in Table 7-6. These results show that the milder 
alkaline extraction using methanol/25 % ammonium hydroxide (20: 1) is suitable 
for benzodiazepine extraction. The lower 7-AF and chlordiazepoxide recoveries 
were not a result of alkaline hydrolysis. Lorazepam was hydrolysed to a greater 
extent than temazepam or oxazepam, which have a similar molecular structure 
to lorazepam. It is possible that the presence of an electron withdrawing 
chlorine atom on both aromatic rings of the lorazepam structure (Figure 7-1) 
increases the lability of the ring C=N to attack by the base used in the 
extraction, promoting hydrolysis. Temazepam and oxazepam only have one 
electron withdrawing chlorine atom and are, therefore, less susceptible to 
hydrolysis. 
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For the evaporation experiment, all benzodiazepines with the exception of 7-AF 
and chlordiazepoxide had a recovery >_ 95 %. 7-AF recovery was 73 % and 
chlord iazepoxide recovery was 87 %, which partly explains the lower extraction 
recoveries found for these analytes. The recovery values for the evaporation 
step are shown in Table 7-6. 
Table 7-6 Benzodiazepine stability during alkaline incubation and evaporation step 
Analyte 
Average % Recovery (% RSD) for n=4 
Alkaline Incubation Evaporation Step 
7-AF 100 (2) 73 (6) 
Chlordiazepoxide 98 (2) 87 (8) 
Diazepam 96 (4) 100 (5) 
Flunitrazepam 99 (4) 107 (1) 
Lorazepam 89 (9) 104 (5) 
Nitrazepam 103 (6) 102 (4) 
Nordiazepam 98 (12) 95 (12) 
Oxazepam 98 (6) 99 (4) 
Temazepam 91 (3) 104 (7) 
7.6.3.4 Intra-Day and Inter-Day Precision 
As shown in Table 7-7 and Table 7-8, the intra-day and inter-day precision were 
all generally acceptable within SOFT regulations of ± 20 %. " The % RSD values 
were generally lower at the higher concentrations. As expected, the intra-day 
precision was lower than the inter-day precision. 
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Table 7-7 Intra-day precision between extracts 
Chapter 7,121 
Analyte 
Intra-Day Precision (% RSD) for n=5 
10 ng/30 mg 50 ng/30 mg 
7-AF 10.9 (5.2) 50.1 (1.4) 
Chlordiaze oxide 9.6 (9.7) 45.3 (6.1) 
Diazepam 9.6 (4.5) 51.4 (4.0) 
Flunitrazepam 8.5 (3.0) 49.3 (2.1) 
Lorazepam 9.5 (7.1) 49.1 (5.8) 
Nitrazepam 10.0 (9.0) 52.4 (4.1) 
Nordiazepam 9.7 (8.8) 45.9 (3.1) 
Oxazepam 7.0 (10.8) 58.6 (7.1) 
Temazepam 9.1 (12.3) 53.3 (4.3) 
Table 7-8 Inter-day precision between extracts 
Inter-Day Precision (% RSD) for n=25 Analyte 10 ng/30 mg 50 ng/30 mg 
7-AF 10.3 (9.9) 50.7 (4.5) 
Chlordiazepoxide 8.0 (19.9)* 53.3 (16.5) 
Diazepam 9.2 (21.1)* 45.9 (11.8) 
Flunitrazepam 9.1 (9.8) 48.8 (6.5) 
Lorazepam 7.9 (21.2) 50.6 (13.5) 
Nitrazepam 8.9 (7.7) 47.9 (11.1) 
Nordiazepam 9.2 (9.3) 48.0 (5.5) 
Oxazepam 6.3 (13.0) 49.2 (19.6) 
Temazepam 7.8 (18.6) 48.2 (10.0) 
'n=24 
7.6.3.5 LOD and LOQ 
The LOD and LOQ for all the benzodiazepines tested ranged from 
0.03-0.62 ng/30 mg and 0.05-1.02 ng/30 mg respectively. The values are shown 
in Table 7-9. 
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Table 7-9 LOD and LOQ 
Chapter 7,122 
Analyte LOD (ng/30 mg) LOQ (ng/30 mg) 
7-AF 0.14 0.23 
Chlordiazepoxide 0.07 0.13 
Diazepam 0.13 0.22 
Flunitrazepam 0.30 0.50 
Lorazepam 0.62 1.02 
Nitrazepam 0.03 0.05 
Nordiazepam 0.24 0.41 
Oxazepam 0.11 0.19 
Temazepam 0.09 0.16 
7.6.3.6 Matrix Effect 
The % ME and % RME are shown in Table 7-10. % RME was calculated as the 
% RSD of the responses for the hair from 5 individuals. The % RSD for five 
unextracted standards is also shown in Table 7-10 to compare against the % RME. 
Table 7-10 Hair matrix effect 
Analyte % ME % RME 
% RSD for n=5 
unextracted 
standards 
7-AF 94 1.6 3.4 
Chlordiazepoxide 77 10.8 12.7 
Diazepam 84 10.5 3.4 
Ftunitrazepam 88 5.7 2.1 
Lorazepam 105 6.5 5.1 
Nitrazepam 79 9.3 8.7 
Nordiazepam 88 5.2 2.0 
Oxazepam 93 9.3 3.9 
Temazepam 96 10.5 1.6 
The % ME results show that there is some ion suppression for most of the 
benzodiazepines. In contrast, the lorazepam response shows slight 
enhancement. The % RME values were within the range of 1.6- 10.8 %. These 
values show that the method allows an acceptable level of precision between 
hair samples collected from five different individuals according to the intra-day 
and inter-day precision guidelines recommended by SOFT. " However acceptable 
% ME and % RME ranges have not been specified for LC-MS-MS yet as there is 
currently not enough data to provide these guidelines. Small differences 
between the values for the standards spiked into hair extracts after SPE (B 
values according to Equation 7-5) indicate that the MS-MS response from the 
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same quantity of analyte is similar in different hair samples. The difference in 
variability was higher for chlordiazepoxide, diazepam and temazepam. This 
indicates that the interferent from the hair matrix that co-elutes at the same 
time as these benzodiazepines is present in different quantities between 
individuals. 
7.6.4 ELISA vs LC-MS-MS Results 
The validated ELISA and LC-MS-MS methods for the detection of benzodiazepines 
in hair were successfully applied to 13 post-mortem positive hair samples. "' 
Overall, the ELISA and LC-MS-MS results correlated well. 13 of the 16 hair 
samples were screened and confirmed as TP using a cut-off value of 0.1 ng/mg 
oxazepam. This cut-off value was used as it produced no FN results. Higher cut- 
off values of 0.2 and 0.5 ng/mg oxazepam produced 1 FN and 2 FN results 
respectively. Using a 0.1 ng/mg cut-off, the sensitivity and specificity of the 
ELISA method were 100 % and 81 % respectively versus LC-MS-MS. The results 
are shown in Table 7-11. 
Table 7-11 ELISA vs LC-MS-MS results for benzodiazepine positive hair samples 
ELISA LC-MS-MS (ng/m g) 
Sample 
Number 
Weight 
(mg) Equivalents 
OXAZ 
(ng/mg) 
Weight 
( g) 
1 8.96 > 0.5 13.23 - - 0.35 - - - 
2 10.18 > 0.5 9.88 <LOD 0.28 0.22 - - - 
3 8.19 > 0.5 9.29 0.65 1.20 0.24 - 0.24 - 
4 4.30 > 0.5 7.13 <LOD 0.36 0.31 0.89 - 0.38 
5 10.03 > 0.5 9.90 <LOQ 0.27 - - - - 
6 6.36 > 0.5 5.94 0.32 0.47 0.36 - - - 
7 10.33 > 0.5 9.86 0.46 - - - - - 
8 10.45 > 0.5 6.47 2.86 1.79 0.73 0.35 - - 
9 20.74 > 0.5 40.56 0.39 1.07 0.30 - - - 
10 10.23 > 0.5 9.95 < LOQ 0.31 0.22 - - - 
11 9.94 > 0.5 10.02 0.03 0.43 - - - - 
12 9.89 > 0.5 9.80 0.06 0.28 0.23 0.59 - - 
13 5.51 0.48 7.96 < LOQ - 0.27 - - - 
DZ=diazepam, Nuc=nomiazepam, I ML=temazepam, UXAL=oxazepam, NTZ=nitrazepam, 
LOR=lorazepam 
The benzodiazepines detected by LC-MS-MS included diazepam (10 samples), 
nordiazepam (10 samples), oxazepam (3 samples), temazepam (10 samples), 
lorazepam (1 sample) and nitrazepam (1 sample). The diazepam levels detected 
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in 3 of the 10 positive samples were below the LOQ therefore only 7 samples 
were reported as positive. Concentrations ranged from 0.01-2.86 ng/mg 
diazepam, 0.27-1.79 ng/mg nordiazepam, 0.35-0.89 ng/mg oxazepam and 0.22- 
0.73 ng/mg temazepam. One sample tested positive for lorazepam at 
0.38 ng/mg while another sample tested positive for nitrazepam at 0.24 ng/mg. 
Chromatograms are shown for a blank hair sample spiked with temazepam at the 
lowest standard concentration (Figure 7-3), a negative sample (Figure 7-4), a 
temazepam positive case sample (Figure 7-5) and a temazepam-d5 internal 
standard (Figure 7-6). 
Figure 7-3 Blank hair sample spiked with temazepam at 2 ng/ 30 mg 
D0®3ý 001 
I. - 
Figure 7-4 Negative hair sample 
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Figure 7-5 Temazepam positive case sample 
{ ,- 
Figure 7-6 Temazepam-d5 internal standard 
7.6.5 Discussion 
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A comparison of the hair and blood results shown in Table 7-12 (provided at the 
end of this chapter), found that diazepam was detected in 10 hair samples 
where a diazepam positive result was found in blood. 1 hair sample contained a 
diazepam level < LOD (0.13 ng/30 mg). Nordiazepam was not detected in 1 
sample in which the blood result was positive. Interestingly, temazepam was 
detected in 4 hair samples in which the blood result was negative. There was 
however 1 sample where the hair tested negative for temazepam in which the 
blood results were positive. The levels of temazepam in blood were very low in 
these cases (0.02 mg/L). These blood levels could have been from a naive user 
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but there was no information in the police report to support this. Oxazepam 
was detected in 1 hair sample in which the blood result was positive. 
Interestingly, it was detected in 2 hair samples where the blood result was 
negative. In contrast, 5 hair samples tested negative for oxazepam where the 
blood result was positive. The blood results were very low in three of these 
cases (samples 3,5 and 13). Lorazepam and nitrazepam were detected in 1 hair 
sample in which the blood result was negative. 
In general, benzodiazepine levels were in the ranges reported in the literature. 
With the exception of sample 8, nordiazepam was detected at a higher 
concentration than diazepam. This finding is consistent with other studies. ", " 
Oxazepam was only detected in 3 samples. A possible reason for this low 
detection rate may be that oxazepam has a relatively short half life compared to 
nordiazepam for example and is a polar compound which may not readily 
incorporate into hair. 22B Temazepam levels have not been widely reported in 
hair. In this study, temazepam levels were present within a relatively small 
range of 0.22-0.36 ng/mg with the exception of sample 8 which had a higher 
temazepam level of 0.73 ng/mg. A possible reason for the lower temazepam 
levels found in this study is that temazepam is likely to be present as a 
metabolite of diazepam, rather than the parent compound. In addition steady. 
state serum levels of oxazepam (0.05-0.40 mg/L) and temazepam (0.1-0.6 mg/L) 
are much lower than nordiazepam following diazepam use. 116 Lorazepam and 
nitrazepam levels in hair have also not been widely reported. The lorazepam 
positive sample was found to contain 0.38 ng/mg, which is slightly higher than 
the reported range of 31-300 pg/mg. 224'23' The nitrazepam level detected in 
sample 3 (0.24 ng/mg) was also higher than the range found in another study 
(0.05-0.13 ng/mg). 235 
Overall, it is difficult to directly compare the benzodiazepine levels detected in 
this study with those reported by other authors because of the range of 
extraction and analytical methods used which will have varying recoveries of the 
drugs from hair. 
It is also difficult to interpret the hair results since the amount and type of drug 
taken over the months prior to death is not known in the majority of cases. The 
individual from which sample 8 was collected was being prescribed 4x5 mg 
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diazepam tablets a day and 5 mg nitrazepam at night. It is not known how long 
the individual had been under this treatment. The highest diazepam level of all 
the hair samples tested was found in this particular sample however no 
nitrazepam was detected. The individual from which sample 12 was collected 
had been prescribed diazepam 6 months prior to death. From the background 
report, it is not known if the individually had been prescribed diazepam for 
chronic or single use. 
Another problem with the interpretation of results is that diazepam is 
metabolised to nordiazepam and temazepam which can both be further 
metabolised to oxazepam. As well as potentially being present in hair samples 
due to diazepam metabolism, nordiazepam, temazepam and oxazepam can also 
be ingested as parent drugs or could be present as an association with both 
metabolism and parent drug use. 
7.6.6 MISPE and SPE Case Results 
The MIP produced was selective for not only diazepam (the template) but also 
for nordiazepam, oxazepam, temazepam and nitrazepam because they are close 
structural analogues of diazepam. 
10 post-mortem hair samples were tested using MISPE to compare with the SPE 
method. The other samples did not have sufficient sample weight to test using 
MISPE as welt. The same incubation method as described in section 7.5.6.2.1 
was used prior to extraction. Benzodiazepines were detected in 9 samples using 
the MISPE method and in 7 samples using the classial SPE method. No 
benzodiazepines were detected by either extraction method in sample 3 where a 
very low level of nordiazepam was detected in the blood (0.01 mg/L). 
Diazepam was detected in 4 samples using MISPE where none was detected using 
SPE. Nordiazepam and oxazepam were also detected in 1 sample (samples 4 and 
2 respectively) at low levels using MISPE where none was detected using SPE. 
The results for sample 10 did, however, show a significantly lower oxazepam 
concentration using MISPE compared to SPE. Temazepam was detected in 2 
samples by SPE where none was detected by MISPE. The nitrazepam results for 
the two methods showed good correlation. 
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The MISPE and SPE results are provided in Table 7-13 (at the end of this chapter) 
along with the corresponding blood concentrations. The sample numbers in 
Table 7-13 do not correspond to the same samples provided in Table 7-12. In 
general, the hair results are in good qualitative agreement using both extraction 
methods. 
7.6.7 MISPE vs SPE Discussion 
The MISPE demonstrated higher extraction recoveries for 6 out of 9 analytes, 
whereas the SPE method achieved lower LOD values for 6 out of 9 analytes. The 
recovery, LOD and LOQ values for both extractions are given in Table 7-14. 
Table 7-14 Spiked recovery, LOD and LOQ of benzodiazepines using MISPE and SPE 
Analyte 
Mean % Recovery 
(% RSD) for n=5 at 
50 ng/30 mg 
LOD (ng/30 mg) LOQ (ng/30 mg) 
MISPE SPE MISPE SPE MISPE SPE 
7-AF 92 (2) 55 (10) 0.03 0.14 0.06 0.23 
Chlordiaze oxide 62 (14) 63 (5) 0.33 0.07 0.57 0.13 
Diazepam 93 (2) 69 (2) 0.09 0.13 0.14 0.22 
Flunitrazepam 39 (5) 89 (6) 0.78 0.30 1.32 0.50 
Lorazepam 97(17) 94(10) 0.66 0.62 1.11 1.02 
Nitrazepam 92 (5) 91 (9) 0.06 0.03 0.11 0.05 
Nordiazepam 103 (10) 82 (5) 0.21 0.24 0.33 0.41 
Oxazepam 73 (9) 83 (8) 0.13 0.11 0.21 0.19 
Temazepam 90 (13) 88 (8) 0.39 0.09 0.63 0.16 
In this study, benzodiazepine concentrations were measured in 9 post-mortem 
hair samples using MISPE and SPE sample preparation methods. The results show 
that diazepam was most frequently detected, followed by its metabolite 
nordiazepam. 
Both the MISPE and SPE methods were validated for 9 benzodiazepines. 94. "' 
However, only diazepam, its metabolites and nitrazepam were detected in the 
samples. The greater number of diazepam and nordiazepam positive samples 
detected using MISPE could be attributed to the higher extraction recovery and 
lower LOD values obtained when using this protocol compared to SPE. 
Conversely, temazepam was detected in less samples using MISPE compared to 
SPE due to the higher LOD value using MISPE. Temazepam recoveries for the two 
methods were comparable. 
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In the samples which tested positive for diazepam using both extraction 
methods, the concentration detected using MISPE was generally similar to those 
detected using SPE. The excellent recognition of the template molecule by the 
MIP resulting in a higher extraction recovery and lower LOD meant that 
diazepam was detected in 4 samples at low levels where SPE detected none. For 
the samples where both extraction methods tested positive for nordiazepam, 
temazepam and oxazepam, the concentrations were always higher for SPE. 
Interestingly, oxazepam was detected in 1 sample using MISPE where none was 
detected using SPE despite its slightly lower LOD. Nitrazepam levels detected 
by the MISPE and SPE methods were comparable. 
Although the MISPE and SPE methods are in good qualitative agreement, there 
are some quantitative differences between the two extraction methods, 
particularly for diazepam metabolites. Concentration differences of this type 
can be due to systematic bias or else they may reflect some degree of selectivity 
by the MIP between the analyte and internal standard during the extraction 
process. Taking the classical SPE method as the Gold Standard procedure, the 
new MISPE method shows in most cases a negative bias, which, in percentage 
terms, is high in some cases. The bias is not completely systematic as the % bias 
varies with concentration. Most of the large differences relate to cases in which 
the concentrations measured are low and close to the LOQ. 
The most likely explanation is that the MIP procedure results in extracts with 
less interference than the SPE procedure (Figure 7-7) and that these 
interferences augment the peak areas in the product ion chromatograms 
obtained for classical SPE extracts. This implies that the classical procedure 
may show lower selectivity than the MIP procedure. 
The results show that the MISPE method is selective for diazepam metabolites 
and other benzodiazepine analogues. It detected diazepam and oxazepam in 
samples which tested negative using the classical SPE approach. Overall, the 
MISPE method appears to be significantly more streamlined than the SPE 
method, providing a simpler and more time efficient procedure. 
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Figure 7-7 Chromatograms of the SPE and MISPE extracts showing LC-MS-MS interference 
in the nordiazepam and diazepam scan segment for the SPE extract only 
7.7 Conclusion 
The validated ELISA and LC-MS-MS methods detected 6 therapeutic 
benzodiazepines in hair. 13 samples screened as TP using the ELISA versus 
LC-MS-MS method. The ELISA method showed 100 % sensitivity and 81 % 
specificity using a cut-off value of 0.1 ng/mg oxazepam. 
The LC-MS-MS method provided the sensitivity necessary for quantitation of 
benzodiazepines in post-mortem hair samples. It appears that mild alkaline 
extraction conditions are suitable for benzodiazepines and do not result in any 
significant hydrolysis. An incubation time of 16 hours in the alkaline medium 
produced the greatest diazepam and nordiazepam recoveries compared to 
shorter incubation times for one case sample. The evaporation step in the SPE 
method resulted in a relatively high loss of 7-AF and chlordiazepoxide, which is 
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partly responsible for the lower recoveries for these analytes. 
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The comparison of the hair and blood results showed that some benzodiazepines 
were detected in hair but not in blood and vice versa. Hair analysis for 
benzodiazepines should be used to complement blood analysis. 
The preliminary study into the use of a diazepam MIP for the detection of 
benzodiazepines in post-mortem hair case samples has shown that it can be 
applied successfully for this purpose. The MISPE method detected a higher 
number of diazepam positive case samples than the classical SPE method 
because of the higher extraction recovery of the MISPE method and the excellent 
molecular recognition of the template molecule (diazepam) imparted by the 
imprinting process. The MISPE method has demonstrated selectivity for other 
benzodiazepine analogues and detected nordiazepam and oxazepam in one 
sample where SPE detected none. The MISPE method was, however, not as 
selective for temazepam as the SPE method. Nordiazepam, oxazepam and 
temazepam concentrations, when detected using both extraction methods, were 
higher using the SPE method. The most likely explanation for this is that the 
MISPE method has a higher selectivity than the SPE method, with fewer matrix 
interferences. Further work is required to investigate the possibility of mixing 
two or more MISPE sorbents in one cartridge to detect a particular drug class and 
also the ability of the MISPE to detect benzodiazepines in single dose hair 
samples. 
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8 Drugs of Abuse in Hair 
8.1 Introduction 
Reports on hair testing in literature generally restrict analysis to one or a few 
drug groups. One of the reasons for this is that with hair analysis the possible 
number of examinations is limited due to a lack of sample. In addition, the 
reproducibility of quantitative analysis of a hair sample is limited by the amount 
of sample and the unknown recovery of the extraction procedure. Therefore, 
semi-quantitative estimations of drug concentrations based on single injections 
are more typical than validated high throughput assays. 13,230 
The usual procedure for hair analysis for drugs of abuse involves an initial screen 
by immunoassay followed by confirmation with a more sensitive and specific 
technique. GC-MS11'231 and LC-MS-MS94 methods have been reported for 
qualitative analysis of the common drugs of abuse in hair and simultaneous 
quantification of two or three targeted drug groups. 22,71,232 A recently published 
article does however describe the simultaneous extraction, identification and 
quantification of four commonly abused drug groups in hair by GC-MS. 233 
LC-MS-MS methods have also been developed in some laboratories for analysing 
more than four commonly abused drug groups94 but this technique is not 
routinely available in most toxicology laboratories. 
For the analysis of hair taken from poly-drug users including drug-related deaths 
and patients undergoing therapy on drug treatment programmes, where several 
drug classes could be present in each sample, it is more efficient to 
simultaneously screen and quantify the different drug classes using a single 
extraction and analysis. The LC-MS-MS method described in this work has been 
validated for the simultaneous identification and quantification of: 
amphetamines, including amphetamine, methamphetamine, MDA, MDMA and 
MDEA; the most commonly abused benzodiazepine in Scotland, diazepam and its 
metabolites; cocaine and its metabolites namely benzoylecgonine, cocaethylene 
and ecgonine methyl ester; and opiates including codeine, dihydrocodeine, 
6-MAM and morphine. 
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Several papers have evaluated different methods for extracting 
amphetamines 1,112, benzodiazepines226,227, cocaine243,244 and heroin 
metabolites"' 79,245 from hair. The methods used were carried out at various 
temperatures and involved solvent extraction, enzymatic digestion and acidic or 
basic digestion from cut or pulverised hair. Basic extraction conditions were 
found to degrade some drugs such as heroin, cocaine and benzodiazepines while 
the enzymatic digestion and solvent extraction methods demonstrated a very 
small amount, if any, degradation. Direct solvent extractions were found to give 
the lowest drug recoveries while complete dissolution of the hair matrix 
produced the highest recoveries for substances that could withstand the extreme 
conditions. After extraction of the drugs from the hair matrix, the analysis is 
carried out using very similar procedures to those used to extract drugs from 
blood or urine. 
8.2 Drugs of Abuse 
8.2.1 Amphetamines 
Amphetamines are central nervous system stimulants used therapeutically in the 
treatment of obesity, narcolepsy and hypotension however they are also abused 
by athletes, addicts and mainly young people at "raves" to enhance their 
performance. Amphetamine abuse has been prevalent in some particular 
geographic areas such as Japan, Far East and the United States. However, there 
is an increasing consumption of amphetamine in Europe where it is reported to 
be the second most commonly abused drug after cannabis. 246 In this study, the 
classical amphetamines, amphetamine and methamphetamine, as well as the 
methylenedioxy-substituted amphetamines methylenedioxyethylamphetamine 
(MDEA), methylenedioxymethamphetamine (MDMA) and 
methylenedioxyamphetamine (MDA) were investigated in post-mortem hair 
samples. The common route of administration for these drugs is by oral means. 
However, amphetamine and methamphetamine have also been taken 
intranasally and by intravenous injection to produce euphoric effects. 
Methamphetamine is manufactured as the hydrochloride salt and is smoked. It 
resembles colourless fragments of ice (Figure 8-1) and hence is known by this 
streetname. The methylenedioxy-substituted amphetamines such as MDMA 
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(Figure 8-2) produce effects such as euphoria, enhanced energy and lowers 
inhibitions. 
;.. ý .ý 
ý, ý. ' `; _ 
ý. 
....,. ý. 
,. d 
`'ý 
. ýý ýý 
ýýý ice, 
4 
ýýýýý 
ýý 
Figure 8-1 Methamphetamine HCI ("Ice") Figure 8-2 MDMA ("ecstasy") tablets 
8.2.1.1 Pharmacokinetics and Metabolism 
Pharmacokinetic data for amphetamine, methamphetamine and MDMA is given in 
Table 8-1. There has been little research on the pharmacokinetics of MDA and 
MDEA and so the data for these two compounds is not provided. 
Table 8-1 Pharmacokinetic and physicochemical data for amphetamines 176 
Half Life (hr) Vd (L/kg) Protein Binding (%) P, 
7-34 
Amphetamine (urine pH 3.2-5.6 16 9.9 
dependent) 
6-15 
Methamphetamine (urine pH 3.0-7.0 10-20 9.9 
dependent) 
MDMA 6-9 5.0-8.0 - - 
Amphetamines are weak bases with low molecular weights and low protein 
binding. Therefore, they can easily diffuse across the cell membrane and 
become incorporated in samples such as hair, nails, sweat and oral fluid. Hair is 
a very useful sample for determining an individual's past history of amphetamine 
abuse. 
Amphetamine is metabolised by hydroxylation of the aromatic ring to 
p-hydroxyamphetamine and by deamination to phenylacetone, with subsequent 
oxidation to benzoic acid. 16 Glucuronide conjugates are also formed during 
metabolism. Methamphetamine is partially metabolised to amphetamine, which 
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is an active metabolite, then further metabolised in the same way as described 
for amphetamine. MDMA and MDEA are metabolised to form MDA. These 
metabolic pathways are shown in Figure 8-3-Figure 8-6. 
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8.2.2 Benzodiazepines 
As discussed in chapter 7, benzodiazepines are commonly prescribed and abused 
drugs. Diazepam is prescribed under the trade name Valium® as an anti-anxiety 
agent, muscle relaxant or anticonvulsant. Temazepam, oxazepam and 
nordiazepam are metabolites of diazepam and can also be prescribed for these 
purposes but this is less frequent in Scotland. 179 
8.2.2.1 Pharmacokinetics and Metabolism 
The pharmacokinetic properties of the drugs are summarised in the previous 
chapter in Table 7-1. Diazepam metabolism is described in section 7.2 and the 
molecular structures of diazepam metabolites are shown in Figure 7-1. 
8.2.3 Cocaine 
Cocaine is the most potent naturally occurring central nervous system stimulant 
and therefore has a long history of use and abuse. 13 Cocaine is extracted from 
the leaves of Erythroxylon coca (Figure 8-7) which is a South American shrub and 
constitutes up to 2% of the leaf's weight. "b 
It was first produced as pure cocaine in 1855 and has been widely used by drug 
users as it produces feelings of euphoria. Illicit cocaine when taken by drug 
users is usually administered intranasally, intravenously or through smoking the 
free base which is known as "crack cocaine" (Figure 8-8). Only 30-70 % of a dose 
of "crack cocaine" is absorbed by smoking due to pyrolysis. "b Intranasal and oral 
routes of administration produced lower plasma concentrations than intravenous 
routes due to slower absorption. 176 
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Figure 8-7 Erythroxylon coca shrub Figure 8-8 "Crack cocaine" 
8.2.3.1 Pharmacokinetics and Metabolism 
Cocaine is rapidly hydrolysed by one or both of the ester linkages to produce 
benzoylecgonine and ecgonine methyl ester which are its two main metabolites 
(Figure 8-9). Both of these are pharmacologically inactive. A number of minor 
metabolites are also produced. "' 
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Figure 8-9 Cocaine metabolism 
Benzoytecgonine 
The pharmacokinetic and physicochemical data is presented for cocaine in Table 
8-2 
Drugs of Abuse in Hair 
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Table 8-2 Pharmacokinetic and physicochemical data for cocaine 176 
Half Life (hr) Vd (L/kg) Protein Pý Binding (%) 
Cocaine 0.7-1.5 1.6-2.7 92 8.6 
Cocaine is a highly lipophilic compound and consequently accumulates in fatty 
tissues during chronic use for a period of 2-3 weeks before excretion. 247 
8.2.4 Opiates 
The term opiate describes natural opium alkaloids and the semisynthetics 
derived from them. Opium is a resin collected from the Papaver Somniferum 
poppy (Figure 8-10). It contains morphine, codeine, papaverine and noscapine. 
Morphine is acetylated in clandestine laboratories to produce diamorphine for 
the black market (Figure 8-11). Codeine is also acetylated to produce 
acetytcodeine during this process. In the UK, heroin is commonly defined as a 
mixture of impurities, reaction intermediates, and breakdown products 
manufactured during the synthesis of diamorphine, including the excipients and 
adulterants used to dilute or cut the drugs. 248 
Figure 8-10 Papaver Somniferum poppy Figure 8-11 Diamorphine 
Opiates have been used medicinally for the treatment of acute pain. They have 
also been used to ease the chronic and severe pain of cancer patients. Some 
opiates are widely abused for their euphoria-producing properties which result 
through oral, intravenous, intranasal or smoking routes of administration. The 
feeling of euphoria gained through opiate use has been associated with the 
psychological dependence and subsequent addiction to these drugs. 13 Opiate 
tolerance is known to rapidly develop to the extent that rapid dose increases are 
required to achieve the euphoric state. 
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8.2.4.1 Pharmacokinetics and Metabolism 
Diamorphine is rapidly absorbed and metabolised in the liver following 
intravenous injection (t112 in plasma is 2-6 minutes). Due to its rapid 
metabolism, it is not usually targeted as evidence of opiate use in body fluids. 
Diamorphine is rapidly metabolised via deacetylation to 6-MAM and then more 
slowly metabolised to morphine, which is the main pharmalogicalty active 
metabolite. 6-MAM is therefore used as a marker of diamorphine use. The 
metabolic pathway for diamorphine is shown in Figure 8-12. As mentioned in 
section 8.4.2, illicit heroin is not just composed of diamorphine but also 
impurities. Codeine is extracted from the Papaver Somniferum poppy as well as 
morphine, papaverine and noscapine. During the acetylation of morphine to 
diamorphine, codeine is also acetylated to produce acetylcodeine. Therefore 
codeine can be present as a result of acetylcodeine metabolism. "b 
Codeine is metabolised in the liver by 0-demethylation to produce morphine and 
by N-demethylation to produce norcodeine. Both compounds are excreted as 
free drug and as glucuronide conjugates. Small amounts of hydrocodone, 
dihydrocodeine and hydromorphone have also been detected in urine. " Codeine 
is commonly prescribed for pain relief and has been used in cough remedies. The 
metabolic pathway for codeine is given in Figure 8-13. 
Dihydrocodeine is a semisynthetic narcotic analgesis which is produced from the 
hydrogenation of codeine. It has been used for pain relief for example in the 
treatment of post-operative pain. It has also been used as an alternative to 
methadone in the treatment of heroin addiction. 249 It is metabolised by 0- and 
N-dealkylation in the same set of steps as codeine. It also forms glucuronide and 
sulphate conjugates at the 3- and 6-hydroxy ring positions. The metabolic 
pathway for dihydrocodeine is given in Figure 8-14. 
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Figure 8-12 Diamorphine metabolism 
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Figure 8-13 Codeine metabolism 
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The pharmacokinetic and physicochemical data for these opiates is shown in 
Table 8-3. 
Table 8-3 Pharmacokinetic and physicochemical data for opiates 
Half Life (hr) Vd (L/kg) Protein Binding (%) PK 
Diamorphine 0.03-0.1 25 40 7.6 
Morphine 1.3-6.7 2-5 35 8.1,10.0 
Codeine 1.9-3.9 3.5 7-25 8.2 
Dihydrocodeine 3.4-4.5 1.0-1.3 - 8.8 
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8.2.5 Methadone 
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Methadone is a morphine substitute and has been made clinically available in the 
United States since 1947.16 It has many of the pharmacological properties of 
morphine but unlike morphine, it accumulates in the body with repeated use, 
causing sedative effects. Daily dosages as high as 180 mg have been used in the 
maintenance treatment of heroin addicts but doses of 50 mg or less can be fatal 
in naive adult users. 176 The drug is produced commercially as the hydrochloride 
salt of the dl-racemic mixture but all pharmacological activity is due to the 
1-isomer. Methadone is metabolised mainly by mono- and di-N-demethylation 
with spontaneous cyclisation of the unstable metabolites to form EDDP and EMDP 
(Figure 8-15). These metabolites are pharmacologically inactive and are not 
present to any significant extent in plasma during therapeutic methadone 
treatment. 16 
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Figure 8-15 Methadone metabolism 
The pharmacokinetic and physicochemical data for methadone are shown in 
CH3 
N 'a 
Table 8-4. 
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Table 8-4 Pharmacokinetic and physicochemical data for methadone 176 
Half Life (hr) Vd (L/kg) Protein Pý Binding (%) 
Methadone 15-55 4-5 87 8.6 
8.3 Aim of Study 
There were two main aims of this study. The first was to develop and validate 
an LC-MS-MS method for the identification and quantification of common drugs 
of abuse in hair and apply the method to routine post-mortem hair samples. The 
second aim was to compare the results of the LC-MS-MS method with in-house 
GC-MS methods for these post-mortem samples. 
8.4 Experimental 
8.4.1 Samples 
All samples were post-mortem scalp hair samples submitted to the toxicology 
Laboratory of the Forensic Medicine and Science Section at the University of 
Glasgow for routine testing. The samples were tested for diagnostic purposes 
and the results were reported to the Procurator Fiscal. 
8.4.2 Chemicals 
Methanol, acetone, acetonitrile, acetic acid, ammonium hydroxide, ethyl 
acetate, formic acid, dichloromethane and propan-2-ol were purchased from 
BDH (Poole, UK) and were of analytical grade. Ammonium formate and sodium 
dodecyl sulfate were purchased from Sigma-Aldrich (Dorset, UK). 
d, (-amphetamine, d, (-methamphetamine, d, 1-MDA, dl-MDMA, d,! -MDEA, 
diazepam, nordiazepam, oxazepam, temazepam, cocaine, benzoylecgonine, 
ecgonine methyl ester, cocaethylene, morphine, 6-MAM, codeine, 
dihydrocodeine, methadone and EDDP were obtained from Promochem 
(Teddington, UK). Deuterated internal standards including d, (-amphetamine-ds, 
d, l-methamphetamine-d5i d, 1-MDA-d5, dl-MDMA-d5, dl-MDEA-d5, diazepam-d5, 
nordiazepam-d5, oxazepam-d5, temazepam-ds, cocaine-d3, benzoylecgonine-d3i 
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ecgonine methyl ester-d3, cocaethylene-d3, morphine-d3,6-MAM-d3, codeine-d3, 
dihydrocodeine-d6, methadone-d9 and EDDP-d3 were obtained from Promochem 
(Teddington, UK). World Wide Monitoring Clean Screen" SPE columns were 
purchased from United Chemical technologies Incorporation (Pennsylvania, US). 
Bond Elut CertifyTM' SPE columns were purchased from Crawford Scientific 
(Strathaven, UK). Potassium dihydrogen phosphate was obtained from BDH 
(Poole, UK). 
8.4.3 Standard Solutions 
Individual drug stock standard solutions and deuterated drug standards were 
obtained as 100 pg/mL prepared in methanol. For LC-MS-MS confirmation, a 
combined working drug solution of dl-amphetamine, dl-methamphetamine, d, 1- 
MDA, d, l-MDMA, d, l-MDEA, diazepam, nordiazepam, oxazepam, temazepam, 
cocaine, benzoylecgonine, ecgonine methyl ester, cocaethylene, morphine, 
6-MAM, codeine, dihydrocodeine, methadone and EDDP was prepared at 1 pg/mL 
by 100-fold dilution with methanol. This was achieved by adding 25 pL of 
100 pg/mL drug solution into a 25 mL volumetric flask and making up the volume 
to the 25 mL mark with methanol. A combined working deuterated standard 
solution of d, l-amphetamine-ds, d, l-methamphetamine-d5, d, 1-MDA-d5, d, 1- 
MDMA-d5, d, 1-MDEA-d5, diazepam-d5, nordiazepam-d5, oxazepam-d5, temazepam- 
ds, cocaine-d3, benzoylecgonine-d3, ecgonine methyl ester-d3, cocaethylene-d3i 
morphine-d3,6-MAM-d3i codeine-d3, dihydrocodeine-d6, methadone-d9 and EDDP- 
d3 was also prepared at 1 pg/mL in the same way as the working drug solution. 
8.4.4 Extraction Solutions and Mobile Phase 
8.4.4.1 Preparation of Phosphate Buffer 
Phosphate buffer (0.1 M, pH 6.0) was prepared as described in section 5.6.4.3. 
The same procedure was followed to prepare the phosphate buffer (0.1 M, pH 
5.0) however the buffer pH was altered to pH 5.0 using orthophosphoric acid. 
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Three mobile phases were investigated as part of the method development 
work. The mobile phases used in system A and B consisted of a mixture of 
aqueous buffer and acetonitrile. The buffers used were: 3 mM ammonium 
formate + 0.001 % formic acid (system A); 10 mM ammonium acetate + 0.001 % 
formic acid (system B). The mobile phase used in system C consisted of (1) 
methanol: acetonitrile: 20 mM ammonium formate (10: 10: 80 v/v) and (2) 
methanol: acetonitrile: 20 mM ammonium formate (35: 35: 65 v/v). 
The buffer used in system A was prepared as described in section 7.5.4.2. To 
prepare buffer B, 0.77 g of ammonium acetate and 10 µL of concentrated formic 
acid were added to a1L volumetric flask which was then filled up to the mark 
with deionised water. To prepare the 20 mM ammonium formate component of 
mobile phase system C, 1.26 g of ammonium formate was added to a1L 
volumetric flask and the flask filled up to the mark with deionised water. 
8.4.5 Instrumentation 
8.4.5.1 ELISA 
A MiniPrep 75 automatic pipettor from Tecan (San Jose, CA) was used. The 
microplate wells were washed and read using a Columbus Plus washer system 
and a Sunrise Remote EIA autoreader also from Tecan (Grödlg, Austria). 
8.4.5.2 LC-MS-MS 
LC-MS-MS analysis was carried out using a Surveyor HPLC system with an LCQ 
Deca XP PlusTM' ion trap mass spectrometer (Thermo Finnigan, San Jose, CA, USA). 
During method development, 3 different LC columns were tested with each 
mobile phase described in section 8.4.4.2. The Gemini and Synergi Hydro RP 
columns were purchased from Phenomenex (Torrance, CA, USA). Both were C18 
columns but the Synergi Hydro RP column also had polar end-capping. The 
Zorbax Stablebond (SB) Phenyl column was purchased from ChromTech 
(Cheshire, UK). This was a non-endcapped phenyl modified silica column. These 
columns were fitted with guard columns with identical packing material which 
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were purchased from the same companies as the LC columns. Guard column 
dimensions were: 4 mm x 2.0 mm, 5 Nm particle size for the Gemini column; 4 
mm x 2.0 mm, 4 pm particle size for the Synergi Hydro RP column; and 12.5 x 
2.1 mm, 5 pm particle size for the Zorbax SB Phenyl column. A list of the mobile 
phases and LC columns is summarised in Table 8-5. 
Table 8-5 Mobile phases and LC columns 
LC Column 
Mobile Phase 
System A 
Mobile Phase 
System B 
Mobile Phase 
System C 
1.10: 10: 80 
1.3 mM 1.10 mm Methanol: 
1. Gemini C18 ammonium ammonium Acetonitrile: 20 mM 
2. Synergi Hydro RP formate + 0.001 acetate + 0.001 ammonium formate 
3. Zorbax SB Phenyl % formic acid % formic acid 2.35: 35: 65 
2. Acetonitrile 2. Acetonitrile Methanol: Acetonitrile: 
20 mM ammonium 
formate 
8.5 LC-MS-MS Method Development 
8.5.1 Optimisation of LC Column and Mobile Phase Combination 
Optimum tuning parameters, precursor and product quantitation ions are shown 
in Table 8-6 for the drugs tested in the method. There was only 1 product ion 
produced during fragmentation for the amphetamines due to their low molecular 
weight. 
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Table 8-6 Optimum tuning parameters, precursor and product ions for each drug of abuse 
Analyte 
Sheath 
Gas 
(AU) 
Auxiliary 
Gas 
(AU) 
Capillary 
Temp 
(°C) 
Collision 
Energy 
(%) 
Precursor 
m/z 
Product 
m/z 
EME 10 10 210 29 200 182*, 168 
Cocaine 10 10 300 30 304 182*, 150 
Cocaethylene 10 10 210 30 318 196*, 150 
Benzoylecgonine 10 10 300 28 290 168*, 150 
Morphine 20 10 200 33 286 201*, 229 
6-MAM 20 10 210 34 328 211 *, 268 
Codeine 10 5 240 34 300 215*, 243 
Dihydrocodeine 10 5 240 33 302 245*, 201 
Diazepam 20 20 300 42 285 257*, 222 
Nordiazepam 20 15 300 41 271 243*, 140 
Oxazepam 20 20 300 29 287 269*, 241 
Temazepam 20 20 300 29 301 283*, 255 
Amphetamine 15 5 210 23 136 119* 
Methamphetamine 15 5 210 28 150 119* 
MDA 15 15 220 21 180 163* 
MDMA 15 15 280 25 194 163* 
MDEA 15 15 220 20 208 163* 
*= quantitation ion 
The analytes shown in Table 8-6 were analysed in 3 separate injections. This 
was done to minimise the number of scan events per time window to achieve 
maximum sensitivity. It is also to maximise the number of points across the 
peak to obtain more accurate analyte quantifications. The first injection was 
for cocaine and its metabolites, opiates, methadone and EDDP. The second 
injection was for amphetamines and the third for benzodiazepines. 
Initially, 3 mobile phase systems and 3 LC columns (Table 8-5) were investigated 
to determine which mobile phase system and column produced the greatest peak 
area response for the target analytes. Column 1 and mobile phase system A 
were used for the analysis of opiates, cocaine and metabolites, amphetamines 
and benzodiazepines in oral fluid by LC/MS/MS. 143 Column 2 and mobile phase 
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system B were used for the quantification of opiates and cocaine and 
metabolites in hair by LC-APCI-MS/MS. 241 Column 3 and mobile phase system C 
was used for screening of drugs of abuse in hair using LC-ESI-MS/MS. 3 
3x 20 pL injections of 50 ng drug/200 pL mobile phase were run for each column 
and mobile phase system. The peak area response (PAR) data and retention 
times for the various columns and mobile phase systems is given in Table 8-7-8- 
9. The mobile phase system producing the greatest average peak area response 
for each drug was recorded as being 100 % and the average peak area responses 
for the other two mobile phase systems were calculated as a% of the optimum 
mobile phase system response. 
Table 8-7 Relative % peak area response using Gemini C18 column 
System A System B System C 
Analyte PAR for 
n=3 
tR in 
mins 
PAR for 
n=3 
tR in 
mins 
PAR for 
n=3 
tR in 
mins 
EME 100.0 3.8 51.2 2.2 90.7 1.8 
Cocaine 31.5 13.7 100.0 18.1 44.5 11.5 
Cocaethylene 16.8 15.9 100.0 19.4 20.1 15.9 
Benzoylecgonine 16.4 10.6 100.0 13.3 24.5 5.7 
Morphine 100.0 5.2 42.0 8.0 45.1 2.3 
6-MAM 77.9 8.6 2.7 12.9 100.0 4.8 
Codeine 76.2 8.2 70.8 11.7 100.0 4.1 
Dihydrocodeine 93.1 7.8 81.6 10.4 100.0 3.4 
Methadone 35.4 18.7 100.0 21.4 52.6 23.8 
EDDP 48.0 17.9 77.5 20.6 100.0 20.7 
Oxazepam 81.2 19.2 100.0 21.4 25.5 23.6 
Temazepam 12.7 20.4 100.0 22.5 59.1 25.1 
Nordiazepam 100.0 20.4 17.7 22.7 2.9 25.8 
Diazepam 100.0 21.5 45.1 23.8 4.9 27.2 
Amphetamine 6.1 7.7 56.2 10.7 100.0 4.2 
Methamphetamine 20.1 8.8 100.0 11.6 96.7 4.9 
MDA 10.0 8.3 26.9 11.5 100.0 4.5 
MDMA 35.8 9.3 92.4 12.2 100.0 5.1 
MDEA 28.2 10.3 86.0 13.7 100.0 6.2 
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Using the Gemini C18 column, mobile phase system C produced the optimum 
response for the greatest number of analytes compared to the other two mobile 
phase systems. 
Table 8-8 Relative % peak area response using Synergi Hydro RP column 
System A System B System C 
Analyte PAR for 
n=3 
tR in 
mins 
PAR for 
n=3 
tR in 
mins 
PAR for 
n=3 
tR in 
mins 
EME 70.6 4.9 13.1 5.8 100.0 1.9 
Cocaine 69.1 19.4 100.0 20.7 48.2 16.8 
Cocaethylene 94.3 20.8 100.0 22.1 50.8 19.9 
Benzoylecgonine 100.0 10.5 99.8 13.4 49.5 6.2 
Morphine 74.7 10.3 44.6 13.9 100.0 3.4 
6-MAM 30.5 15.2 28.7 17.5 100.0 8.5 
Codeine 41.4 14.7 33.8 17.3 100.0 7.9 
Dihydrocodeine 55.4 13.8 48.4 16.6 100.0 5.7 
Methadone 86.6 24.4 48.7 26.2 100.0 26.6 
EDDP 46.7 23.3 20.0 25.2 100.0 23.5 
Oxazepam 100.0 19.2 87.4 21.3 20.3 23.8 
Temazepam 100.0 20.4 78.5 22.6 1.5 25.7 
Nordiazepam 100.0 20.6 65.7 22.8 9.6 26.4 
Diazepam 100.0 21.9 29.9 24.3 7.9 28.3 
Amphetamine 100.0 10.8 30.0 15.3 22.3 5.2 
Methamphetamine 100.0 12.1 13.9 17.2 23.9 6.5 
MDA 46.6 11.7 45.3 15.8 100.0 5.6 
MDMA 100.0 13.2 52.8 17.1 48.8 6.7 
MDEA 100.0 13.6 44.1 18.0 47.0 8.2 
Using the Synergi Hydro RP column, mobile phase system A produced the 
optimum response for the greatest number of analytes. 
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Table 8-9 Relative % peak area response using Zorbax Phenyl column 
System A System B System C 
Analyte PAR for 
n=3 
tR in 
mins 
PAR for 
n=3 
tR in 
mins 
PAR for 
n=3 
tR in 
mins 
EME 79.2 3.7 83.1 3.2 100.0 1.3 
Cocaine 100.0 22.9 89.8 21.7 43.2 13.9 
Cocaethylene 100.0 24.3 58.4 23.8 42.2 18.2 
Benzoylecgonine 100.0 9.2 99.6 11.7 68.5 4.5 
Morphine 51.8 11.5 33.7 9.5 100.0 2.1 
6-MAM 89.1 18.1 40.9 16.1 100.0 6.0 
Codeine 60.2 17.1 39.8 14.3 100.0 4.4 
Dihydrocodeine 73.4 16.9 48.1 13.3 100.0 3.9 
Methadone 100.0 28.3 21.5 29.9 91.5 25.2 
EDDP 50.0 28.6 4.4 30.0 100.0 23.4 
Oxazepam 44.8 17.4 100.0 19.4 9.0 18.9 
Temazepam 92.1 18.6 100.0 20.5 14.7 21.2 
Nordiazepam 100.0 18.6 62.8 20.5 18.1 21.6 
Diazepam 100.0 19.7 63.6 21.7 22.5 23.5 
Amphetamine 14.4 13.9 100.0 9.6 40.8 3.0 
Methamphetamine 5.7 18.3 100.0 12.3 25.6 3.8 
MDA 80.8 16.2 100.0 12.1 40.5 3.7 
MDMA 61.5 19.9 100.0 14.5 53.9 5.0 
MDEA 36.5 20.7 100.0 16.7 44.3 6.4 
Using the Zorbax Phenyl column, mobile phase system B produced the optimum 
response for the greatest number of analytes. 
The average peak area response was then compared for each drug using the 
optimum mobile phase system determined for each of the three columns. The 
mobile phase system and column producing the greatest average peak area 
response was recorded as being 100 % and the average peak area responses for 
the other two mobile phase systems and columns were calculated as a% of the 
optimum mobile phase system and column response. 
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Table 8-10 Relative % peak area response for the 3 optimum mobile phase and column 
combinations 
Relative % Pe ak Area Response (n=3) 
Analyte 
Gemini + 
Mobile 
Phase 
System C 
Synergi 
Hydro RP + 
Mobile 
Phase 
System A 
Zorbax 
Phenyl + 
Mobile 
Phase 
System B 
EME 100.0 59.5 62.9 
Cocaine 46.6 67.8 100.0 
Cocaethylene 48.1 100.0 71.0 
Benzoylecgonine 42.4 100.0 72.3 
Morphine 100.0 89.7 47.3 
6-MAM 100.0 28.2 33.5 
Codeine 100.0 34.2 31.2 
Dihydrocodeine 100.0 43.2 43.3 
Methadone 89.3 100.0 18.7 
EDDP 100.0 50.5 3.2 
Oxazepam 45.1 100.0 79.9 
Temazepam 37.8 59.0 100.0 
Nordiazepam 4.0 100.0 83.4 
Diazepam 4.3 100.0 49.5 
Amphetamine 85.2 68.7 100.0 
Methamphetamine 31.3 71.4 100.0 
MDA 89.2 33.8 100.0 
MDMA 46.2 57.5 100.0 
MDEA 54.0 53.6 100.0 
The Zorbax Phenyl column and mobile phase system B produced the greatest 
average peak area response for the greatest number of analytes compared to the 
other two columns and mobile phase systems. This column and mobile phase 
combination was therefore selected for further optimisation. 
8.5.2 Mobile Phase Optimisation 
Since the Zorbax SB Phenyl column and mobile phase system B produced the 
greatest average peak area response for the greatest number of analytes, it was 
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decided to investigate the effect of using different concentrations of ammonium 
acetate and formic acid in the mobile phase on analyte response. 
The ammonium acetate buffer concentrations tested were 2,5,10 and 25 mM. 
These concentrations were prepared by adding 0.15,0.30,0.77,1.6 g of 
ammonium acetate to a1L volumetric flask and filling the flask up to the mark 
with deionised water. The formic acid concentration of 0.001 % was kept 
constant to determine the effects of changing buffer concentration only. The 
average peak area (n=3) was calculated for each analyte. The ammonium 
acetate concentration and the relative average % peak area response for a 
selection of analytes from different drug classes are shown in Figure 8-16. 
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Figure 8-16 Analyte responses for increasing ammonium acetate concentration 
With the exception of the opiates, analyte response decreased with the lower 
ammonium acetate concentrations. The highest opiate response was observed 
using 25 mM ammonium acetate. Higher responses were observed using 2 mM 
than 5 mM or 10 mM ammonium acetate. 
Higher concentrations of ammonium acetate were not tested since the use of 
high concentrations of electrolytes has the disadvantage of forming salt clusters 
and cluster ions by direct solvent evaporation. 166 10 mM ammonium acetate was 
selected for further work since the greatest analyte response was observed for 
the highest number of analytes at this concentration. 
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The concentration of formic acid was then investigated to determine the effect, 
if any, on analyte response. The 10 mM ammonium acetate was prepared using 
three formic acid concentrations- 0.001,0.005 and 0.01 %. The average peak 
area response (n=3) was compared for each formic acid concentration. The 
formic acid concentration which produced the greatest average peak area 
response was recorded as being 100 % and the average peak area responses for 
the other two formic acid concentrations were calculated as a% of the optimum 
formic acid concentration response. 
The relative average % peak area response for a selection of analytes from 
different drug classes is given in Figure 8-17. The results showed that the 
optimum formic acid concentration was 0.001 % for most anatytes. 
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Figure 8-17 Analyte responses for increasing formic acid concentration 
As the Zorbax SB phenyl column is narrow-bore, it has a smaller internal volume 
than a standard bore column and the flow rate for optimal column efficiency is 
proportionately smaller. The flow rates recommended by the column 
manufacturer are 0.15 to 0.25 mL/min as the column has an internal diameter of 
2.1 mm. A flow rate of 0.25 mL/min was therefore selected for future work 
since faster flow rates result in faster sample throughput. 
Although the Zorbax phenyl column was initially selected for further work, a 
pressure problem was encountered during method development. The pressure 
00.001%   0.005% Q 0.010% 
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would not stabilise and exceeded the instrument's maximum pressure setting of 
5800 psi. 
The manufacturers recommend using mobile phases such as acetonitrile/water 
mixtures as the column is moderately non-polar in nature so the mobile phase 
selection was theoretically suitable. However it was not feasible to use this 
column in practice. The Synergi Hydro RP column and mobile phase system A 
were selected for further work since this column and mobile phase combination 
produced a higher relative average % peak area response for more analytes 
compared with the Gemini column and mobile phase system C (Table 8-10). 
8.5.3 Selection of Incubation Medium 
A previously published SPE method which was used for the extraction of common 
drugs of abuse from oral fluid was used to clean up hair samples which had been 
incubated in various media. 143 The elution step was modified slightly from 3 mL 
ethyl acetate with 2% ammonia to 1.5 mL ethyl acetate with 2% ammonia and 
1.5 mL dichloromethane/isopropanol/ammonium hydroxide (78: 20: 2 v/v). 
In order to assess the suitability of the methanol/25 % aqueous ammonium 
hydroxide (20: 1 v/v) incubation used for benzodiazepines in chapter 7 for 
extracting other drugs of abuse in hair, 2 post-mortem hair samples with positive 
blood results were extracted. 
The hair samples were tested for the drug classes found in the corresponding 
blood sample. The results are shown in Table 8-11. 
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Table 8-11 Hair samples incubated in methanol/25 % aqueous ammonium hydroxide 
Hair Sample Number Blood result (mg/L) Hair result (ng/mg) 
Morphine 0.27 
Morphine 5.89 
Codeine 0.04 
Codeine 1.55 
Methadone 0.37 
6-MAM 70.70 
EME 0.20 
Diazepam 0.29 
Nordiazepam 0.79 
Codeine 0.06 
Temazepam 0.05 
2 Nordiazepam 1.40 
Oxazepam 0.06 
Dihydrocodeine 0.26 
Morphine 0.14 
Codeine 0.01 
The methanol/25 % aqueous ammonium hydroxide incubation successfully 
extracted opiates and benzodiazepines from post-mortem hair samples. 6-MAM, 
a useful marker for heroin use, was detected in hair sample 1 but was not 
detected in the corresponding blood sample. This is because the 6-MAM half-life 
is short in blood, between 6-25 minutes. "' 
Dihydrocodeine was detected in hair sample 2 and was not detected in blood. 
This provided additional information on the individual's prior drug use. 
One concern with using the MeOH/25 % aqueous NH40H incubation was the 
potential for analyte hydrolysis, in particular cocaine and 6-MAM, as the 
hydrolysis of 6-MAM to morphine and also cocaine to BZE and EME has been 
demonstrated at alkaline pH. 208 The stability of cocaine and 6-MAM was 
therefore investigated using this incubation medium. 
8.5.3.1 Stability of 6-MAM and cocaine using the methanol/25 
ammonium hydroxide incubation 
Three samples were prepared by spiking 1.5 mL of MeOH/25 % aqueous 
ammonium hydroxide with 50 ng of cocaine and 6-MAM and these were 
subsequently left to incubate for 18 hours at room temperature. After this time, 
50 ng of cocaine-d3 and 6-MAM-d3 were added to the vials and the vial contents 
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were evaporated to dryness at room temperature under nitrogen. The 
deuterated internal standards were added at this point in the experiment so that 
the results obtained were only affected by degradation during the incubation 
step. Three unextracted standards were prepared at the same concentration 
and kept in the fridge during the incubation period. 50 ng of deuterated 
internal standard was added to the unextracted standards at the same time as 
the incubated samples and the vial contents evaporated to dryness under 
nitrogen. The samples once dry were reconstituted in 200 pL of mobile phase 
initial conditions and 20 pL was injected. 
The results from this experiment showed that 6-MAM was hydrolysed to a great 
extent (= 95 %) using this incubation medium. Cocaine was also significantly 
hydrolysed (= 22 %). Therefore this method does not produce true 
representative concentrations of 6-MAM, morphine, cocaine or benzoylecgonine 
in hair. Partial hydrolysis of 6-MAM will have occurred in hair sample 1 shown in 
Table 8-11. It was decided not to use this incubation and hence other 
incubations were investigated. The % recovery values are shown in Table 8-12 . 
Table 8-12 % Recovery of 6-MAM and cocaine without matrix 
Cocaine (% Recovery, n=3) 6-MAM (% Recovery, n=3) 
Mean S. D. Mean S. D. 
77.6 2.3 4.9 0.4 
8.5.3.2 Stability of 6-MAM and cocaine in different incubation media 
This alkaline methanol/25 % aqueous ammonium hydroxide extraction is suitable 
for extracting opiates and benzodiazepines from authentic hair samples as shown 
in section 8.5.3, although it significantly degrades 6-MAM and cocaine. 
Therefore, the same stability experiment as described in section 8.5.3.1 was 
carried out using 1,2,5 and 10 % aqueous ammonium hydroxide in methanol. In 
addition to this, the stability was assessed in aqueous acidic media (0.01,0.1 
and 1M HCl), methanol and phosphate buffer (0.1 M, pH 5.0) by incubating for 
18 hours at 45 °C. 
The % recovery of 6-MAM and cocaine in the different incubation media are given 
in Table 8-13. 
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Table 8-13 % Recovery of cocaine and 6-MAM in various incubation media 
Incubation Cocaine % Recovery (n=3) 6-MAM % Recovery (n=3) 
Medium Mean S. D. Mean S. D. 
Methanol 99.4 5.5 88.6 4.2 
Phosphate 
102.3 1.4 102.9 10.9 
Buffer pH 5 
0.1 M HCL 101.5 5.2 47.3 5.5 
0.05 M HCl 100.6 1.1 59.1 3.1 
0.01 M HCl 103.7 4.3 87.4 5.3 
Methanol/ 
97.5 3.2 67.2 5.0 
1% NH4OH 
Methanol/ 
91.8 3.5 37.2 3.1 
2%NH40H 
Methanol/ 
89.7 2.8 18.5 1.2 
5%NH40H 
Methanol/ 
86.1 0.5 5.5 0.5 
10%NH40H 
Methanol/ 
77.6 2.3 4.9 0.4 
25 % NH4OH 
The extent of 6-MAM and cocaine degradation was negligible using the methanol 
and phosphate buffer incubations. In contrast, all concentrations of aqueous 
acidic media resulted in significant 6-MAM hydrolysis whereas cocaine 
degradation was negligible. This result was in agreement with previously 
published results. "' 
The results obtained for the aqueous alkaline media showed an increased 6-MAM 
and cocaine hydrolysis with increasing concentration of aqueous ammonium 
hydroxide. 6-MAM was hydrolysed to a greater extent than cocaine under 
alkaline conditions. Graphs of % recovery vs % aqueous ammonium hydroxide in 
methanol are shown in Figure 8-18. The 6-MAM graph demonstrates a hyperbolic 
decrease in % recovery with increasing ammonium hydroxide concentration, 
whereas the cocaine graph shows a linear decrease, with a good correlation 
between % recovery and % ammonium hydroxide in methanol (R2=0.9117). 
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Figure 8-18 % Recovery vs % aqueous NH4OH in methanol for 6-MAM and cocaine 
Both the acidic and alkaline incubation media produced significant hydrolysis of 
6-MAM. Cocaine showed significant hydrolysis using 25 % aqueous ammonium 
hydroxide in methanol. It was therefore decided to compare the methanol and 
phosphate buffer incubation media for future work since both cocaine and 
6-MAM were relatively stable using these methods. The methanol and phosphate 
buffer incubation media produced 6-MAM recoveries of 88.6 % and 102.9 % 
respectively while cocaine recoveries were 99.4 and 102.3 % respectively. 
8.5.3.3 Methanol vs Phosphate Buffer Incubation 
3 post-mortem hair samples which had positive blood results were 
decontaminated as described before in section 6.4.1. The root-0.5 cm segment 
was removed and the 0.5-3.5 cm segment was cut up into smaller segments of 
2-3 mm in length. This cut up segment was subsequently split to compare the 
methanol and phosphate buffer incubation methods. The samples were analysed 
for the drug classes detected in the blood. The blood and hair results are shown 
in Table 8-14 and Table 8-15 respectively. 
With the exception of the cocaine concentration detected in hair sample 1 and 
the methadone concentration in hair sample 3, the phosphate buffer extraction 
produced higher quantitative results overall, extracting greater concentrations 
of EME, benzoylecgonine, 6-MAM, codeine and amphetamine. Furthermore, the 
05 10 15 20 25 30 
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methadone metabolite, EDDP was detected using the phosphate buffer 
incubation where none was detected using the methanol incubation. Morphine 
was not detected in hair sample 3 by either incubation method. A possible 
explanation for this is the low levels of 6-MAM detected in the samples. The 
6-MAM/morphine ratios observed in the case samples tested in section 8.9.1.2 
ranged from 0.14-28.00 (5.47 mean). If this mean 6-MAM/morphine ratio was 
applied to calculate a predicted morphine concentration from the 6-MAM 
concentration found, it would be 0.15 ng/mg, a concentration which is lower 
than the LOQ of the method. 
Table 8-14 Blood results for post-mortem hair case samples (mg/L) 
Hair Sample Cocaine + Opiates and Amphetamines Benzodiazepines 
Number Metabolites Methadone 
EME 5.13 
1 COC 3.58 - - - 
BZE 3.98 
2 - - AMP 0.66 
MOR 0.37 DZ 0.06 
3 - COD 0.01 - NDZ 0.09 
MD 0.17 TMZ 0.02 
"EME"= Ecgonine Methyl Ester, "CUL"= cocaine, **bLt"= tsenzoyLecgomne, **MUK"= Morphine, 
"COD"= Codeine, "MD"= Methadone, "AMP"= Amphetamine, "DZ"= Diazepam, 
"N DZ"=Nordiazepam, "TMZ"=Temazepam 
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Overall, the phosphate buffer incubation was better for the simultaneous 
detection of cocaine and its metabolites, amphetamine and opiates. In addition, 
EDDP was detected in sample 3 using the phosphate buffer incubation while none 
was detected using the methanol incubation. Benzodiazepines were not 
detected in any of the samples to compare the two incubations. Furthermore, 
the stability data using the phosphate buffer incubation is excellent for 6-MAM 
and cocaine which have been shown to hydrolyse under acidic and basic 
conditions245, the hair extracts are cleaner and the analysis is simpler with less 
sample manipulation. Analyte recoveries for the methanol incubation were 
generally lower for most analytes as reported in various studies. 11,111,245 It has 
been proposed that the generally higher recoveries obtained using a phosphate 
buffer incubation is a result of the water molecules penetrating the keratinised 
hair to a greater extent than an organic solvent. " Furthermore, the non- 
keratinous hair regions could potentially provide diffusion channels, both into 
and out of the hair, for small drug molecules in the presence of water. 61 
8.5.4 Comparison of SPE methods 
Bond Elut Certifym and Clean Screen® DAU SPE columns were investigated for the 
simultaneous extraction of the drugs of abuse from hair. Both columns are 
mixed-mode bonded silica, with both hydrophobic and ion-exchange properties, 
which are suitable for the extraction of acidic, neutral and basic analytes. The 
silanol groups in these columns are partially derivatised with medium length 
alkyl chains and cation exchange substituents which allow at least two types of 
analyte-sorbent interactions. 250 
8.5.4.1 Bond Elut Certify"" SPE 
This method is previously published and was applied in the simultaneous 
screening of acidic, neutral and basic drugs from oral fluid. 143 Bond But Certify" 
LRC cartridges were conditioned sequentially with 2 mL methanol and 2 mL 
phosphate buffer (0.1 M, pH 6.0). 2 mL of sample in phosphate buffer (0.1 M, 
pH 6.0) was applied to the cartridge and allowed to drip through without the 
presence of a vacuum. The cartridges were then washed with 1 mL deionised 
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water, 0.5 mL 0.01 M acetic acid and dried for 10 minutes under full vacuum. 
50 pL of methanol was added and the cartridges were dried for a further 2 
minutes under full vacuum. The acidic/neutral fraction was eluted using 4 mL 
acetone/dichloromethane (1: 1 v/v) while the basic drugs were eluted using 
Ix1.5 mL ethyl acetate with 2% aqueous ammonium hydroxide and Ix1.5 mL 
dichloromethane: isopropanot: aqueous ammonium hydroxide (78: 20: 2 v/v), with 
a2 minute drying step between the two basic eluants. The acidic/neutral and 
the basic fractions were combined. This was particularly significant since the 
benzodiazepines were eluted in both fractions. 
8.5.4.2 Clean Screen® SPE 
This SPE was a modified version of an extraction procedure for drugs of abuse in 
urine provided by the SPE manufacturers. Clean Screen® (ZSDAU 020) extraction 
cartridges were conditioned sequentially with 3 mL methanol, 3 mL deionised 
water and 1 mL phosphate buffer (0.1 M, pH 5.0). The vortexed samples were 
loaded in 2 mL phosphate buffer (0.1 M, pH 5.0) and allowed to drip through 
without vacuum. The columns were then washed with 3 mL phosphate buffer 
(0.1 M, pH 5.0), 1 mL acetic acid (1.0 M) and dried for 5 minutes under full 
vacuum. The drugs were eluted using 2 mL methanol/2 % aqueous ammonium 
hydroxide. 
8.5.4.3 Analyte recovery without hair matrix 
To ensure that the SPE methods were appropriate for the drugs of abuse, the 
recovery was investigated in an experiment without hair matrix. 
50 ng of drug was added to two test tubes along with 2 mL phosphate buffer 
(0.1 M, pH 5.0). Two unextracted samples were prepared at the same 
concentration and kept in the fridge during the extractions. 50 ng of deuterated 
internal standard was added to the eluant after the extraction and also to the 
unextracted samples. The samples were evaporated to dryness at room 
temperature under nitrogen and subsequently reconstituted in 200 pL of mobile 
phase initial conditions. 20 pL was injected for each sample. The results are 
displayed in Table 8-16. 
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Table 8-16 Bond ElutT. and Clean Screen recovery without matrix (n=2) 
Mean % Recovery (n=2) 
Analyte 
Bond Elut Certify' Clean Screen® 
EME 76.6 100.7 
Cocaine 100.7 84.0 
Cocaethylene 96.4 95.8 
Benzoylecgonine 95.2 97.8 
Morphine 77.4 87.2 
6-MAM 74.1 74.6 
Codeine 102.4 83.9 
Dihydrocodeine 91.6 97.6 
Methadone 92.9 82.6 
EDDP 70.1 98.6 
Oxazepam 82.9 92.7 
Temazepam 94.5 99.0 
Nordiazepam 93.3 97.6 
Diazepam 95.9 95.2 
Amphetamine 95.6 98.9 
Methamphetamine 78.7 90.4 
MDA 88.8 84.2 
MDMA 97.6 101.2 
MDEA 90.7 100.4 
Without matrix, the Clean Screen' method produced higher recoveries for a 
greater number of analytes compared to the Bond Elut Certify v method. The 
experiment was then repeated with hair matrix as discussed in section 8.5.4.4. 
8.5.4.4 Analyte Recovery with Hair Matrix 
10 mg ± 0.1 mg blank hair was weighed out into three vials and it was then 
spiked with 50 ng analyte. Two unextracted samples were prepared at the same 
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concentration and kept in the fridge during the extractions. The samples were 
then incubated in phosphate buffer (pH 5.0) as detailed in section 8.5.3.2 and 
extracted by the Bond Elut Certify" and Clean Screen' methods previously 
described in sections 8.5.4.1 and 8.5.4.2.50 ng of deuterated internal standard 
was added to the eluant after the extractions and also to the unextracted 
samples. The samples were evaporated to dryness at room temperature under 
nitrogen and subsequently reconstituted in 200 pL of mobile phase initial 
conditions. 20 pL was injected for each sample. The results are shown in Table 
8-17. 
Table 8-17 Bond ElutM and Clean Screen® recovery with matrix 
Analyte 
Mean % Recovery (% RSD) (n=3) at 50 ng 
Bond Elut Certify Clean Screen 
Ecgonine methyl ester 73.7 (0.5) 101.1 (5.6) 
Cocaine 92.3 (5.0) 98.6 (4.8) 
Cocaethylene 100.3 (6.1) 104.9 (11.1) 
Benzoylecgonine 91.8 (10.0) 98.0 (6.5) 
Morphine 75.9 (3.8) 94.5 (5.4) 
6-MAM 94.6 (6.1) 98.3 (6.3) 
Codeine 90.1 (2.2) 95.0 (6.2) 
Dihydrocodeine 94.8 (5.4) 107.4 (3.6) 
Methadone 124.6 (12.6) 87.8 (15.5) 
EDDP 80.2 (8.3) 86.8 (3.3) 
Oxazepam 90.3 (14.2) 77.0 (5.5) 
Temazepam 99.3 (7.9) 107.6 (2.0) 
Nordiazepam 79.8 (2.8) 99.1 (8.7) 
Diazepam 81.4 (8.4) 80.5 (4.1) 
Amphetamine 97.9 (8.3) 109.9 (11.9) 
Methamphetamine 91.6 (3.1) 109.1 (1.5) 
MDA 88.3 (2.1) 78.8 (6.0) 
MDMA 78.5 (1.0) 99.5 (2.2) 
MDEA 95.4 (2.8) 85.9 (2.5) 
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The Clean Screen® method produced higher recoveries for a greater number of 
analytes compared to the Bond Elut® method for spiked hair. All of these were 
77 % or greater. 
8.5.4.5 SPE Clean-Up 
Hair was collected from five members of laboratory personnel. 10 mg ± 0.1 mg 
hair was washed via the procedure described previously in section 6.4.1 and 
subsequently extracted using the Bond Elut Certify" and Clean Screen" methods. 
The chromatograms for each blank hair extract using both SPE methods were 
compared visually to determine which method produced the cleanest extracts 
overall. 
The Clean Screen® method produced the cleanest extracts overall for all drug 
classes and for hair from all five individuals. An example LC-MS-MS 
chromatogram of blank hair collected from one individual using both the Bond 
Elut Certify' and Clean Screen® extraction methods is shown in Figure 8-19. At 
the time of using this particular LC column, the diazepam retention time (tR) was 
22.7 minutes. It is apparent from the chromatograms that there was greater 
matrix interference at the diazepam tR, as indicated by the larger peak area, 
using the Bond Elut Certify1m column compared with the Clean Screen' column. 
RT 20.00-25.00 SM: 5G 
RT. 22.73 
MA: 214549 
NL 1.07E4 
. 
5-257.5 F: c -/-256 
ESI Full m. 2 
285.00®41 00 ý 
75.00-X00.001 VAS BEC 
INTER1AP 
RT: 22 83 NL 503E2 
AA 11193 m/ý 235,3-257.6 F. c 
ESI Full 
28 55.00@41l 1.00 
001 5 CIS Aý Clrr. n Scr.. n Inbr1 bp 
4 
8 
21 0 21 5 22.0 22.5 230 23.5 24.0 24.5 25.0 
Time (min) 
Figure 8-19 Bond Elut CertifyTM vs Clean Screen® interference at diazepam tR 
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8.5.4.6 LOD and LOQ 
Chapter 8,169 
The LOD was calculated for each analyte using Equation 7-1 and Equation 7-2. 
The LOQ was calculated for each analyte using Equation 7-3 and Equation 7-4, 
however ten standard deviations (10sg) of the blank was used in Equation 7-3. 
The LOD and LOQ values are shown in Table 8-18 for both SPE methods. 
The Clean Screen® SPE method produced lower LOD and LOQ values for the 
majority of analytes. The LOD range was 0.15-0.92 ng/10 mg hair and the LOQ 
range was 0.51-3.07 ng/10 mg hair. Furthermore, there was a relatively large 
difference for cocaine, oxazepam and MDA. This is because of reduced matrix 
interference observed using the Clean Screen" method compared to the Bond 
Elut Certify"' method. The Clean Screen method was therefore validated in 
further work. 
Table 8-18 LOD and LOQ values for the Bond Elut CertifyTm and Clean Screen® SPE methods 
Bond Elut Certify Clean Screen' 
Analyte LOD 
(ng/10 mg) 
LOQ 
(ng/10 mg) 
LOD 
(ng/10 mg) 
LOQ 
(ng/10 mg) 
EME 0.33 1.08 0.25 0.83 
Cocaine 1.02 3.41 0.37 1.25 
Cocaethylene 0.37 1.24 0.42 1.39 
Benzoylecgonine 0.34 1.12 0.15 0.51 
Morphine 0.97 3.24 0.68 2.25 
6-MAM 1.14 3.80 0.92 3.07 
Codeine 0.68 2.26 0.64 2.15 
Dihydrocodeine 0.32 1.05 0.48 1.62 
Methadone 0.48 1.59 0.40 1.32 
EDDP 0.59 1.96 0.54 1.79 
Oxazepam 0.94 3.13 0.17 0.57 
Temazepam 0.35 1.18 0.77 2.56 
Nordiazepam 0.82 2.73 0.69 2.31 
Diazepam 0.33 1.10 0.56 1.56 
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Table 8-19 LOD and LOQ values for the Bond Elut CertifyTM and Clean Screen® SPE methods 
(continued) 
Bond Elut Certify Clean Screen 
Analyte LOD 
(ng/10 mg) 
LOQ 
(ng/10 mg) 
LOD 
(ng/10 mg) 
LOQ 
(ng/10 mg) 
Amphetamine 0.79 2.64 0.30 1.00 
Methamphetamine 0.39 1.31 0.38 1.26 
MDA 0.97 3.24 0.20 0.67 
MDMA 0.24 0.78 0.37 1.25 
MDEA 0.26 0.88 0.26 0.86 
8.6 LC-MS-MS Method Validation 
In the method validation, the sample was reconstituted in 150 pL of mobile 
phase instead of 200 pL as used in the method development. This was to enable 
maximum assay sensitivity by injecting a greater quantity of drug onto the LC 
column. 
8.6.1 Linearity 
Linearity was determined over the concentration range 2-100 ng/10 mg hair. 
This sample weight was chosen for the validation since the hair case samples 
were analysed in segments and the sample weights were generally low. 
8.6.2 Recovery 
The % recovery was determined for each analyte at 5,10 and 50 ng. Drug 
standard solution was spiked into 10 mg blank hair prior to or following SPE. 
50 ng of deuterated internal standard was added after SPE. % Recovery was 
calculated as the mean peak area ratio of product ion/internal standard for the 
samples in which the standard solution was added before SPE (n=3) divided by 
the mean peak area ratio of product ion/internal standard for the samples in 
which the standard solution was added following SPE (n=3). The recovery from 
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authentic hair samples will however be lower than those quoted for spiked hair 
since the drug is incorporated. 
8.6.3 Matrix Effect 
Matrix effect was assessed by comparing the mean peak area ratio of product 
ion/internal standard of extracted blank hair samples spiked with standard 
solution following SPE (A) (n=6) versus the mean peak area ratio of product 
ion/internal standard of unextracted standards prepared in mobile phase at 
equivalent concentrations (B) (n=6). Matrix effect (%) was calculated for a low 
standard concentration of 5 ng by dividing A by B (Equation 7-5) and multiplying 
by 100 to express it as a percentage. 
8.6.4 Intra- and Inter-Day Precision and Accuracy 
Intra-and inter-day precision and accuracy were assessed over the linear range 
for 5 extracted hair spikes at a low, medium and high concentration (5,10 and 
50 ng). The intra-day precision was expressed as a% RSD calculated using the 5 
individual values obtained on the same day. Inter-day precision was evaluated 
for five replicate hair extracts spiked at these concentrations on five separate 
days (ntotat = 25). It was expressed as a% RSD value which was calculated using 
all 25 individual values. 
Accuracy was calculated by dividing the mean measured concentration of 5 or 25 
extracts (intra- and inter-day precision) by the theoretical spike concentration 
and was expressed as a percentage of the theoretical spike concentration. 
8.7 Validation Problems for Methadone and EDDP 
Methadone and EDDP were not included in the method validation as problems 
were encountered with the reproducibility of the product quantitation 
ion/internal standard ratio for both compounds. As demonstrated in Figure 8-20, 
the linearity was poor for methadone and EDDP over the range 2-100 ng. The 
variability of internal standard peak areas was assessed by calculating % RSD for 
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the peak areas of 3 consecutive injections of unextracted methadone-d9 and 
EDDP-d3 internal prepared in mobile phase at a concentration of 50 ng. The % 
RSD was < 20 % for both internal standards and this is acceptable precision 
according to published SOFT guidelines. " However, the % RSD for the peak areas 
of 3 consecutive injections of unextracted methadone and EDDP standards 
prepared in mobile phase at the same concentration as the internal standards 
(50 ng) were > 120 % for both compounds. Therefore the fragmentation of the 
methadone and EDDP was not consistent throughout and this resulted in poor 
linearity. The average peak area response for the methadone and EDDP product 
ions and the % RSD for these values are shown in Table 8-20. 
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Figure 8-20 Methadone and EDDP calibration plots 
Table 8-20 Methadone and EDDP product ion reproducibility 
" Methadon 
EDDP 
Methadone EDDP 
Peak Area 
(mlz 265) 
Average 
Peak 
Area 
Standard 
Deviation % RSD 
Peak Area 
(m/z 249) 
Average 
Peak Area 
Standard 
Deviation % RSD 
55314657 446705203 
6910990 21496050 29379853 136.7 82689910 187304511 226043876 120.7 
2262503 32518419 
Only one product ion was investigated for methadone and EDDP as the mass 
spectrums identified these as the only product ions produced after 
fragmentation. 
0 
p 20 40 60 BO 100 120 
Concentration ng 
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8.8 LC-MS-MS Validation Results 
8.8.1 Linearity 
Examples of the gradient and intercept values are shown in Table 8-21, along 
with the correlation coefficient (R2) values for the analyte regression lines. All 
regression lines had an R2 > 0.99. Graphs of regression lines for selected analytes 
are shown in Figure 8-21. 
3 
2.5 
2 
1.5 
0.5 
Figure 8-21 Regression lines for selected analytes 
Table 8-21 Gradient, intercept and R2 values for regression lines 
" Amphetamine 
Codeine 
Diazepam 
Cocaine 
Linear 
_(A 
pph tamine) 
L r(Codeine) 
Linear (Diazepam) 
- Linear (Cocaine) 
Analyte Equation of line R 
EME y=0.0057x-0.0055 0.9996 
Cocaine y=0.0082x-0.0023 0.9989 
Cocaethylene y=0.0065x-0.0045 0.9998 
Benzoylecgonine y=0.0074x+0.0019 0.9981 
Morphine y=0.0033x-0.0037 0.9924 
6-MAM y=0.0018x+0.0028 0.9916 
Codeine y=0.0019x+0.0115 0.9934 
Dihydrocodeine y=0.0044x+0.011 0.9960 
Oxazepam y=0.0172x-0.0531 0.9933 
Temazepam y=0.0145x+0.0017 0.9983 
Nordiazepam y=0.0023x-0.0002 0.9987 
0 
0 20 40 60 80 100 120 
Concentration ng/1O mg blank hair 
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Table 8-21 Gradient, intercept and R2 values for regression lines (continued) 
Analyte Equation of line R 
Diazepam y=0.001 9x-0.003 0.9974 
Amphetamine y=0.0273x-0.0346 0.9975 
Methamphetamine y=0.01 15x-0.0396 0.9902 
MDA y=0.0019x+0.002 0.9990 
MDMA y=0.0133x-0.0446 0.9972 
MDEA y=0.0018x-0.0043 0.9955 
The reason why the ratios for drug -to-deuterated internal standard is not 1: 1 
when both are present in equal amounts is due to the different types of scan 
mode used for the drugs and deuterated internal standard. As mentioned 
previously, the drugs were analysed in full MS-MS mode whereas the deuterated 
internal standards were analysed in SIM mode. 
8.8.2 Recovery 
The recovery values for all the analytes in spiked hair are given in Table 8-22. 
All gave high recoveries (> 79 %) at all three concentrations and % RSD values for 
these were <_ 17 %. 
Table 8-22 Recovery for drugs of abuse extracted from hair (n=3) 
Analyte 
% Recovery (n=3) 
5 ng/10 mg 10 ng/10 mg 50 ng/10 mg 
EME 99.2 (6.6) 96.4 (3.7) 97.7 (1.0) 
Cocaine 87.2 (8.9) 91.8 (4.9) 97.3 (3.1) 
Cocaethylene 79.4 (13.5) 97.8 (6.6) 92.5 (2.8) 
Benzoylecgonine 95.3 (8.5) 100.7 (4.5) 99.4 (3.2) 
Morphine 91.2 (2.2) 80.1 (6.7) 92.3 (1.1) 
6-MAM 109.6 (7.7) 104.5 (4.6) 94.3 (2.5) 
Codeine 99.6 (2.3) 94.4 (5.4) 99.3 (0.2) 
Dihydrocodeine 86.5 (7.5) 80.9 (3.2) 100.2 (0.7) 
Oxazepam 108.0 (8.8) 96.1 (3.8) 100.6 (3.3) 
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Table 8-22 Recovery for drugs of abuse extracted from hair (n=3) (continued) 
Chapter 8,175 
Analyte 
% Recovery (n=3) 
5 ng/10 mg 10 ng/10 mg 50 ng/10 mg 
Temazepam 76.3 (7.2) 96.5 (9.4) 95.7 (6.4) 
Nordiazepam 97.9 (5.6) 94.7 (3.7) 93.2 (2.7) 
Diazepam 96.9 (6.0) 98.3 (2.1) 94.7 (0.6) 
Amphetamine 108.1 (17.0) 99.6 (6.0) 91.0 (0.6) 
Methamphetamine 93.6 (2.2) 106.0 (0.8) 94.2 (2.3) 
MDA 82.8 (7.9) 106.2 (12.5) 97.6 (6.1) 
MDMA 98.3 (12.6) 100.0 (9.7) 98.2 (0.6) 
MDEA 102.5 (13.2) 104.3 (10.3) 90.8 (1.6) 
8.8.3 Matrix Effect 
Most analytes (12 out of 17) demonstrated ion suppression, some being affected 
to a greater extent than others. Oxazepam and temazepam product ions were 
suppressed the most. The product ions for 5 analytes demonstrated 
enhancement. Nordiazepam and methamphetamine product ions were enhanced 
the most. The results are given in Table 8-23. 
The existence of the matrix effect demonstrates the importance of using 
deuterated internal standards in the method. Deuterated internal standards will 
be affected by ion suppression or enhancement to a similar extent as the 
corresponding standard. The use of deuterated internal standards will therefore 
minimise fluctuations in instrument readings and will standardise analyte 
responses with respect to the response provided by the deuterated internal 
standard. 
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Table 8-23 % Matrix effect at 5 ng spiked hair extracts (n=6) 
Chapter 8,176 
Analyte % Matrix Effect 
EME 119.2 
Cocaine 96.4 
Cocaethytene 82.9 
Benzoylecgonine 85.1 
Morphine 85.4 
6-MAM 110.6 
Codeine 92.6 
Dihydrocodeine 102.8 
Oxazepam 67.6 
Temazepam 63.5 
Nordiazepam 130.3 
Diazepam 95.5 
Amphetamine 97.9 
Methamphetamine 135.6 
MDA 76.4 
MDMA 90.4 
MDEA 91.1 
8.8.4 Intra-day Accuracy and Precision 
The intra-day accuracy and precision values were acceptable within SOFT 
regulations of ± 20 %" for the 3 concentrations tested. The results are given in 
Table 8-24. Intra-day accuracy ranged from 80-116 %. Precision (% RSD) ranged 
from 1.4-18.7 %. As expected, lower precision was observed at the lower 
concentrations. 
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Table 8-24 Intra-day accuracy and precision (n=5) 
Chapter 8,177 
Analyte 
Spiked 
Quantity 
(ng) 
Mean 
Measured 
Concentration 
(ng) 
% RSD % Accuracy 
5 5.3 5.5 106.0 
EME 10 9.9 4.9 99.0 
50 54.8 3.8 109.6 
5 4.1 7.2 82.0 
Cocaine 10 9.6 5.8 96.0 
50 46.8 3.0 93.6 
5 4.8 10.0 96.0 
Cocaethylene 10 10.3 5.0 103.0 
50 48.1 3.7 96.2 
5 4.6 7.1 92.0 
BZE 10 9.2 6.3 92.0 
50 49.8 3.6 99.6 
5 4.7 8.4 94.0 
Morphine 10 9.1 7.5 91.0 
50 50.3 6.9 100.6 
5 4.5 11.4 90.0 
6-MAM 10 8.7 5.2 87.0 
50 50.8 4.8 101.6 
Codeine 5 4.7 8.9 94.0 
10 10.7 6.5 107.0 
50 54.2 2.0 108.4 
Dihydrocodeine 5 4.9 7.0 98.0 
10 11.6 5.3 116.0 
50 50.2 1.4 100.4 
Oxazepam 5 5.0 11.6 100.0 
10 10.6 8.9 106.0 
50 50.8 6.0 101.6 
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Table 8-24 Intra-day accuracy and precision (n=5) (continued) 
Chapter 8,178 
Analyte 
Spiked 
Quantity 
(ng) 
Mean 
Measured 
Concentration 
(ng) 
% RSD % Accuracy 
Temazepam 5 4.4 18.7 88.0 
10 9.4 13.9 94.0 
50 52.9 9.4 105.8 
Nordiazepam 5 5.7 14.4 114.0 
10 11.0 9.6 111.0 
50 48.8 6.6 97.6 
Diazepam 5 4.8 6.6 96.0 
10 9.8 5.6 98.0 
50 48.6 2.9 97.2 
Amphetamine 5 5.6 9.2 112.0 
10 8.0 6.7 80.0 
50 52.1 7.0 104.2 
Methamphetamine 5 5.8 6.0 116.0 
10 9.2 6.1 92.0 
50 44.3 4.4 88.6 
MDA 5 4.4 9.1 88.0 
10 9.5 5.0 95.0 
50 49.6 7.1 99.2 
MDMA 
5 5.2 10.6 104.0 
10 8.9 6.6 89.0 
50 50.8 5.9 101.6 
5 5.7 6.7 114.0 
MDEA 10 8.8 6.6 88.0 
50 55.0 3.5 110.0 
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8.8.5 Inter-Day Precision 
The inter-day precision was generally acceptable within SOFT regulations of 
± 20 %h1 for the 3 concentrations tested. Nordiazepam was slightly higher at the 
lower concentrations however the SOFT regulations also state that ± 25-30 % may 
be acceptable for some analytes. Precision (% RSD) ranged from 5.6-24.3 %. As 
found in the intra-day precision experiment, the % RSD was higher at lower 
concentrations. The % RSD range was higher for inter-day precision compared to 
intra-day precision due to instrumental and extraction inter-day variation and 
also a greater number of data values. Some analyte data in Table 8-25 was 
calculated for n=24. This was due to the removal of an outlier in the data sets. 
Table 8-25 Inter-day precision (n=25) 
Analyte 
Inter-day Precision (% RSD) 
5 ng 10 ng 50 ng 
EME 5.5 (18.3) 8.8 (9.9) 49.4 (5.6) 
Cocaine 4.5 (10.1) 10.1 (7.7) 50.9 (7.1) 
Cocaethylene 5.1 (19.0)* 10.0 (15.8) 50.5 (10.2) 
BZE 5.3 (22.5) 10.1 (12.0) 48.6 (8.8) 
Morphine 5.1 (16.4) 9.8 (15.5)* 55.2 (11.0) 
6-MAM 4.6 (20.5) 10.5 (13.6) 51.9 (8.2) 
Codeine 5.0 (18.7) 10.9 (17.5) 54.3 (9.3) 
DHC 4.8 (18.2) 10.6 (12.9) 51.9 (8.5) 
Oxazepam 5.2 (16.8) 9.9 (14.2)* 49.7 (10.8)* 
Temazepam 5.2 (20.2)* 10.1 (18.9) 51.9 (10.6) 
Nordiazepam 5.6 (24.3)* 9.2 (22.9)* 47.4 (10.6) 
Diazepam 4.7 (13.3) 9.8 (12.2) 47.3 (9.2) 
AMP 5.0 (16.9) 9.3 (15.7) 48.9 (12.2) 
MAMP 4.9 (20.7) 8.9 (8.9) 51.5 (8.6) 
MDA 5.6 (20.8) 10.6 (19.4) 52.0 (19.6) 
MDMA 5.1 (15.9) 8.9 (10.8) 52.6 (10.0) 
MDEA 4.8 (15.1) 9.4 (11.0) 52.4 (9.8) 
*n=24 
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8.8.6 LOD and LOQ 
The LOD and LOQ values for the Clean Screen® method are provided in Table 8- 
19. The LOD values ranged from 0.15-0.92 ng/10 mg hair and the LOQ ranged 
from 0.51-3.07 ng/10 mg hair. 
8.9 Case Samples 
The validated LC-MS-MS method was used to analyse 17 post-mortem scalp hair 
samples. All samples were submitted to the toxicology laboratory of the 
Forensic Medicine and Science Section at the University of Glasgow for routine 
testing. The samples were tested for diagnostic purposes and the results were 
reported to the Procurator Fiscal. 
The hair samples were decontaminated as described in section 6.4.1, segmented 
and split between 3 vials where sufficient sample was available. This was 
carried out for the purposes of comparing the LC-MS-MS results with GC-MS 
results obtained using routine in-house methods and also with ELISA screening 
results obtained using the validated methods described in chapters 6 and 7. 
8.9.1 Comparison of LC-MS-MS vs Routine GC-MS Methods 
8.9.1.1 Methods 
The validated LC-MS-MS method analysed each case sample for amphetamines, 
benzodiazepines, cocaine and its metabolites and opiates while the GC-Ms 
methods analysed individual drug groups. 
The GC-MS methods for opiates and cocaine were detailed in section 6.6.4. In 
brief, the GC-MS method for amphetamine extraction from hair involved 
ultrasonicating the hair for 1 hour in phosphate buffer (pH 6.0) then incubating 
at 40 °C for 2 hours. The extracts were cleaned up using Bond Elut Certify'M SPE 
cartridges. The amphetamines were derivatised at 60 °C for 20 minutes using 
PFPA/ethyl acetate (2: 1 v/v) prior to GC-MS analysis. 
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The LOD and LOQ were approximately 1 ng/30 mg and 2 ng/30 mg respectively 
for all compounds in the in-house GC-MS methods. 
8.9.1.2 Results 
The LC-MS-MS and GC-MS results are given in Table 8-26. The drug groups 
analysed by GC-MS are provided in the footnote for Table 8-26. The 
abbreviations in Table 8-26 are as follows: "MOR"=Morphine; "6-MAM"=6- 
Monoacetylmorphine; "COD"=Codeine; "DHC"=Dihydrocodeine; "COC"=Cocaine; 
"BZE"=Benzoylecgonine; "COCAETH"=Cocaethylene; "EME"=Ecgonine Methyl 
Ester; "AMP"=Amphetamine; "DZ"=Diazepam; "NDZ"=Nordiazepam; 
"OXAZ"=Oxazepam; and "TMZ"=Temazepam. 
Table 8-26 LC-MS-MS vs GC-MS results 
LC-MS-MS 
Hair Sample LC-MS-MS GC-MS Weight GC-MS Results 
Results 
Number Weight (mg) (mg) (ng/mg) 
(ng/mg) 
(1)t 2.85 0.91 MOR 2.56 NEG for MOR 
Root- 0.5 cm 0.97 6-MAM NEG for 6-MAM 
1.38 COD 0.08 COD 
2.93 DHC 4.98 DHC 
(1)t 23.80 2.02 MOR 23.36 6.14 MOR 
0.5-3.5 cm 1.31 6-MAM 2.87 6-MAM 
0.37 COD 1.08 COD 
1.22 DHC 3.32 DHC 
0.10 DZ 
0.37 NDZ 
(2)t 2.05 1.67 MOR 2.21 0.18 MOR 
Root-0.5 cm 1.96 6-MAM NEG for 6-MAM 
NEG for COD 0.41 COD 
0.34 DZ 
2.26 NDZ 
TGC-MS ana[ysis or opiates ana cocaine onLy, NI =Not I estea, NEG=Negative 
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Table 8-26 LC-MS-MS vs GC-MS results (continued) 
Chapter 8,182 
LC-MS-MS 
Hair Sample LC-MS-MS GC-MS Weight GC-MS Results 
Results 
Number Weight (mg) (mg) (ng/mg) 
(ng/mg) 
(2) t 25.45 1.23 MOR 25.63 3.11 MOR 
0.5-3.5 cm 0.12 6-MAM NEG for 6-MAM 
0.45 COD 0.75 COD 
0.13 DHC 0.16 DHC 
0.06 COC 0.09 COC 
0.42 BZE 0.63 BZE 
1.03 MDMA 
0.22 OXAZ 
0.10 TMZ 
0.52 DZ 
0.67 NDZ 
(3) fi 2.74 NEG for all 2.76 NEG for opiates 
Root-0.5 cm drug groups and cocaine 
(3) t 19.09 0.09 MOR 19.48 0.01 MOR 
0.5-3.5 cm 0.52 6-MAM 0.72 6-MAM 
0.21 COD 0.13 COD 
NEG for DHC 0.05 DHC 
0.29 COC 1.28 COC 
0.16 BZE 0.29 BZE 
1.26 MDMA 
0.12 DZ 
0.36 NDZ 
(3) t 18.60 NEG for MOR 18.97 0.08 MOR 
3.5-6.5 cm 0.53 6-MAM 1.06 6-MAM 
NEG for COD 0.05 COD 
NEG for DHC 0.05 DHC 
0.96 COC 3.85 COC 
0.45 BZE 0.64 BZE 
1.60 MDMA NT 
tGC-MS analysis tor opiates ana cocaine only, NT=Not Tested, NW=Negative 
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Table 8-26 LC-MS-MS vs GC-MS results (continued) 
Chapter 8,183 
Hair Sample LC-MS-MS 
LC-MS-MS 
Results GC-MS Weight GC-MS Results Number Weight (mg) (ng/mg) (mg) (ng/mg) 
(4) t 3.21 0.58 MOR 3.39 NEG for MOR 
Root-0.5 cm 0.77 6-MAM NEG for 6-MAM 
0.32 DHC NEG for DHC 
1.40 NDZ 
(4) j- 21.12 0.16 MOR 21.11 0.24 M0R 
0.5-3.5 cm 0.58 6-MAM 0.71 6-MAM 
0.20 COD 0.09 COD 
0.09 DHC 0.19 DHC 
0.86 COC 0.61 COC 
0.11 BZE 0.21 BZE 
0.19 AMP 
1.42 MDMA 
0.04 DZ 
0.29 NDZ 
(5)$ 1.71 1.39 6-MAM 2.11 NEG for 6-MAM 
Root-0.5 cm 
(5) 1 12.62 0.22 MOR 12.47 0.11 MOR 
0.5-3.5 cm 0.49 6-MAM NEG for 6-MAM 
0.32 COD 0.10 COD 
10.18 COC 
3.11 BZE 
0.43 COCAETH 
0.24 EME 
0.11 MDMA 
0.17 DZ 
0.52 NDZ 
(6) fi 1.03 NEG for all 1.33 NEG for opiates 
Root-0.5 cm drug groups 
fGC-AAS analysis for opiates and cocaine only, # GC-MS analysis for opiates only, NT=Not tested, 
NEG=Negative 
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Table 8-26 LC-MS-MS vs GC-MS results (continued) 
Chapter 8,184 
Hair Sample LC-MS-MS LC-MS-MS Results GC-MS Weight GC-MS Results 
Number Weight (mg) (ng/mg) (mg) (ng/mg) 
(6) t 18.49 2.32 COD 18.31 5.52 COD 
0.5-3.5 cm 
(7)4 1.49 NEG for MOR 1.68 5.23 MOR 
Root-0.5 cm NEG for 6-MAM 3.03 6-MAM 
0.13 COD 1.75 COD 
(7)$ 8.38 1.10 MOR 8.62 2.77 M0R 
0.5-3.5 cm 4.55 6-MAM 3.36 6-MAM 
0.11 COD 0.32 COD 
(8)$ 1.05 NEG for DHC 1.52 1.91 DHC 
Root-0.5 cm 
(8)$ 9.24 NEG for MOR 9.34 0.24 MOR 
0.5-3.5 cm 0.58 6-MAM 0.85 6-MAM 
0.08 COD NEG for COD 
0.21 DHC 1.07 DHC 
(9)t 3.16 0.71 6-MAM 3.24 1.49 6-MAM 
Root-0.5 cm 2.05 COC 4.78 COC 
0.31 BZE 1.56 BZE 
0.25 COCAETH NEG for 
COCAETH 
(9)t 28.55 0.04 MOR 28.72 0.45 MOR 
0.5-3.5 cm 1.12 6-MAM 1.55 6-MAM 
NEG for COD 0.13 COD 
13.99 COC 19.34 COC 
4.73 BZE 4.92 BZE 
0.21 EME Not reported 
0.54 COCAETH 1.07 COCAETH 
0.21 AMP 
0.18 DZ 
0.17 NDZ 
tGC-MS analysis for opiates and cocaine only $ GC-MS analysis for opiates only, NT=Not Tested, 
NEG=Negative 
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Table 8-26 LC-MS-MS vs GC-MS results (continued) 
Chapter 8,185 
Hair LC-MS-MS Weight LC-MS-MS GC-MS Weight GC-MS Results Sample (mg) Results (mg) (ng/mg) Number (ng/mg) 
(10)t 3.27 0.60 COC 3.34 2.40 COC 
Root-0.5 cm 0.18 BZE 1.25 BZE 
0.24 COCAETH NEG for COCAETH 
0.31 DZ 
0.34 NDZ 
(10)t 29.47 0.08 6-MAM 29.71 0.20 6-MAM 
0.5-3.5 cm 2.50 COC 5.09 COC 
1.88 BZE 2.35 BZE 
0.05 COCAETH 0.10 COCAETH 
0.15 EME Not reported 
0.26 OXAZ 
0.14 TMZ 
0.24 DZ 
0.64 NDZ 
(11)1 8.55 NEG for COD 8.86 0.27 COD 
0.5-3.5 cm 0.49 MDMA 
(11)1 8.69 0.02 COD 9.00 0.48 COD 
3.5-6.5 cm 
(12)1 0.35 14.48 DHC 0.84 11.26 DHC 
Root-0.5 cm 
(12) 1 10.40 0.87 MOR 10.36 0.64 M0R 
0.5-3.5 cm 0.12 6-MAM NEG for 6-MAM 
16.18 DHC 14.60 DHC 
0.46 MDMA 
3.51 OXAZ 
0.68 DZ 
0.92 NDZ 
tGC-MS analysis for opiates and cocaine only, $ GC-MS analysis for opiates only, NT=Not Tested, 
NEG=Negative 
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Table 8-26 LC-MS-MS vs GC-MS results (continued) 
Chapter 8,186 
Hair Sample LC-MS-MS LC-MS-MS Results GC-MS Weight GC-MS Results Number Weight (mg) (ng/mg) (mg) (ng/mg) 
(13)$ 0.21 NEG for all 0.54 NEG for 
Root-0.5 cm drug groups opiates 
(13)t 3.79 NEG for MOR 3.58 0.05 MOR 
0.5-3.5 cm 0.71 6-MAM 0.19 6-MAM 
(14)1 1.25 NEG for COD 1.47 2.57 COD 
0.5-1.5 cm 
(15)t 1.75 3.54 MOR 2.45 5.71 MOR 
Root-0.5 cm 1.31 6-MAM 1.05 6-MAM 
NEG for COD 2.59 COD 
NEG for DHC 0.83 DHC 
(15)t 18.66 1.03 MOR 18.94 3.01 MOR 
0.5-3.5 cm 1.32 6-MAM 2.28 6-MAM 
0.31 COD 1.27 COD 
10.72 DHC 12.45 DHC 
(16) t 4.90 NEG for all 5.36 NEG for 
Root-0.5 cm drug groups opiates 
(16) t 20.62 NEG for all 21.10 NEG for 
0.5-3.5 cm drug groups opiates 
(16) t 17.30 NEG for all 25.63 NEG for 
3.5-6.5 cm drug groups opiates 
(17) * 2.49 5.59 AMP 3.02 NEG for AMP 
Root-0.5 cm 
(17)* 18.21 7.29 AMP 18.01 1.75 AMP 
0.5-3.5 cm 
TGC-MS analysis for opiates and cocaine only, $ GC-MS analysis for opiates only, NT=Not Tested, 
NEG=Negative 
In general, the LC-MS-MS method was better for detecting a wider range of 
analytes compared to the GC-MS methods which targeted individual drug groups 
using similar sample weights between the two methods. 
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8.9.1.3 Qualitative Root Results 
Chapter 8,187 
Some analytes were detected in root samples of low weight by LC-MS-MS 
(<_ 3.27 mg) due to the low LOD/LOQ of the method where none were detected 
using GC-MS: morphine in root samples 1 and 4; 6-MAM in root samples 2,4 and 
5; dihydrocodeine in root sample 4; and cocaethylene in root samples 9 and 10. 
Morphine was detected in the blood samples corresponding to root samples 1 and 
4.6-MAM was detected in the blood samples corresponding to root samples 2 
and 5. No 6-MAM was detected in the blood sample corresponding to root 
sample 4, probably due to its short half life of 2-4 minutes in blood. 176 There was 
no dihydrocodeine detected in the blood sample corresponding to root sample 4. 
The routine blood method does not analyse for cocaethylene so it is not possible 
to compare cocaethylene results for blood with the root results for samples 9 
and 10. 
The GC-MS method detected opiates in root samples of low weight (<_ 2.05 mg) 
where LC-MS-MS detected none: morphine and 6-MAM in root sample 7; codeine 
in root samples 2 and 15; and dihydrocodeine in root samples 8 and 15. The 
blood results for morphine, 6-MAM and codeine showed excellent correlation 
with the root samples however no dihydrocodeine was detected in the blood 
samples corresponding to root samples 8 and 10. The GC-MS method has a 
higher opiate recovery than the LC-MS-MS method as it is targeting the opiate 
drug group so this could explain the detection of these opiates by GC-MS where 
LC-MS-MS failed to detect them. However the opiate concentrations detected by 
GC-MS in these root samples were relatively high and so another explanation for 
the LC-MS-MS results being negative for these samples may be due to uneven 
splitting of root segments between the two methods. The root-0.5 cm segment 
of a growing hair would contain incorporated drug whereas a hair at the end of 
its growth cycle would not have incorporated drug into the root segment. 
8.9.1.4 Qualitative results for segments excluding roots 
A higher GC-MS recovery for opiates and cocaine and its metabolites was 
observed in the 0.5-3.5 cm (and in 1 case 3.5-6.5 cm segment) which had a 
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sufficiently high sample weight compared with root segments. Although the 
LC-MS-MS method produced lower recoveries for opiates and cocaine and its 
metabolites compared to the GC-MS method, it generally detected the analytes 
in the 0.5-3.5 cm segments which were detected by GC-MS. However, the 
analytes that were detected by GC-MS but not LC-MS-MS were morphine (sample 
3,8 and 13), codeine (sample 3,9 and 11) and dihydrocodeine (sample 3). The 
analyte concentrations in these samples as determined by GC-MS were low. The 
blood results corresponding to hair samples 3,8 and 13 were positive for 
morphine. Codeine was detected in the blood samples corresponding to hair 
samples 9 and 11. The blood and hair results for hair sample 3 were both 
negative for codeine and dihydrocodeine where the hair results for GC-MS were 
positive. The better opiate recovery obtained using the GC-MS method explains 
the positive GC-MS results where the LC-MS-MS results were negative. 
The LC-MS-MS method did however detect some analytes in the 0.5-3.5 cm 
segments where GC-MS failed to detect them. This was 6-MAM in samples 2,5 
and 12 and codeine in sample 8. The concentrations detected in these samples 
as determined by LC-MS-MS were also low. The results for the blood samples 
corresponding to hair samples 2 and 5 were positive for 6-MAM. However no 
6-MAM was found in the blood sample corresponding to hair sample 12 and no 
codeine was detected in the blood sample corresponding to hair sample 8. 
The LC-MS-MS and GC-MS results showed excellent qualitative correlation for 
cocaine, benzoylecgonine and cocaethylene in the 5 positive samples tested for 
these analytes by both methods. The GC-MS method recovery was higher than 
that for LC-MS-MS as higher quantities of cocaine, benzoylecgonine and 
cocathylene were detected in the 0.5-3.5 cm segments. EME was identified and 
quantified in samples 9 and 10 by LC-MS-MS however the GC-MS method was 
incapable of identifying and quantifying EME due to a co-eluting peak in the 
method and therefore EME concentrations were not reported for GC-MS. The 
corresponding blood results for hair sample 9 did not detect EME but did detect 
benzoylecgonine. The corresponding blood results for hair sample 10 detected 
EME as well as cocaine and benzoylecgonine. 
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A higher quantity of amphetamine was recovered in sample 17 using the LC-MS- 
MS method. This was the only sample that was tested for amphetamines using 
GC-MS. The LC-MS-MS method also detected amphetamine in the root where 
none was detected by GC-MS. The LC-MS-MS method involved incubating the 
hair overnight in phosphate buffer (pH 5.0) while the GC-MS method involved 
incubating the hair for 2 hours in phosphate buffer (pH 6.0). The higher 
amphetamine recovery for the LC-MS-MS method could be a result of the longer 
incubation time or the pH of the extraction. The blood result for this hair 
sample was also positive for amphetamine at a concentration of 0.66 mg/L. The 
LC-MS-MS method also detected amphetamine in samples 4 and 9 but as the GC- 
MS method did not test for amphetamine and there was a lack of sample to 
analyse using the routine GC-MS method for amphetamine, it was not possible to 
compare these. The blood results corresponding to hair samples 4 and 9 were 
negative for amphetamine. MDMA was detected by LC-MS-MS in 6 of the 17 
samples (samples 2,3,4,5,10 and 12) which were not tested for amphetamines 
by GC-MS. The corresponding blood results for these 6 samples were negative 
for MDMA. 
The GC-MS method did not test for benzodiazepines. However the LC-MS-MS 
method detected diazepam and nordiazepam in the 0.5-3.5 cm (and in 1 case 
3.5-6.5 cm) segments of 8 samples. Oxazepam and temazepam were also 
detected in 2 of these 8 samples. 
8.9.1.5 Discussion 
8.9.1.5.1 Points to consider for interpretation 
It is not possible to directly correlate the amount of drug taken with the amount 
of drug detected in hair because the dose is unknown in all cases. Also studies 
have demonstrated that different quantities of drug incorporate into hair of 
individuals who have received the same dose. 25, '" 
Using the LC-MS-MS method, each of the 12 opiate positive samples tested 
positive for 6-MAM, which is a marker of heroin use. The detection of 6-MAM is 
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however not definitive of heroin use as it is possible that 6-MAM could be present 
as a reaction side-product of the incomplete conversion of morphine to 
diamorphine during the acetylation process. In hair samples collected from 20 
known heroin users, 6-MAM was predominantly found over morphine and codeine 
and usually in higher concentrations. 13,252 In one study it was proposed that to 
confirm heroin use, a morphine/codeine ratio of 5: 1 should be in place for low 
morphine levels (< 1 ng/mg) and 2: 1 for morphine concentrations >1 ng/mg. 
The same authors also found a 6-MAM/morphine ratio range of 1.3-10.0. ' 
Another group of authors proposed that 6-MAM/morphine ratios and 
6-MAM/codeine ratios should be greater than 7.14 and 50 respectively to 
interpret the results as consistent with heroin use. In another study, the same 
authors defined three levels of use (low, medium and high) in relation to the 6- 
MAM marker found in hair after heroin use. 253 Low use was defined as containing 
<2 ng/mg, medium 2-10 ng/mg and high > 10 ng/mg 6-MAM. The cut-off 
proposed in this study was 0.5 ng/mg 6-MAM. An important point of 
consideration when applying these recommended ratios is the type of extraction 
used. In both of these papers proposing 6-MAM/morphine and 6-MAM/codeine 
ratios, the opiates were extracted by acidic hydrolysis. 6-MAM can hydrolyse to 
some extent under acidic conditions so the ratios proposed using acidic 
extraction will be different to the ratios observed using a phosphate buffer 
extraction in which 6-MAM is stable. It is more meaningful to compare the ratios 
obtained using the same type of extraction medium. 
7 out of 8 cocaine positive samples tested positive for benzoylecgonine which 
suggests cocaine use. The presence of benzoylecgonine is not however definitive 
of cocaine use as it was shown in one study that small quantities of 
benzoylecgonine were formed in hair as a result of environmental contamination 
with cocaine-"' In addition, this study also found that benzoylecgonine could be 
absorbed from illicit cocaine contamined with benzoylecgonine. Current Society 
of Hair guidelines propose a benzoylecgonine/cocaine ratio of 5 %. 10° It was 
proposed that this value was not appropriate for some cocaine users' hair which 
can produce levels <5%. 255 
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Amphetamine and MDMA were detected in 8 out of 17 samples. No MDA was 
detected in the MDMA positive hair samples; however, these would be reported 
as positive according to current SoHT guidelines which recommend a cut-off of 
0.2 ng/mg for individual amphetamines. 10° There are no recommendations in 
these guidelines for a cut-off value for the MDMA metabolite, MDA. 
Diazepam and nordiazepam were detected in 8 out of 17 samples which also 
contained heroin metabolites. There are currently no recommended cut-off 
values for benzodiazepines in hair. 
MDMA, EME, oxazepam and temazepam were not detected in the root-0.5 cm 
segments by LC-MS-MS where the 0.5-3.5 cm segments were positive. The drug 
group specific GC-MS methods did not detect cocaethylene or amphetamine in 
the root-0.5 cm segments where the 0.5-3.5 cm segments were positive. LC-MS- 
MS found these root segments positive for cocaethylene and amphetamine. 
As there are no definitive markers of heroin or cocaine use in hair per se, it is 
very useful to examine an individual's past drug use history if provided in the 
pathologist's background report. Other additional information from the police 
reports may include drug findings at the location of death which could aid the 
toxicology interpretation. An example is the recovery of a syringe filled with 
heroin in situ. This information would be very useful in a suspected heroin death 
where no 6-MAM was found in the hair. Table 8-27 provides information on the 
individual case histories. 
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Table 8-27 Case Histories 
Chapter 8,192 
Case Age Prescription and Illicit Drugs Useful Cause of Death 
Number findings in 
situ/at 
post- 
mortem 
32 History of heroin abuse. Needles in Bronchopneumonia 
a small bag due to heroin 
History of overdoses and recovered intoxication. 
depression. from his 
bedroom. 
Not on any prescribed 
medication at the time of 3 recent 
death. needle 
puncture 
marks on 
arms. 
2 - - - - 
3 30 History of multi-substance Heroin and alcohol 
abuse including heroin and intoxication. 
cocaine. 
History of extensive alcohol 
abuse. 
Not on any prescribed 
medication at the time of 
death. 
4 27 Not known. Needle Bronchopneumonia 
puncture due to aspiration of 
History of mental illness. mark in gastric contents due 
right groin. to morphine 
Being treated for intoxication. 
schizophrenia. 
5 30 Known to abuse anabolic Various Heroin intoxication. 
steroids and possibly heroin. tablets 
He was taking a large number found in his 
of herbal tablets and other house plus 
substances, including a box of 
Tamoxifen. needles. 
Not known. 
6 33 History of chronic alcohol Not Gastrointestinal 
abuse. applicable. haemorrhage due to 
Using street methadone oesophageal ulcers 
(about 150 mL per week). due to chronic 
alcohol abuse. 
Liver problems. 
"-"= No information (external post-mortem) 
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Table 8-27 Case Histories (continued) 
Chapter 8,193 
Case Age Prescription and Illicit Useful findings Primary cause of 
Number Drugs in situ/at post- death 
mortem to aid 
toxicology 
interpretation 
7 39 History of heroin abuse. A syringe was Heroin 
found on the intoxication. 
floor next to the 
fireplace. 
A sharps 
container with 
syringes was also 
found. 
Potential needle 
marks noted on 
the hands, feet 
and bend of 
right elbow. 
8 35 History of drug misuse. 2 puncture Heroin 
wounds in the intoxication. 
bend of the right 
elbow. 
9 20 History of drug abuse. A number of Morphine (heroin) 
drug productions intoxication. 
Prescribed olanzapine. were recovered 
from the scene. 
Regular cannabis user. 
Never known to have taken 
heroin. 
Taking olanzapine for 
schizophrenia. 
10 16 No previous history of Drug Cocaine, heroin 
heroin use. paraphernalia at and diazepam 
scene including intoxication. 
On day of death, took a bag tinfoil and citric 
of Valium tablets and 3g acid found in 
cocaine to step-brother's bedroom 
house. however step- 
brother was 
known to be an 
intravenous drug 
user. 
Multiple needle 
puncture marks 
in body. 
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Table 8-27 Case Histories (continued) 
Chapter 8,194 
Case 
Number 
Age Prescription and Illicit Drugs Useful 
findings in 
situ/at post- 
mortem to 
aid toxicology 
interpretation 
Primary 
cause of 
death 
11 32 History of alcohol and heroin Drug Heroin and 
dependency. paraphernalia alcohol 
found in the intoxication. 
Prescribed campral, room. 
chlordiazepoxide, propanolol, 
dothiepin and vitamins. Tourniquet 
around the 
History of self-harm, depression. right arm with 
a syringe lying 
A number of previous overdose on the floor 
attempts. between the 
legs and arms. 
Placed on methadone programme 
in 2002, taking 50 mg daily. Several needle 
puncture 
Liver tests abnormal in 2005. marks in the 
bend of the 
right elbow 
and a 
tourniquet 
round the 
lower arm. 
12 32 Previously addicted to heroin. Large quantity Sertraline, 
of medication methadone 
Prescribed methadone 20 mL next to bed and 
daily, oxazepam, epilim, including morphine 
dihydrocodeine, diazepam, sertraline, overdose. 
sertraline and olanzapine. olanzapine 
and a 
Severe brain injury following a methadone 
road traffic accident from which bottle. 
he subsequently had epilepsy and 
a compound fracture in his left 
leg. 
Long history of self-harm. 
Been on methadone programmes 
had a number of episodes where 
he cut himself and overdoses. 
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Table 8-27 Case Histories (continued) 
Chapter 8,195 
Case Age Prescription and Illicit Drugs Useful findings Primary 
Number in situ/at post- cause of 
mortem to aid death 
toxicology 
interpretation 
13 36 Heroin addiction. Needle puncture Heroin 
mark in the bend intoxication. 
Not on any prescribed of the left 
medication. elbow. 
Known to have smoked hash. 
14 34 Chronic alcohol abuse. - Cerebro- 
vascular 
Prescribed several medications accident 
for hypertension and ('stroke') 
depression. 
Chronic alcohol abuse, 
depression and hypertyension 
15 35 Longstanding drug abuse since Drug Heroin 
1988. Initially Temgesic and paraphernalia intoxication. 
temazepam but subsequently associated with 
diamorphine and the body, an 
benzodiazepines. empty syringe 
pack and a used 
Currently prescribed syringe below it. 
beclometasone and salbutamol An empty 
inhalers, dihydrocodeine and diazepam box 
diazepam. and a 
nitrazepam 
History of asthma. bottle were also 
found. 
Attended numerous 
rehabilitation centres. Possible needle 
puncture mark 
detected and 
there was a 
blood trail on 
the right arm. 
16 37 Alcoholic for 15 years. Cannabis resin Fatty 
found on bedside degeneration 
Used cannabis in past. cabinet nearby of liver due 
along with 2 to chronic 
empty Buckfast alcohol 
bottles and abuse. 
several empty 
beer cans. 
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Table 8-27 Case Histories (continued) 
Chapter 8,196 
Case 
Number 
Age Prescription and Illicit Drugs Useful 
findings in 
situ/at post- 
mortem to 
aid toxicology 
interpretation 
Primary 
cause of 
death 
17 52 Known to use cannabis. Several Amphetamine 
syringes found intoxication. 
Past history of depression and lying near to 
arthritis. the deceased. 
Also some foil, 
plastic cup 
with a residue 
and a burner. 
Drugs found 
were 
citalopram, 
Celecoxib and 
Arthrotec. 
8.9.1.5.2 Quantitative Root Results 
The opiate ranges and number of positive root-0.5 cm segments found by LC-MS- 
MS and GC-MS are shown in Table 8-28. 
Table 8-28 Opiate concentration ranges and number of opiate positive root segments for 
LC-MS-MS and GC-MS 
LC-MS-MS GC-MS 
Analyte Concentration 
Range 
(ng/mg) 
Number of 
Positive 
Samples 
Concentration 
Range 
(ng/mg) 
Number of 
Positive 
Samples 
Morphine 0.58-3.54 4 0.18-5.71 3 
6-MAM 0.71-1.96 6 1.05-3.03 3 
Codeine 0.13-1.38 2 0.08-2.59 4 
Dihydrocodeine 0.32-14.48 3 0.83-11.26 4 
The results in Table 8-28 show that the LC-MS-MS method detected morphine 
and 6-MAM in a greater number of root-0.5 cm segments compared to the GC-MS 
method. Conversely, the GC-MS method detected codeine and dihydrocodeine in 
a greater number of root-0.5 cm segments. The lowest concentration from the 
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LC-MS-MS and GC-MS ranges for 6-MAM and dihydrocodeine was found using LC- 
MS-MS. In contrast, the lowest concentration from the LC-MS-MS and GC-MS 
ranges for morphine and codeine was found using GC-MS. The method sensitivity 
appears to be better for 6-MAM and dihydrocodeine using LC-MS-MS while the 
method sensitivity appears to be better for morphine and codeine using GC-MS. 
The difference in method sensitivity may however be due to the uneven splitting 
of root-0.5 segments between the two methods. As mentioned previously, drugs 
ingested when a hair is in its growth phase would be incorporated into the hair 
whereas no drugs would be incorporated into the hair at the end of its growth 
cycle. The highest concentration from the LC-MS-MS and GC-MS ranges for 
morphine, 6-MAM and codeine was found using the GC-MS method. The higher 
opiate recovery of the GC-MS method would explain this. 
In the 4 root samples (samples 1,2,4 and 15) containing both 6-MAM and 
morphine, the 6-MAM/morphine ratios ranged from 0.37-1.33 (mean 0.99) using 
the LC-MS-MS method. A 6-MAM/morphine ratio range of 0.37-6.45 was observed 
for hair samples in another study which used a phosphate buffer (pH 5.0) 
extraction. " 6-MAM and morphine were detected together in 2 root samples 
(samples 7 and 15) using GC-MS. The 6-MAM/morphine ratios were 0.58 and 0.18 
(mean 0.38) in these samples. These ratios are lower than the ratios proposed in 
other studies which used acidic hydrolysis to extract opiates from hair, as 
discussed in section 8.9.1.5.1. As expected, the mean 6-MAM/morphine ratio for 
the GC-MS method was lower than that for the LC-MS-MS method. This is 
because of the different extraction methods used in the two methods. The GC- 
MS method used hydrochloric acid for part of the extraction and this may have 
resulted in some hydrolysis of 6-MAM to morphine, leading to lower ratios. On 
the other hand, the phosphate buffer extraction used in the LC-MS-MS method 
does not cause hydrolysis of 6-MAM so the ratios should be higher. Acetylated 
opiates (6-MAM and acetylcodeine) were found to significantly decompose (70-86 
%) using 0.1 M hydrochloric acid at 55 °C for 16 hours and the reproducibility of 
the hydrolysis was poor. 82 
Codeine was only detected in 1 root sample (sample 1) using LC-MS-MS. 6-MAM 
and morphine were also present in this root sample by LC-MS-MS. The 
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morphine/codeine ratio was 0.66 in this sample which is in the reported range of 
0.38-6.45 which was found for hair samples extracted using a phosphate buffer 
extraction. " Codeine was detected in 4 root samples (samples 1,2,7 and 15) 
using GC-MS. In root sample 1, codeine was found by GC-MS without any other 
heroin metabolites so the results could have been interpreted as codeine use. 
However the LC-MS-MS results for this root sample detected 6-MAM, morphine 
and codeine which could indicate heroin use. Heroin metabolites were detected 
in the other 3 root samples. 2 of these root samples (samples 7 and 15) would 
have been reported as positive using the criteria proposed in section 8.9.1.5.1. 
As the GC-MS method results in the partial hydrolysis of 6-MAM to morphine, the 
morphine/codeine ratios should be higher using this method compared to the LC- 
MS-MS method which uses a phosphate buffer extraction which does not cause 6- 
MAM hydrolysis. 
Dihydrocodeine was detected in root segment 8 (1.9 ng/mg) where LC-MS-MS 
failed to detect it. The LC-MS-MS sample weight and GC-MS sample weight were 
very low in this case therefore the better recovery of the GC-MS method could 
explain this result. Alternatively, the root-0.5 cm segments may not have been 
split evenly between the two methods. Hair growing at the time of ingestion 
would have incorporated dihydrocodeine whereas hair at the end of its growth 
cycle would not. There are a limited number of scientific papers concerning 
dihydrocodeine levels in hair. One study found 13 hair samples collected from 
suspected heroin users positive for dihydrocodeine in the range 1.2-31.2 
ng/mg. 256 Both the LC-MS-MS and GC-MS methods detected lower dihydrocodeine 
concentrations in root segments 4 and 15 respectively than the lowest 
concentration reported in this study. The rest of the positive samples did 
however have concentrations within this reported range. 
Cocaine and benzoylecgonine were detected in 2 root segments (samples 9 and 
10) using LC-MS-MS and GC-MS. The root sample weights were >3 mg for both 
methods. Cocaethytene was also detected in these samples by LC-MS-MS but not 
by GC-MS. Root segment 9 contained 2.05 ng/mg cocaine, 0.31 ng/mg 
benzoylecgonine and 0.25 ng/mg cocaethylene as determined by LC-MS-MS. The 
GC-MS method detected higher cocaine and benzoytecgonine levels (4.78 ng/mg 
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cocaine and 1.56 ng/mg benzoylecgonine) in root sample 9. The higher recovery 
of the extraction method could explain these results. As the root segment 
weights were similar for LC-MS-MS and GC-MS analysis, it appears that the LC- 
MS-MS method sensitivity is better for cocaethylene however the result could 
also be due to uneven splitting of the root segments. The ratio of 
benzoylecgonine/cocaine was > 0.05 in the positive root samples analysed by 
both methods. This ratio is recommended cut-off proposed by the SoHT. 10° 
As mentioned previously, amphetamine was detected in root sample 17 where 
none was detected by GC-MS. GC-MS did not test for benzodiazepines however 
the LC-MS-MS method detected diazepam (samples 2 and 10) and nordiazepam 
(samples 2,4 and 10) were detected in the ranges of 0.31-0.34 ng/mg and 0.34- 
2.26 ng/mg respectively. Nordiazepam/diazepam ratios were 1.10 and 6.65 for 
these samples. These ratios are within the ranges reported by other studies. "' 
8.9.1.5.3 Quantitative results for segments excluding roots 
The drug ranges and number of segments excluding roots found positive by LC- 
MS-MS and GC-MS are summarised in Table 8-29. The opiate ranges were much 
broader than the ranges obtained for the root segments shown in Table 8-28. 
Table 8-29 Drug ranges and number of positive segments excluding roots 
LC-MS-MS GC- MS 
Analyte Concentration Range 
(ng/mg) 
Number of 
Positive 
Segments 
Concentration 
Range 
(ng/mg) 
Number of 
Positive 
Segments 
Morphine 0.04-2.02 10 0.01-6.14 12 
6-MAM 0.08-4.55 12 0.19-3.36 10 
Codeine 0.02-2.32 10 0.05-5.52 13 
Dihydrocodeine 0.09-16.18 6 0.05-14.60 8 
Cocaine 0.06-13.99 7 0.09-19.34 6 
Benzoytecgonine 0.11-4.73 7 0.21-4.92 6 
Cocaethylene 0.04-0.53 3 0.10-1.07 2 
EME 0.21-0.24 2 Not reported N/A 
Amphetamine 0.19-7.29 3 1.75 1 
MDMA 0.46-1.60 6 Not tested N/A 
Diazepam 0.04-0.52 7 Not tested N/A 
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Table 8-29 Drug ranges and number of positive segments excluding roots (continued) 
Nordiazepam 0.17-0.67 7 Not tested N/A 
Oxazepam 0.22-0.26 2 Not tested N/A 
Temazepam 0.10-0.14 2 Not tested N/A 
Using LC-MS-MS, 6-MAM was detected in 12 segments without roots in this 
current study which suggests heroin use. 7 of these samples contained morphine 
and codeine which can support heroin consumption when 6-MAM is also present. 
The morphine and codeine ranges as determined by LC-MS-MS were 0.04-2.02 
ng/mg and 0.02-2.32 ng/mg. For GC-MS, the morphine and codeine ranges were 
0.01 -6.14 ng/mg and 0.05-5.52 ng/mg respectively. The higher range for GC-MS 
for morphine and codeine highlights the better extraction capability of the GC- 
MS method compared to the LC-MS-MS method. The morphine/codeine ratios in 
these samples ranged from 0.43-10.00 (mean 3.35). Morphine was detected at a 
higher concentration than codeine in 4 of these 7 samples. As well as being a 
metabolite of 6-MAM, morphine is also a metabolite of codeine. In samples 3 
and 4, the codeine concentration is higher than the morphine concentration. 
However due to the possible consumption of codeine, these ratios can be higher 
and as found in samples 3 and 4, can be found at a greater concentration than 
morphine. In these cases, it is extremely important to detect 6-MAM to 
distinguish heroin use from codeine use. The morphine/codeine ratios reported 
in another study ranged from 0.38-6.45 as reported for 23 morphine and codeine 
positive hair samples which used a method involving a phosphate buffer (pH 5.0) 
extraction. " According to the criteria discussed in section 8.9.1.5.1, a sample 
should be reported positive for heroin use when there is a morphine /codeine 
ratio of 5: 1 in cases where the morphine level is <1 ng/mg. Samples 3 and 4 
would be reported as negative for heroin use according to these reported ratios. 
However 6-MAM was found in these samples and the 6-MAM/morphine ratios 
were 5.8 and 3.6 respectively which would fit the criteria proposed by one of 
the studies' for reporting heroin use but not the other study which proposes a 
6-MAM/morphine ratio > 7.14.253 The information provided in the pathology 
reports for sample 3 was that the individual had a past history of multi- 
substance abuse, including heroin abuse. Morphine, diazepam, nordiazepam and 
alcohol were found in the blood sample. The information provided in the 
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pathology report for sample 4 provided no information on past drug abuse 
history. Morphine, diazepam, nordiazepam, oxazepam and procyclidine were 
detected in the blood sample. It would appear that the proposed 
morphine /codeine ratios of 5: 1 are not appropriate in these cases where the 
background information indicates past heroin use and where no information to 
support codeine use was found. 
Using LC-MS-MS, 9 out of 12 opiate positive segments without roots contained 
both morphine and 6-MAM. In contrast using GC-MS, 5 out of 12 opiate positive 
segments without roots contained both 6-MAM and morphine. In general there 
was good correlation between the qualitative opiate results for LC-MS-MS and 
GC-MS. However some analytes were detected by LC-MS-MS where GC-MS failed 
to detect them and vice versa. 
The 6-MAM concentrations detected by LC-MS-MS and GC-MS were in the range 
0.08-4.55 ng/mg and 0.19-3.36 ng/mg respectively, with most being categorised 
as low (91.6 %) users according to the proposals in the previously mentioned 
study. 253 The concentrations detected in sample 7 by LC-MS-MS and GC-MS were 
indicative of medium level use. According to this proposed categorisation, 3 of 
the segments would be reported as negative using the LC-MS-MS method and 1 of 
these segments would be reported as positive since the 6-MAM concentrations 
were < 0.5 ng/mg. This finding highlights the importance of establishing cut-off 
values appropriate to a particular method. However, recent recommendations 
by the SoHT state that a cut-off of 0.2 ng/mg 6-MAM is acceptable for 
interpreting heroin use. 10° Using LC-MS-MS, 6-MAM levels detected in 3 segments 
(samples 2,10 and 12) were below this cut-off level. The GC-MS results for 
samples 2 and 12 did not detect any 6-MAM so these results would have been 
reported as negative by both methods. The GC-MS method detected 6-MAM at 
the SoHT cut-off concentration of 0.2 ng/mg in sample 10 where the LC-MS-MS 
found a concentration < 0.2 ng/mg. 
There was no background information available for sample 2. There was drug 
paraphernalia and multiple needle marks on the individual from which sample 10 
was collected, which is consistent with heroin use. Morphine, codeine, EME, 
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cocaine, benzoylecgonine, diazepam, nordiazepam, oxazepam and temazepam 
were found in the blood sample. Information from the pathology reports 
revealed that hair sample 12 was collected from an individual with a previous 
addiction to heroin and had been attending methadone programmes. Morphine 
was detected in the blood sample, as well as diazepam, nordiazepam, 
oxazepam, temazepam, methadone, sodium valproate and sertraline. 
The 6-MAM/morphine ratios are shown in Table 8-30. With the exception of 
sample 3, the ratios for the GC-MS method are lower than those for the LC-MS- 
MS method. This is a result of the different extraction methods used. The LC- 
MS-MS ratios for 6-MAM/morphine are mostly higher than the ratios determined 
in another study which used a phosphate buffer (pH 5.0) extraction. 
Table 8-30 6-MAM/morphine ratios in hair by LC-MS-MS and GC-MS 
Hair Sample Number 6-MAM/Morphine by 
LC-MS-MS 
6-MAM/Morphine by 
GC-MS 
(1) 0.5-3.5 cm 0.65 0.47 
(2) 0.5-3.5 cm 0.10 N/A 
(3) 0.5-3.5 cm 5.78 72.00 
(3) 3.5-6.5 cm N/A 13.30 
(4) 0.5-3.5 cm 3.63 2.96 
(7) 0.5-3.5 cm 4.14 0.58 
(8) 0.5-3.5 cm N/A 3.54 
(9) 0.5-3.5 cm 28.00 3.44 
(12) 0.5-3.5 cm 0.14 N/A 
(13) 0.5-3.5 cm N/A 3.80 
(15) 0.5-3.5 cm 1.28 0.76 
As mentioned previously, dihydrocodeine levels have not been commonly 
reported in hair. The LC-MS-MS and GC-MS concentrations found in the segments 
excluding roots ranged from 0.09-16.18 ng/mg and 0.05-14.60 ng/mg. The LC- 
MS-MS method appears to extract more dihydrocodeine than the GC-MS method. 
The concentrations found by both methods were lower than the range reported 
in another study. 24' Dihydrocodeine was found in hair samples 12 and 15 at 
relatively high levels. The background reports stated that the individuals from 
which samples 12 and 15 were collected were being currently prescribed 
dihydrocodeine. 
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Cocaine and benzoylecgonine were detected in 7 segments excluding roots by 
LC-MS-MS. The benzoylecgonine/cocaine metabolite to parent drug ratios were 
>_ 0.05 in all samples which is the cut-off value proposed by the SoHT. 97 Further 
suggestion of cocaine use was the presence of cocaethylene in 3 of these 
segments (samples 5,9 and 10) and the presence of EME in 2 segments (samples 
9 and 10). Cocaine concentrations by LC-MS-MS ranged from 0.06-13.99 ng/mg, 
benzoylecgonine from 0.11-4.73 ng/mg, cocaethylene from 0.04-0.53 ng/mg and 
0.21-0.24 ng/mg EME. These ranges correspond with other studies. ' 133 One 
study which used phosphate buffer (pH 5.0) incubation for the extraction of 
cocaine and its metabolites from 103 hair samples from known drug users 
detected cocaine levels in 74 of these samples ranging between 0.01-21.37 
ng/mg, benzoylecgonine levels between 0.03-10.51 ng/mg and cocaethylene 
levels between 0.05-1.26 ng/mg. 81 The method did not analyse for EME. 
Benzoylecgonine/cocaine ratios in this study ranged form 0.43-1.85. There was 
excellent qualitative agreement between the LC-MS-MS and GC-MS results for 
cocaine and benzoylecgonine. The GC-MS method was applied for the analysis of 
cocaine and its metabolites in 6 segments excluding roots. Cocaine and 
benzoylecgonine were detected in these segments also found to be positive by 
LC-MS-MS. Cocaethylene was also detected in samples 9 and 10. As mentioned 
previously, EME results were not reported for the GC-MS method due to an 
interferent at the EME retention time. Quantitatively, the GC-MS method 
generally extracted greater quantities of cocaine and its metabolites due to a 
higher extraction recovery. The benzoylecgonine/cocaine metabolite to parent 
drug ratios were >_ 0.05 in all samples. Cocaine concentrations by GC-MS ranged 
from 0.09-19.34 ng/mg, benzoylecgonine from 0.21-4.92 ng/mg and 
cocaethylene from 0.10-1.07 ng/mg. The cocaine range found is lower than 
reported in another study which used acidic hydrolysis with hydrochloric acid at 
50 °C overnight to extract cocaine and its metabolites from hair. 248 
Benzoylecgonine concentrations were however within the range reported in this 
study. 
For the segments excluding roots, the LC-MS-MS concentrations of amphetamine 
in hair ranged from 0.19-7.29 ng/mg which is in agreement with other studies. 
The GC-MS method was only applied to sample 17 and found a concentration of 
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1.75 ng/mg where the LC-MS-MS detected a level of 7.29 ng/mg. Amphetamine 
was also found in the blood sample at a concentration of 0.66 mg/L and the 
cause of death was amphetamine intoxication. One study reported 
amphetamine concentrations of 0.01-4.46 ng/mg in hair of 40 volunteers who 
were on drug rehabilitation programmes and were known drug users. ' 
The GC-MS method for amphetamines was only applied to sample 17 however 
the LC-MS-MS method analysed for amphetamines in all hair samples. MDMA was 
detected in 4 samples (samples 2,3,4 and 5) by LC-MS-MS. Concentrations 
ranged from 0.46-1.60 ng/mg which corresponds with other scientific literature. 
According to the current SoHT guidelines these would be reported as positive.,, 
1 of the samples (sample 4) was positive for both MDMA and amphetamine. The 
presence of amphetamine in this sample could be due to ingesting amphetamine 
tablets or alternatively the amphetamine could be present as an impurity in the 
MDMA tablets. There was no MDMA metabolite, MDA detected in the samples. A 
possible explanation for this is the low levels of MDMA detected in the samples. 
One study examined MDA/MDMA metabolite to parent drug ratios in hair samples 
collected from 40 suspected drug users. 249 The MDA/MDMA ratios ranged from 
0.03-1.10 (mean 0.15). If this mean MDA/MDMA ratio was applied to calculate a 
predicted MDA concentration range from the MDMA concentration range found, it 
would be 0.70-2.4 ng/mg. The lower value in this range is the LOQ of the 
method and this may explain why MDA was not reported as positive in this 
sample. In one study, MDMA concentrations ranging from 0.12-6.4 ng/mg were 
detected in the hair of 20 known users. 25° The range of MDMA concentrations in 
another study analysing hair collected from suspected abusers was 0.56-34.06 
ng/mg. 249 MDA was also detected in this study in the range 0.13-6.44 ng/mg. 
The GC-MS method did not analyse for benzodiazepines. The LC-MS-MS method 
however detected nordiazepam most frequently in the hair samples tested in 
this study and was generally present at a higher level than diazepam, as found in 
other studies. '", "' These results were consistent with the findings of the 
benzodiazepine study carried out in chapter 7. Diazepam concentrations ranged 
from 0.04-0.52 ng/mg, nordiazepam from 0.17-0.67 ng/mg, 0.22-0.26 ng/mg 
oxazepam and 0.10-0.14 ng/mg temazepam. Oxazepam and temazepam were 
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generally detected at lower levels than found in the other study in chapter 7 as 
a result of the different extraction method used. They were also detected in 
fewer samples compared to diazepam and nordiazepam. This would suggest 
diazepam use in these cases. However, oxazepam was detected at a higher 
concentration in sample 12 compared to diazepam and nordiazepam which may 
indicate combined diazepam and oxazepam use. 
The LC-MS-MS chromatograms for hair samples that were positive for each drug 
class are given in Figures 8-22-8-25. 
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Figure 8-23 Hair sample positive for diazepam and nordiazepam (left to right) 
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Figure 8-24 Hair sample positive for morphine, codeine, dihydrocodeine and 6-MAM (left to 
right) 
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Figure 8-25 Hair sample positive for EME, cocaine, cocaethylene and benzoylecgonine (left 
to right) 
8.9.2 ELISA vs LC-MS-MS 
The validated ELISA and LC-MS-MS method for the detection of drugs of abuse in 
hair were successfully applied to 7 post-mortem positive hair samples. The hair 
samples were screened by ELISA when there was sufficient sample present after 
quantification by LC-MS-MS. The results are given in Tables 8-31-8-35. 
Table 8-31 Amphetamines ELISA results 
ELISA LC-MS-MS (ng/mg) 
Sample 
Number 
Weight 
( g) 
Equivalents 
(ng/mg) 
Weight 
( g) 
AMP P MDA MDMA MDEA 
(9)0.5-3.5 5.14 < 0.2 28.55 0.21 - - - - 
(3) 0.5-3.5 5.71 < 0.2 19.09 - - - 1.26 - 
(10)0 5-3.5 4.14 < 0.2 29.47 - - - - - 
(8) 0.5-3 2.02 < 0.2 9.24 - - - - - 
(12) 0.5-3.5 3.89 < 0.2 10.40 - - - 0.46 - 
(1) 0.5-3.5 4.41 < 0.2 23.80 - - - - - 
(15) 0.5-3.5 7.43 < 0.2 18.66 - - - - - 
"AMP"=Amphetamine, "MAMP"=Methamphetamine 
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Table 8-32 Benzodiazepine ELISA results 
Chapter 8,208 
ELISA LC-MS-MS (ng/mg) 
Sample 
Number 
Weight 
(mg) 
OXAZ 
Equivalents 
(ng/mg) 
Weight 
(mg) DZ NDZ OXAZ TMZ 
(9) 0.5-3.5 5.14 0.27 28.55 0.18 0.17 - - 
(3) 0.5-3.5 5.71 0.14 19.09 0.12 0.36 
(10) 0.5-3.5 4.14 > 0.5 29.47 0.24 0.64 0.26 0.14 
(8) 0.5-3 2.02 0.13 9.24 - - - - 
(12) 0.5-3.5 3.89 > 1.0 10.40 0.68 0.92 3.51 - 
(1) 0.5-3.5 4.41 0.36 23.80 0.10 0.37 - - 
(15) 0.5-3.5 7.43 0.12 18.66 - - - - 
"DZ"= Diazepam, "NDZ"= Nordiazepam, "OXAZ"=Oxazepam, "TMZ"=Temazepam 
Table 8-33 Cocaine ELISA Results 
ELISA LC-MS-MS (ng/mg) 
Sample 
Number 
Weight 
(mg) Ecoc quivalents (ng/mg) 
Weight 
(mg) COC BZE COCAETH EME 
(9) 0.5-3.5 5.14 > 2.5 28.55 13.99 4.73 0.53 - 
(3) 0.5-3.5 5.71 0.64 19.09 0.29 0.16 - - 
(10) 0.5-3.5 4.14 > 2.5 29.47 0.60 0.18 0.04 - 
(8) 0.5-3 2.02 < 0.5 9.24 0.08 - - - 
(12) 0.5-3.5 3.89 < 0.5 10.40 - - - - 
(1) 0.5-3.5 4.41 < 0.5 23.80 - - - - 
(15) 0.5-3.5 7.43 < 0.5 18.66 - - - - 
"COC"= Cocaine, "BZE"= Benzoylecgonine, "COCAETH"= Cocaethylene, "EME"=Ecgonine Methyl 
Ester 
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Table 8-34 Methamphetamine ELISA results 
Chapter 8,209 
ELISA LC-MS-MS (ng/m g) 
Sample 
Number 
Weight 
(mg) 
d-MAMP 
Equivalents 
(ng/mg) 
Weight 
(mg) AMP MAMP MDA MDMA MDEA 
(9) 0.5-3.5 5.14 0.24 28.55 0.21 - - - - 
(3) 0.5-3.5 5.71 0.60 19.09 - - - 1.26 - 
(10) 0.5-3.5 4.14 < 0.2 29.47 - - - - - 
(8) 0.5-3 2.02 < 0.2 9.24 - - - - - 
(12) 0.5-3.5 3.89 0.31 10.40 - - - 0.46 
(1) 0.5-3.5 4.41 < 0.2 23.80 - - - - - 
(15) 0.5-3.5 7.43 0.42 18.66 - - - - - 
"AMP"=Amphetamine, "MAMP"=Methamphetamine 
Table 8-35 Opiate ELISA Results 
ELISA LC-MS-MS (ng/mg) 
Sample 
Number 
Weight 
(mg) 
MOR 
Equivalents 
(ng/mg) 
Weight 
(mg) MOR 6-MAM COD DHC 
(9) 0.5-3.5 5.14 0.43 28.55 0.04 1.12 - - 
(3) 0.5-3.5 5.71 < 0.2 19.09 0.09 0.52 - - 
(10) 0.5-3.5 4.14 < 0.2 29.47 - 0.08 
(8)6. -5-3 2.02 < 0.2 9.24 - 0.58 - - 
(12) 0.5-3.5 3.89 > 1.0 10.40 0.87 0.12 - 16.18 
(1) 0.5-3.5 4.41 0.20 23.80 2.02 - - - 
(15) 0.5-3.5 7.43 > 1.0 18.66 1.03 1.32 0.31 10.72 
"MOR"=Morphine, "6-MAM"= 6-monoacetytmorphine, "COD"= Codeine, "DHC"= Dihydrocodeine 
The sample weights used for ELISA were low (< 10 mg and in most cases <5 mg). 
The drug levels detected in some samples using LC-MS-MS were low even using a 
higher sample weight of 10-30 mg therefore the sample weight limited the ELISA 
method. 
The methamphetamine kit produced a greater number of true results compared 
with the amphetamine kit which produced 3 FN results. This is due to the 
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different cross reactivity of the 2 kits. The methamphetamine kit has a very 
high cross reactivity with MDMA and 2 of the samples were confirmed as positive 
using LC-MS-MS for MDMA. 
The benzodiazepine kit produced 5 TP and 2 FP results using a cut-off of 
0.1 ng/mg oxazepam. The 2 FP concentrations were calculated as the actual 
cut-off value. There may have been benzodiazepines present in these samples 
other than diazepam and its metabolites which could have cross reacted with 
the ELISA kit to produce these FP results. 
Using the recommended SoHT cut-off value of 0.5 ng/mg cocaine, the kit 
detected 3 TP, 3 TN and I FN result. The FN result produced a low positive 
result for cocaine and so using this cut-off, the sample would have been 
reported as negative. 
The opiates kit detected 4 TP and 3 FN results using a cut-off of 0.2 ng/mg 
morphine. The FN results were samples which contained low levels of opiates as 
determined by LC-MS-MS. 
On the whole, ELISA is a useful method for screening provided there is sufficient 
sample (> 10 mg). The validated LC-MS-MS method was capable of detecting 
drug levels in very low weight root samples as shown in Table 8-26. This was not 
the case for ELISA screening of low sample weights as there were FN results for 
all drug classes tested except benzodiazepines. Furthermore the superior LC-MS- 
MS specificity means that screening and quantification could be carried out using 
the LC-MS-MS method described. 
8.10 Conclusion 
The developed and validated LC-MS-MS method is capable of simultaneously 
identifying and quantifying amphetamines, diazepam and its metabolites, 
cocaine and its metabolites and opiates from one hair sample of 8-30 mg. It is 
also capable of detecting these drug groups in root segments of low weight (in 
some cases <1 mg). Although the opiate and cocaine recoveries are generally 
lower from real hair samples using the LC-MS-MS compared to the in-house GC- 
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MS methods targeting specific drug groups, the sensitivity and therefore the 
qualitative data was better, especially for morphine, 6-MAM and cocaethylene in 
low weight root samples. 
As a result of the lower opiate and cocaine recoveries using this LC-MS-MS 
method compared to GC-MS, it should be borne in mind that there may be cases 
where the GC-MS method would detect the analyte where the LC-MS-MS method 
would not. This has been shown in a few samples for morphine and codeine. 
Dihydrocodeine was however detected in 2 samples where LC-MS-MS failed to 
detect it. The LC-MS-MS and GC-MS data showed excellent qualitative 
correlation for cocaine, benzoylecgonine and cocaethylene but the GC-MS 
method extracted greater quantities of cocaine and benzoylecgonine. 
Cocaethylene and EME were detected in some samples by LC-MS-MS were GC-MS 
detected none. A disadvantage of the GC-MS method is its inability to report 
EME levels due to a co-eluting interferent peak at the EME retention time. 
Amphetamine recovery was higher using the LC-MS-MS in 1 sample compared to 
GC-MS. 
The method was useful for the analysis of 17 drugs of abuse from post-mortem 
hair in forensic toxicology cases. Maximum information is obtained from 1 hair 
sample which is extremely useful when the sample weight is limited. As it is 
currently not possible to relate the quantity of drug detected in hair with 
amount of drug ingested or the frequency of drug use, a qualitative screening 
method may provide all the required information for as accurate an 
interpretation as possible at this time. The ability of the LC-MS-MS method to 
extract and analyse a greater number of drug groups from one hair sample 
highlights the advantages of using this method over GC-MS which targets 
individual drug groups and requires splitting the sample. 
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9 Conclusion 
An investigation was carried out into the potential use of ELISA and LC-MS-MS for 
the analysis of biological samples in forensic toxicology. Both analytical 
techniques have been found to be extremely useful however as with any 
technique, each has its own set of benefits and limitations. 
A highly sensitive and specific ELISA method was developed for the successful 
detection of buprenorphine in 21 urine samples. This level of sensitivity is 
essential as therapeutic concentrations of buprenorphine can be low. The limit 
of detection was 0.5 ng/mL. Norbuprenorphine cross reactivity was relatively 
high which is a good feature of the kit since norbuprenorphine levels in urine are 
generally higher than buprenorphine levels. Using 0.5 ng/mL as the ELISA cut 
off, the sensitivity and specificity were both 100 % compared with an in-house 
LC-MS method. 
A single ELISA method was successfully validated for amphetamines, 
benzodiazepines, cocaine, methamphetamine, methadone and opiates in hair 
and subsequently applied to the screening of case samples. The kits were found 
to be very sensitive with LOD values _< 0.1 ng/mg using a 10 mg hair sample. 
Intra-day precision and inter-day precision levels were acceptable (< 9% and 
< 18 % respectively) and appropriate cross reactivity was demonstrated with 
drugs and drug metabolites relevant to hair. 
The ELISA cut-off values used for the post-mortem hair samples in chapters 6 
and 8 were recommended by the Society of Hair Testing (SoHT) for 
amphetamines, cocaine and opiates. The ELISA sensitivity and specificity were 
89 % and 79 % for 27 opiate positive samples. The 3 FN results could be 
explained by low sample weights <_ 5 mg and in 1 case, the presence of a low 
level of dihydrocodeine which has been shown to cross react with the kit by 43 
%. The ELISA sensitivity for 20 benzodiazepine positive hair samples was 100 % 
however specificity was 67 % using a cut-off value of 0.1 ng/mg. It was shown 
that FN results were produced at higher ELISA cut-off values. In the 
collaboration with the Korean laboratory, 29 methamphetamine positive hair 
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samples were screened at a cut-off of 0.5 ng/mg. 28 out of 29 samples were TP 
results and there was 1 FN which was very close to the ELISA cut-off value. 
There were a relatively small number of cocaine, methadone and amphetamine 
positive hair samples available for ELISA screening as the majority of the sample 
required to be analysed by a more specific confirmatory method first. Therefore 
no substantiated conclusions can be drawn regarding the recommended SoHT 
cut-off values for cocaine and amphetamine. Interestingly, 2 of the 3 FN 
cocaine results contained only cocaine at concentrations < 0.5 ng/mg as 
determined by GC-MS. This could be a result of contamination or low use. 
According to current SoHT guidelines, these 2 samples would be reported as 
negative as the guidelines stipulate that a benzoylecgonine/cocaine ratio z 0.05 
should be used as a cut-off. There were only 3 samples confirmed as positive for 
amphetamines by LC-MS-MS. 2 of these samples were positive for MDMA and 
tested negative using the amphetamines ELISA due to very low MDMA cross 
reactivity but tested positive using the methamphetamine kit which has a high 
MDMA cross reactivity. 1 sample was positive for amphetamine and only tested 
positive using the methamphetamine kit. The LC-MS-MS concentration 
calculated for amphetamine was the actual cut-off so this explains the negative 
result using the amphetamines kit. 5 out of 6 methadone positive samples 
screened as positive at a cut-off of 0.2 ng/mg. The 1 FN result was probably a 
result of a very low sample weight (1 mg) as the GC-MS concentration detected 
was 3.7 ng/mg. 
The ELISA method was applied successfully for the detection of 
methamphetamine in hair of methamphetamine abusers. The kit demonstrated 
a sensitivity and specificity of 97 % and 100 % respectively using a cut-off value 
of 0.5 ng/mg d-methamphetamine. The amphetamine to methamphetamine 
ratios ranged from 0.02-0.159 in 28 samples excluding roots. 
An LC-MS-MS method was successfully validated for the detection of 9 
benzodiazepines in hair as described in chapter 7. The method was sufficiently 
sensitive for their detection in post-mortem hair samples. 13 post-mortem 
samples were found to be positive for benzodiazepines using this method. A 
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mild alkaline incubation lasting 16 hours was shown to be most suitable for 
benzodiazepine extraction and there was no significant hydrolysis observed. 
Recoveries in spiked hair ranged from 53-98 % and the LOD range was 0.03-0.62 
ng/30 mg hair. The matrix effect ranged from 77-105 % with most analytes 
displaying ion suppression. The evaporation step in the SPE method was 
identified as means of 7-aminoflunitrazepam and chlordiazepoxide loss, which is 
partly responsible for the lower recoveries of these analytes. 
Also in chapter 7, a preliminary study was carried out into the use of a diazepam 
molecularly imprinted polymer for the detection of benzodiazepines in post- 
mortem hair case samples. It was shown that it can be applied successfully for 
this purpose and detected a higher number of diazepam positive cases compared 
to the classical SPE method because of higher extraction recovery and the 
excellent molecular recognition of the template molecule (diazepam) imparted 
by the imprinting process. 
The method developed in chapter 8 was successfully validated for 17 drugs of 
abuse in hair. It enabled the simultaneous identification and quantification of 
amphetamines, diazepam and its metabolites, cocaine and its metabolites and 
opiates from 1 hair extract using 3 LC-MS-MS injections. 3 injections were used 
to enhance assay sensitivity by minimising the number of scan events per time 
window. This also maximised the number of points across the peak to obtain 
more accurate analyte quantifications. 
17 post-mortem hair samples were analysed using this method and the results 
were compared to the GC-MS results obtained by in-house methods. At least one 
drug class was detected in 16 out of 17 samples. 1 sample was negative by both 
the LC-MS-MS and GC-MS methods. In general, there was a good qualitative 
correlation between LC-MS-MS and GC-MS results for opiates, cocaine and 
amphetamine, particularly in the 0.5-3.5 cm segments which were of sufficiently 
high sample weight. Morphine and codeine were detected in 2 segments 
excluding roots using GC-MS where LC-MS detected none. However this did not 
affect the reported result in accordance with current SoHT guidelines. 
Dihydrocodeine was also detected in 2 segments excluding roots by GC"MS where 
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LC-MS-MS failed to detect it. On the other hand, the LC-MS-MS method detected 
cocaethylene and EME in 2 samples where GC-MS did not detect any and in the 
case of EME could not report the GC-MS result due to co-eluting interferent at 
the EME retention time. Overall, the LC-MS-MS method was capable of testing 
for more drug groups using one hair sample and extraction method compared to 
the drug class specific GC-MS methods which involved splitting the hair sample 
and the use of different extraction methods. On the other hand, the GC-MS 
methods generally extracted greater quantities of opiates and cocaine and its 
metabolites since they were targeting these particular drug groups. The 
methods had been developed and validated with a view to detecting one 
particular drug group therefore the extraction and analysis conditions were 
optimum for that drug group. The LC-MS-MS method however was developed 
and validated with a view to detecting 4 different drug groups. Therefore, a 
compromise on extraction and analysis conditions had to be reached for the LC- 
MS-MS method. The LC-MS-MS method detected amphetamine, MDMA, diazepam 
and its metabolites in some samples however the GC-MS method did not test for 
these drug groups as there was insufficient sample after testing for opiates and 
in some cases cocaine and its metabolites. The ability of the LC-MS-MS method 
to extract and analyse a greater number of drug groups from one hair sample 
highlights the advantages of using this method over GC-MS which targets 
individual drug groups and requires splitting the sample. 
In conclusion, ELISA screening is a highly sensitive method which can be applied 
for the detection of drugs of abuse in hair and urine. LC-MS-MS has 
demonstrated excellent reliability, sensitivity and specificity and it is an 
extremely useful instrument in a forensic toxicology laboratory. Using LC-MS-MS, 
the sensitivity and therefore the qualitative data was better for post-mortem 
samples discussed in chapter 8, especially for 6-MAM and morphine in low weight 
root samples. The LC-MS-MS method was useful for the analysis of targeted 
unknown drugs from hair in forensic toxicology cases and could even be used in 
place of ELISA for a more specific screening procedure or in cases where 
minimum sample is available. However GC-MS is still better for some compounds 
and should ideally be used in tandem with LC-MS-MS to enable the analysis of a 
large number of compounds. 
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10 Further Work 
The application of ELISA for the detection of drugs of abuse in hair has been 
demonstrated. The ELISA study in this thesis was limited by the number of 
samples available and the weight of the sample. It was therefore not possible to 
draw any definitive conclusions about the suitability of proposed cut-off values 
by the Society of Hair Testing (SoHT). Screening a greater number of samples of 
sufficient weight (> 10 mg) in order to recommend appropriate in-house values 
would therefore be an area of interest for future work. In addition, ELISA kits 
which have recently become commercially available e. g. zolpidem and 
fluoxetine should be tested for potential use in hair screening. 
Although the LC-MS-MS method in chapter 7 was successfully validated and 
applied in the analysis of 13 post-mortem hair samples from chronic users, only 6 
of the 9 benzodiazepines included in the method were detected in the samples. 
The method should be applied to hair samples containing chlord iazepoxide, 
flunitrazepam and 7-aminoflunitrazepam to ensure that the method is suitable 
for extracting these drugs when they are actually incorporated. As some 
7-aminoflunitrazepam and chlordiazepoxide were lost during the evaporation 
step in the method, an experiment should be carried out to test their recovery 
when tartaric acid is added to the extract prior to evaporating the extracts to 
dryness using nitrogen. Further work is also required to investigate the 
detection of single dose benzodiazepine in hair which can be used to sedate a 
victim in a "date-rape" situation. With respect to the molecularly imprinted 
polymer work, the possibility of mixing two or more sorbents in one cartridge to 
detect a particular drug group should be investigated. Further work is also 
required to investigate the ability of the MISPE to detect benzodiazepines in 
single dose hair samples. 
The newly validated LC-MS-MS method described in chapter 8 should be applied 
to a greater number of hair samples and the results compared with current 
GC-MS methods to obtain more statistically valid data. This data could be used 
to establish whether the guidelines and cut-offs proposed by the Society of Hair 
Testing are appropriate for the LC-MS-MS method. There is scope for the 
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inclusion of other analytes in the method which would improve the method's 
screening capability. An in-house LC-MS-MS library could be built up for this 
method although this is more difficult than for GC-MS as the LC-MS spectra vary 
depending on instrument, chromatographic conditions and fragmentation 
voltages. However if the instrument used in chapter 8 was to be used for all 
routine hair analysis then this would be possible. The matrix effect observed for 
17 drugs of abuse in the method ranged between 64-136 %. An experiment using 
an atmospheric pressure chemical ionisation (APCI) source could be carried out 
to compare validation results with the electrospray (ESI) results as APCI is 
thought to produce less matrix effects than ESI. This is because of the presence 
of excess reagent ions which produce charged species in APCI, making it less 
susceptible to matrix effects. 
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TECHNICAL NOTE: Validation of the Immunalysiso Microplate 
ELISA for the Detection of Buprenorphine and Its Metabolite 
Norbuprenorphine in Urine 
Miller, Eleanor 1.1, Torrance, Hazel J. 1, Oliver, John S 
1 Forensic Medicine and Science Department, University of Glasgow, University 
Place, Glasgow, G12 8QQ, Scotland 
The purpose of this study was to validate the Immunalysis Buprenorphine 
Microplate enzyme-Linked immunosorbent assay (ELISA) for the detection of 
buprenorphine in urine samples. Sixty-nine urine samples were obtained from 
volunteers on the Subutexo treatment program and from routine samples 
submitted to the laboratory for buprenorphine testing. For ELISA analysis, 
samples were diluted 1: 10 with K2HPO4 (0-1M, pH 7.0). The limit of detection 
was calculated as 0.5 ng/mL buprenorphine. The intra-assay and interday 
precision was 3.8% (n = 10) and 8.6% (n = 50) respectively at 1 ng/mL 
buprenorphine. At a low concentration of norbuprenorphine (1 ng/mL), the 
immunoassay demonstrated a cross- reactivity of 78%. A higher cross -reactivity of 
116% was observed at a higher concentration of norbuprenorphine (10 ng/mL). 
Dihydrocodeine, codeine, tramadol, morphine, propoxyphene, methadone, and 
EDDP were tested at concentrations of 10 ng/mL and 10,000 ng/mL and 
demonstrated no cross- reactivity with the assay. For liquid chromatography- 
tandem mass spectrometry (LC-MS-MS), deuterated internal standard mixture, 
1M acetate buffer (pH 5.0), and b-glucuronidase were added to the standards 
and samples, which were then incubated for 3h at 600C. After incubation, 3 mL 
K2HP04 (0.1M, pH 6.0) was added and the pH altered to pH 6.0 using IM KOH. 
Buprenorphine and norbuprenorphine were subsequently extracted by solid- 
phase. Twenty-one samples were confirmed positive and 48 samples were 
confirmed negative by LC-MS-MS. Using a cut-off value of 0.5 ng/mL 
buprenorphine, the immunoassay demonstrated a sensitivity and specificity of 
100%. 
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VaLidation of the ImmunaLysise Microplate ELISA for the 
Detection of Metharnphetarnine in Hair 
Han, Eunyoung', Miller, Eleanor 2, Lee, Juseon', Park, Yonghoon', Lim, 
Miael, Chung, Heesun', Wylie, Fiona M. 21 Oliver, John S. 2 
1 Department of Narcotics Analysis, National Institute of Scientific Investigation, 
331 -1 Shinwol 7-Dong, Yang-Chun Gu, Seoul, South Korea 
2 Forensic Medicine and 
Science Department, University of Glasgow, University Place, Glasgow, G12 8QQ, 
Scotland 
The object of this study was to validate the Immunalysis Methamphetamine 
Microptate ELISA for detecting methamphetamine in hair. Twenty-nine scalp hair 
samples were obtained as routine cases submitted to the National Institute of 
Scientific Investigation in Seoul by the police. The hair samples were washed 
with 0.1% sodium dodecyl sulfate, distilled water, and dichtoromethane. The 
samples were screened using the Immunalysis Methamphetamine Microplate 
ELISA and confirmed using gas chromatography- mass spectrometry (GC-MS). 
Twenty-eight hair samples were screened and confirmed as positive for 
methamphetamine. For ELISA analysis, the samples were extracted by incubation 
in monobasic phosphate buffer for 1h at 600C. For GC-MS, the samples were 
extracted for 20 h in methanol containing 1% hydrochloric acid. The 
methanot/acid solution was evaporated to dryness and the resulting residue was 
derivatized with triftuoroacetic anhydride. Methamphetamine and amphetamine 
were detected using selective ion monitoring (SIM) mode. The Immunatysis 
Methamphetamine Microptate ELISA demonstrated a sensitivity and specificity of 
97% and 100%, respectively, using a cut-off concentration of 0.5 ng/mg d. 
methamphetamine. The ELISA kit showed 63% cross- reactivity with dJ- 
methamphetamine and did not cross-react to any significant extent with the licit 
t-methamphetamine isomer. The intra- and interassay precisions were 2.5% and 
3.7%, respectively. 
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Detection of Benzodiazepines in Hair Using ELISA and LC-ESI- 
ms-ms 
Miller, Eleanor 1.1, Wylie, Fiona M. 1, Oliver, John S. ' 
1 Forensic Medicine and Science Department, University of Glasgow, University 
Place, Glasgow, G12 8QQ, Scotland 
This study was designed to validate an enzyme-linked immunosorbent assay 
(ELISA) and liquid ch romatography- tandem mass spectrometry (LC-MS-MS) 
method for the detection of nine benzodiazepines in hair. Sixteen hair case 
samples were tested from drug-related deaths where a positive benzodiazepine 
blood result was obtained. The case samples were decontaminated with 0.1 % 
sodium dodecyL sulfate, distilled water, and dichloromethane. For ELISA 
analysis, the samples were extracted by incubation in monobasic phosphate 
buffer for 1h and then neutralized with dibasic phosphate buffer. They were 
diluted 1: 5 with phosphate buffer saline (PBS) prior to analysis. For LC-MS-MS, 
the samples were incubated overnight in methanol/25% ammonium hydroxide 
(20: 1). The benzodiazepines were extracted by solid phase. Thirteen samples 
were confirmed positive by LC-MS-MS. The benzodiazepines detected included 
diazepam, nordiazepam, temazepam, oxazepam, nitrazepam, and lorazepam. 
Using a cut-off concentration of 0.1 ng/mg oxazepam, the Immunalysis" 
Benzodiazepine Microptate ELISA demonstrated a sensitivity and specificity of 
100% and 81%, respectively, compared with LC-MS-MS results. 
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Benzodiazepine detection in hair by MISPE v. SPE. 
Ariffin, Marinah M. 1, Miller, Eleanor 1.1, Cormack, Peter A. G. 2, Anderson, Robert 
A. 1. 
1 Forensic Medicine and Science Department, University of Glasgow, University 
Place, Glasgow, G12 8QQ, Scotland 2 WESTCHEM, Department of Pure and 
Applied Chemistry, University of Strathclyde, Thomas Graham Building, 295 
Cathedral Street, Glasgow, G1 1XL. 
Abstract 
Background: This preliminary study compares the results of benzodiazepine 
analysis in scalp hair samples in ten post-mortem cases using a validated 
conventional solid-phase extraction (SPE) system and an anti-diazepam 
molecularly imprinted polymer solid-phase extraction (MISPE) system. 
Methods: The ten hair samples tested were from drug-related deaths in which a 
positive benzodiazepine blood result was obtained. The case samples were 
decontaminated with 0.1 % sodium dodecyt sulfate, distilled water and 
dichloromethane, incubated overnight in methanol/25 % ammonium hydroxide 
(20: 1) and subsequently extracted by SPE or MISPE followed by LC-MS-MS 
analysis. 
Results: Diazepam, nordiazepam, oxazepam, temazepam and nitrazeparn were 
detected in the samples using both extraction methods. The recovery values for 
diazepam, nordiazepam, oxazepam, temazeparn and nitrazeparn in MISPE and 
SPE methods were between 73-103 % and 69-91 % respectively. LOD levels 
between 0.06-0.39 ng/30 mg hair and 0.03-0.24 ng/30 mg hair were obtained 
with the MISPE and SPE methods, respectively. Diazeparn was detected in more 
case samples using MISPE due to the lower LOD values and higher extraction 
recovery, as a result of excellent recognition of the template. The LOD and 
recovery values for diazepam by MISPE are 0.09 ng/30 mg hair and 93 %P 
respectively compared to 0.13 ng/30 mg and 69 % by SPE. Nitrazepam levels 
detected by both methods were very similar. The MISPE method however was 
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less sensitive for temazepam, nordiazepam and oxazepam determination 
compared to the conventional SPE method. 
Conclusion: The molecularly imprinted polymer used for this study 
demonstrated good selectivity for the 5 benzodiazepines tested, especially the 
template substance, diazepam. The MISPE method coutod be used as an 
alternative to conventional SPE extraction for the analysis of benzodiazepine 
positive hair samples collected from chronic users. 
Keywords: Benzodiazepines; Hair; SPE; MISPE; LC-MS-MS 
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Simultaneous identification and quantification of cocaine 
and its metabolites, opiates, amphetamines and diazepam 
and its metabolites from a single hair extract 
Miller, Eleanor 1.1, Wylie Fiona M. 1, Oliver JS1. 
1 Forensic Medicine and Science Department, University of Glasgow, University 
Place, Glasgow, G12 8QQ, Scotland 
A liquid chromatography tandem mass spectrometry (LC-MS/MS) method was 
developed and validated for the simultaneous identification and quantification 
of opiates, cocainics, amphetamines and diazepam and its metabolites from a 
single hair extract. Three different LC columns (Gemini C18, Synergi Hydro RP 
and Zorbax Phenyl) and three different mobile phase combinations were 
investigated. Two mixed mode SPE extraction cartridges (Bond Elut Certifyo and 
Clean Screeno'ZSDAU 020) were compared, with the Clean Screen" cartridge 
producing higher recoveries, lower LODs and cleaner extracts. Methanol and 
phosphate buffer (pH 5) incubation methods were compared for three authentic 
hair samples, with the phosphate buffer incubation producing better qualitative 
and quantitative results. The optimised validated method used the Synergi 
Hydro RP column with 3 mM ammonium formate + 0.001 % formic 
acid /Acetonitrile mobile phase, Clean Screen extraction cartridge and phosphate 
buffer incubation. 
The authentic hair samples used in the validation were from cases where the 
blood result was positive for at least one drug class. After segmentation, the 
samples were decontaminated by washing with 0.1 % sodium dodecyl sulfate, 
deionised water and dichloromethane. Drugs were extracted for 18 h at 45 OC 
using phosphate buffer (pH 5), followed by SPE clean-up using a mixed mode 
Clean Screeno extraction cartridge. Analytes were identified by their full MS/MS 
spectra and quantification was based on data from the major product ion. 
Deuterated internal standards were used for all analytes and the data was 
collected using selected ion monitoring (SIM) mode. The method was applied to 
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15 authentic post-mortem scalp samples, detecting at least one drug class in 
each sample. 
